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Abstract
Despite the success of recent global malaria control efforts, which have halved global malaria 
mortality since 2000, malaria is still one of the world’s most deadly diseases causing an 
estimated half a million deaths, mostly among African children, and around a quarter of billion 
clinical episodes every year as reported in 2014 Drug resistance is one of the most important 
challenges to malaria elimination. To contain drug resistance, many efforts have been put forth 
including improvement of surveillance systems and mass treatment in order to stop or slow 
down the transmission of the resistant strain. To find out whether a population-level treatment 
strategy can have any benefit in containing drug resistance, mathematical models are an 
appropriate approach to this problem and individual-based models allow us to have a better 
understanding of the effect of individual heterogeneities on the outcome.
The first part of the thesis is about building and validating an individual based microsimulation. 
The model is implemented as an individual-based discrete-time event simulation model in C++. 
The behaviors and the state changes of human individuals are determined by relevant events 
and mathematical formulas. This integrated model combines components that reproduce the 
most important features of malaria transmission and epidemiology: the infectiousness of human 
populations; clinical model of acute illness; heterogeneities in individuals’ age, biting-rate 
level, drug absorption, drug action, multiple parasite populations, and human immunity.
To validate this individual-based model, two types of validation have been done. The model’s 
parameters were obtained from field or clinical data were used directly in the model. For those 
parameters that cannot be obtained directly from literature review, sensitivity analysis has been 
done to find how variation in parameter values affects certain key features of malaria 
epidemiology.
The second part of the thesis focused on the comparison between population-scaled treatment 
strategies. The results showed that using multiple first-line therapies (MFT) results in a lower 
number of treatment failures compared to other strategies where a single first-line ACT is
recommended. This result is robust to various epidemiological, pharmacological, and 
evolutionary features of malaria transmission. In addition, including non-ACT therapy in an 
MFT strategy seems to have a significant benefit in reducing the pressure on artemisinin- 
resistance evolution, delaying its emergence and slowing its spread.
The third part of the thesis focused on individual-level treatment strategies to combat 
artemisinin resistance. The results showed that lengthening an ACT course or using multiple 
courses of ACT can reduce the long-term number of treatment failures significantly.
The work reported here introduces a novel individual-based simulation that includes drug 
resistance evolution and the ability to be scaled up to millions number of individuals. The 
challenge that remains is to evaluate the feasibility of these novel treatment strategies given 
that they will need to be implemented in the real world of malaria control programs, their 
operations, human behavior, and economic realities.
v
Table of Contents
Dedication........................................................................................................................................ ii
Acknowledgement...............   iii
Abstract........................................................................................................................................... iv
Table of Contents.......................................................................................................................... vi
List of Tables  .......................................................................................................................... xi
List of Figures...;................................................  xii
List of Abbreviations......................    xvi
Chapter 1 Introduction and Literature Review....................................... ............................... 1
1.1 Malaria..............................................................................................................................2.
1.2 Malaria Control Strategies............................................................................................... 3
1.2.1 Vector Control and Protection against Mosquito Bites......................................... 3
1.2.2 Treatment Strategy in Individual-scaled and Population-scaled............................5
1.3 Mathematical Model for Malaria..................................................................................... 7
1.3.1 Compartmental Model............................................................................................. 7
1.3.2 Individual-based M odel......................................................................................... 12
1.4 Rationale of the Thesis................................................................   19
1.5 Aims................................................................................................................................. 20
Chapter 2 Software Design for Malaria Simulation...............................................................22
2.1 Introduction......................................................................................................................22
2.2 System Design.................................................................................................................23
2.2.1 Malaria Model Component....................................................................................24
2.2.2 Scheduler Component............................................................................................ 26
2.2.3 Random Generator Component............................................................................ 26
2.2.4 Configuration Component......................................................................................27
2.2.5 Statistic and Data Collection Component.............................................................30
2.2.6 Reporting Component............................................................................................ 30
2.2.7 Human Population Component............................................................................. 32
2.3 The Combination of Time-Step and Discrete-Event Simulation (details of scheduler 
and event)................................   34
2.4 Parasite and Drug Resistant Genotype design............................................................. 36
2.5 Object Index for Faster Calculation and Reducing Memory Usage.......................... 37
2.6 Memory Management with Obj ect Pool.......................................................................39
Chapter 3 Model Construction and Model Validation.......................................................... 41
3.1 Model Description......................................................................................................... 42
3.2 Gametocytaemia and Infectivity................................................................................... 47
3.3 Duration of Infection...................................................................................................... 48
3.4 Probability that an Infectious Bite Causes an Infection.............................................. 49
3.5 Age-specific All-cause and Malaria Mortality......................    50
3.6 Age Structure...............................................................  53
3.7 Parasite Density Levels.................................................................................................. 54
3.7.1 Asymptomatic Hosts.............................................................................................. 54
3.7.2 Symptomatic Hosts.................................................................................................55
3.7.3 Detection Level of Microscopy..............................................................................55
3.8 Pharmacokinetics / Pharmacodynamics........................................................................55
3.9 Model of Immunity and Symptoms.............................................................................. 58
3.10 Incidence of Clinical Episodes by A ge.......................................... ............................. 61
3.11 Prevalence of Symptoms and Blood-Slide Prevalence ((p value)............................... 66
3.12 Relationship between EIR and Malaria Prevalence.................................................... 68
3.13 Prevalence by A ge......................................................................................................... 70
3.14 Multiplicity of Infection.................................................................................................70
3.15 Biting-Rate Heterogeneity and Prevalence.................................................................. 73
Chapter 4 Optimal Population-Level Deployment of Artemisinin-Combination
Therapies....................................................................................................................................... 75
4.1 Introduction......................................................................................... .......................... 75
4.2 Strategy Comparison and Evaluation Criteria............................................................. 78
4.2.1 Strategies..................................................................................................................79
4.2.2 Evaluation Criteria.......................   80
4.3 Ecological Rationale for M FT...................................................................................... 82
4.4 Results............................................................................................................................. 83,^
-4.4.1 Strategy Comparisons............................................................................................. 83
4.4.2 Further Options for Artemisinin Conservation.....................................................90
4.4.3 Sensitivity Analysis............................................................................................... 92
4.4.4 Comparison to Results in Antao-Hastings (2012)...............................................96
4.4.5 Age-targeting Distribution...................................................................................101
4.4.6 Varying the Parameter K  Which Describes the Relationship between Drug
Concentration and Mutation Probability.......................  102
4.4.7 Varying the Transmission Setting....................................................................... 103
4.4.8 Changing Distribution Based On Drug Half-Life.................................. .......... 104
4.4.9 Variation in the Surveillance Window That Determines The 10% Treatment
Threshold.............................................................................................................................. 105
4.4.10 Robustness of the Biting Model.......................................................................... 105
4.4.11 Smaller Population Size....................................................................................... 107
4.5 Conclusions.................................................................................................... 107
Chapter 5 Introducing New Biological Features......................................................   109
5.1 New Genotype Representation....................................................................................110
5.2 Partial Resistance.........................................................................................................112
5.3 Change in Infectivity Function and parasite_zeroJevel to 100 Total Parasites (2 x 
10'5/pl)l 13
5.4 Variation in Maximum Parasitaemia.............................   114
5.5 Validation................................................   115
Chapter 6 Comparison of Standard 3-Day Artemisinin Combination Therapies with 
Shorter and Longer Dosing Schedules.................................................................   120
6.1 Introduction...................................................................................................................120
6.2 Rationale for lengthen dosing schedule..................................................................... 122
6.3 Results - Changing the Length of a Single ACT Course..........................................126
6.3.1 Effect of Lengthen Dosing on Population-Level Treatment Strategies...........126
6.3.2 Comparing Different Treatment Strategies with Different ACT Course
Durations 129
6.4 Treatment Strategy Employing Multiple ACT Courses (MAC).............................. 132
6.5 Results — Evaluation of MAC Strategies................................................................... 134
6.6 Conclusions ........................................................................................................... 136
Chapter 7 Discussion................................................................................................................. 137
7.1 Individual-based Model Development........................................................................ 137
7.2 Benefits o f Multiple First-line Therapies.................................................................... 139
7.3 Benefits of Multiple ACT Courses in Individual Patients.........................................143
REFERENCES  ................................................................................................................ 147
APPENDIX............................   158
Parameter Description.............................................................................................................. 158
x
List of Tables
Table 3.1. Averaged age-specific mortality (per 1000 person-years) from seven sites in Burkina Faso,
Ghana, Kenya, Tanzania, and M ozambique........................................................................................... 51
Table 3.2. Annual mortality (per 1000) by age group, data extracted from Becher et a l 137 and Abdullah
et a l 136............................................................................................................................................................51
Table 3.3. Expected age-specific mortality per 1000 persons per year in a high-transmission region. ..51
Table 3.4. Population distribution of Tanzania................................................................................................53
Table 3.5. Maximum parasite killing rates for different antimalarial drugs123............................................ 57
Table 3.6. Half-lives o f antimalarial drugs........................................................................................................ 57
Table 3.7. EIR and clinical episodes/year by for ages 2 ,10 , and 17, extracted from 4 referenced studies.
   62
Table 4.1. Varying transmission intensity in sensitivity analysis.................................................................. 92
Table 4.2. Transmission settings used to compare with Antao-Hasting model........................................... 97
Table 5.1. Example o f EC50 matrix for 3 mono drugs (with 7 days half-life), the mutation position is 
associated with the drug ID, i.e. mutation at locus 1 cause resistance to drug 1, and each locus
have 2 alleles (naive is 0 and mutation is 1).......................................................................................... 113
Table 5.2. Efficacies o f  3 ACTs on the different genotypes......................................................................... 115
List of Figures
Figure 2.1. Individual-based simulation system design.........................................................   24
Figure 2.2. Model class diagram ........................................................................................................................ 25
Figure 2.3. Flow activity o f a simulation........................................................................................................... 25
Figure 2.4 Random class diagram....................................................................   27
Figure 2.5. Example YAML-format input file..................................................................................................28
Figure 2.6. Configuration Component class diagram ......................................................................................29
Figure 2.7. Reporter class diagram..................................................................................................................... 31
Figure 2.8. Person class diagram.........................................................................................................................33
Figure 2.9. Event class hierarchy....................................................................................................................... 35
Figure 2.10. Overall view o f the Scheduler....................................................................................................... 36
Figure 2.11. Person Index Hierarchy..................         38
Figure 2.12. Example C++ code for adding and removing a person pointer o f the
PersonlndexedByBittingLevel object.................................................... ..................................................39
Figure 2.13. Object Pool class diagram.................................................................................... *........................40
Figure 3.1. Immune acquisition by age under different kappas..................................................................... 61
Figure 3.2. The probability o f progressing to clinical disease after in infectious bite, based on host’s
immune level and the parameter z........................................................................ ................................... 61
Figure 3.3. The ratio o f the number of annual clinical episodes in 2-year olds to the number in 10-year
olds under different transmission intensity................. ........................................................................... 64
Figure 3.4. As Figure 3.3, in these simulations the treatment coverage was f -  0.5 with a drug with a 7-
day half-life.................................................................................................................................................. 64
Figure 3.5. The age-specific clinical pattern under different transmission intensity (EIR increases from
left to right and from top to bottom).........................................................................................................65
Figure 3.6. As Figure 3.5, in these simulations the treatment coverage was f -  0.5 with a drug with a 7-
day halflife....................................................................................................................................................65
Figure 3.7. The ^-value by age-group................................................................................................................ 67
Figure 3.8. As Figure 3.7, with treatment coverage was set to f -  0.5 with a single 7-day half-life drug 
o f approximately 80% efficacy..................................................................................... ............................67
Figure 3.9. Relationship between EIR and blood slide prevalence............................................................... 69
Figure 3.10. As Figure 3.9, treatment coverage is/ =  0.5 with a single 7-day half-life drug o f
approximately 80% efficacy.......................................................................................................................69
Figure 3.11. Age-specific blood-slide prevalence for different transmission intensities; k  -  1, z = 4,
treatment coverage / =  0................   71
Figure 3.12. Age-specific blood-slide prevalence for different transmission intensities; k  = 1, z = 4,
treated coverage/ =  0.5, with a single 7-day half-life drug o f approximately 80% efficacy...........71
Figure 3.13. Distribution o f number of clones per infection.......................................................................... 72
Figure 3.14. Distribution o f number o f clones per infection...........................................................................72
Figure 3.15. The sensitivities o f four key model relationships to the standard deviation in relative biting
rate. Treatment coverage/is set to 0.0.................................................  74
Figure 3.16. The sensitivities o f four key model relationships to the standard deviation in relative biting
rate. Treatment coverage/is set to 0.5.................................................................................................... 74
Figure 4.1. Expected paths o f drug-resistance evolution and corresponding malaria prevalence under
three different treatment regimes.......................           85
Figure 4.2. As Figure 4.1, 70 stochastic simulations were run in a population of one million individuals, 
in a high transmission setting (EIR=18) with 60% treatment coverage and an assumed cost o f
resistance o f 0.5% for all resistant genotypes. ...................          86
Figure 4.3. Comparisons o f MFT, five-year cycling, and sequential deployment......................   87
Figure 4.4. As Figure 4.3, figure shows NTF values from the same simulations that are plotted against
the time it takes the average resistance level to reach 1% frequency in the population................... 88
Figure 4.5. Comparisons o f artemisinin monotherapy use (AMU) for MFT, five-year cycling, and
sequential deployment................................................................................................................................. 89
Figure 4.6. Comparison using a non-ACT drug included in MFT strategy..................................................91
Figure 4.7. This boxplot shows the percent reduction in NTF achieved by using an MFT policy, when 
compared to sequential deployment (orange) and five-year cycling (red), across all parameter
combinations in the sensitivity analysis....................................................................................................94
Figure 4.8. This boxplot shows the percent reduction in NTF achieved by using an MFT policy, when 
compared to sequential deployment (orange) and five-year cycling (red), across all parameter 
combinations in the sensitivity analysis....................................................................................................94
Figure 4.9. As Figure 4.7 and Figure 4.8, stratified by EIR and partner drug half-life..............................95
Figure 4.10. Comparison of MFT and Sequential Deployment (one hundred simulations for each
strategy) under the Antao-Hastings scenario o f MOI = 2 ..................................................................... 99
Figure 4.11. Useful therapeutic lives (UTLs) o f drug strategies from Figure 4.10. All p  <  10'15 when
comparing MFT to other strategies........................................................................................................... 99
Figure 4.12. Comparison o f MFT and Sequential Deployment (one hundred simulations for each
strategy) under the Antao-Hastings scenario o f MOI - 4 ....................................................................100
Figure 4.13. Useful therapeutic lives (UTLs) o f drug strategies from Figure 4.12...................................100
Figure 4.14. Age-specific relationship between EIR and the fraction o f infected hosts that are
symptomatic................................................................................................................................................ 101
Figure 4.15. As Figure 4.3, but with k  =  0.5; i.e. the probability o f a drug-resistance mutation is
proportional to drug concentration  ................................................    102
Figure 4.16. As Figure 4.5, but with k  = 0.5; i.e. the probability o f a drug-resistance mutation is
proportional to drug concentration ................................... ............................ ............................. 102
Figure 4.17. As Figure 4.3 but in a moderate transmission setting corresponding to the fifth scenario
. listed in the Table 4 .1 .:............. ....:................................................     103
Figure 4.18. As Figure 4.3 of the main text but in a high transmission setting corresponding to the first
scenario listed in Table 4 .1 . ...........................            .103
Figure 4.19. As Figure 4.3, but two new strategies are added: MFT235 and MFT532  ............ .^..... 104
Figure 4.20. As Figure 4.19, but the mutation rate is proportional to drug concentration ( k  =  0.5)..... 104
Figure 4.21. Epidemiological scenario from Figure 4.3.......    105
Figure 4.22. Epidemiological scenario from Figure 4.3............................................................................   106
Figure 4.23. Epidemiological scenario from Figure 4.17.............................................................................. 106
Figure 4.24. As Figure 4.3 (with cost o f resistance fixed at c r  =  0.005), and population size is varied
here to see if  there are any unexpected effects at small population size........................................... 107
Figure 5.1. Class diagrams of Allele and Locus class.................................................................................... I l l
Figure 5.2. Pseudo code describes the drug resistance mutation process...................................................111
Figure 5.3. Pseudo code to calculate the cost o f resistance for a genotype............................................... I l l
Figure 5.4. Pseudo code to generate genotype string from a given ID........................................................112
xiv
Figure 5.5. Change in infectivity function. Red line shows the curve for the old version and the blue
one represents the curve for the new version.........................................................................................114
Figure 5.6. Expected paths o f drug-resistance evolution and corresponding malaria prevalence under
three different treatment regimes.............................................................................................................118
Figure 5.7. As Figure 5.6, but the mutation rate is ten times higher.......................................................... 118
Figure 5.8. As Figure 4.3, but with new model features as described in this chapter............................. 119
Figure 6.1. The effect o f different dosing days on treatment efficacy as measured by microscopy and
PCR..................................................................................................................................................  124
Figure 6.2. The asexual parasite density over 28 days when lengthening dosing from 1 to 6 days 124
Figure 6.3. As Figure 6.2, but ASAQ is used instead o f AL....................................................................... 125
Figure 6.4. As Figure 6.2, but DHA-PPQ is used instead o f AL................................................................125
Figure 6.5. The effect o f lengthen dosing days for MFT Strategy...............................................................127
Figure 6.6. As Figure 6.5, the strategy is Sequential Deployment Strategy. ........   128
Figure 6.7. As Figure 6.5, the strategy is 5-year Cycling Strategy.................      128
Figure 6.8. Comparisons of MFT, five-year cycling, and sequential deploym ent. ................   130
. Figure 6.9. As Figure 6.8, all therapies are 3-day dosing.......................... 130
Figure 6.10. As Figure 6:8, all therapies are 4-day dosing............................................   131
Figure 6.11. As Figure 6.8, all therapies are 5-day dosing..............................................    131
Figure 6.12. As Figure 6.8, all therapies are 6-day dosing......................................         131
Figure 6.13. Comparisons of MFT and MAC strategies................................................ ...........    135
xv
List of Abbreviations
ACT Artemisinin Combination Therapy
AL Artemether-Lumefantrine
AMU Artemisinin Monotherapy Use
ASAQ Artesunate-Amodiaquine
ASMQ Artesunate-Mefloquine
ASSP Artesunate-SP
CQ Chloroquine
DDT Dichloro Diphenyl Trichloroethane
DHA-PPQ Dihydroartemisinin-Piperaquine
DES Discrete Event Simulation
E IR  Entomological Inoculation Rate
GM PD Geometric Mean Parasite Density
GUI Graphical User Interface
H PC Human Population Component
IRS Indoor Residual Spraying
ITN Insecticide-Treated Bed Net
LLIN Long-lasting Insecticide-Treated Nets
M AC Multiple Artemisinin Courses
M ACR Multiple Artemisinin Courses Randomization
MDA Mass Drug Administration
MSAT Mass Screen And Treat
M FT Multiple First-line Therapy
M O I Multiplicity O f Infection
NTF Number of Treatment Failures
PK/PD Pharmacokinetic/Pharmacodynamic
RDT Rapid Diagnostic Test
SDC Statistic and Data Collection
Seq DepI Sequential Deployment
SP Sulfadoxine-Pyremethamine
TM E Targeted Malaria Elimination
UTL Useful Therapeutic Life
W HO World Health Organization
ws60 60-day Window Size
w sl20 120-day Window Size
w sl80 180-day Window Size
xvi
Chapter 1. Introduction and Literature Review
Chapter 1 
Introduction and Literature Review
Malaria is one of the world’s most deadly diseases and is believed to have existed in humans 
for tens of thousands of years2-4, and detailed records of malaria clinical symptoms, 
transmission routes, and treatment options began to be recorded at the end of the 19th century5. 
In the middle of the 20th century, malaria was endemic in more than 143 countries, with over 
half of the world’s population at risk of infection6,7. The two major and geographically most 
expansive species were, and still are, Plasmodium falciparum and Plasmodium vivax, with three 
other human-adapted Plasmodium species accounting for an unknown proportion of 
infections8. In the 1950s and 1960s, rapid economic development in some regions of the world 
along with a World Health Organization (WHO) malaria eradication campaign helped shrink 
the global malaria map, but the disease is still endemic in most of Africa and parts of Asia and 
South America9. At the turn of the century, malaria caused approximately 300 million annual 
clinical malaria episodes and over one million deaths10. After a renewal of interest in global 
malaria control over the past ten years, case numbers have been cut approximately in half, and 
the number of malaria deaths is around 500,000 per year1.
Treatments for malaria have existed for hundreds of years, and the 20th century saw an 
acceleration of discovery of new antimalarial drugs11,12. The discoveiy of these new drugs, 
however, was accompanied by the evolution of drug resistance in one or some of the parasite 
species that cause malaria12,13. Chloroquine (CQ), the most commonly used antimalarial in the 
20th century, lost its efficacy in the 1970s and 1980s; this was followed by an increase in usage 
of sulfadoxine-pyremethamine (SP), and SP-resistance appeared soon thereafter12-16. Of the 
dozens of widely used antimalarials, only the artemisinin-class drugs have not been adversely 
affected by drug-resistance evolution, but recently a several P. falciparum genotypes partially- 
resistant to artemisinin have emerged in Southeast Asia17-21.
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As malaria elimination and eradication plans move forward in the 21st century, these massive 
global health efforts must be pursued alongside a rational drug management strategy that seeks 
to minimize both (1) the future expected level of drug-resistance, and (2) the number of malaria 
cases and deaths in the world each year. This complex problem is amenable to analysis by 
mathematical modeling, and my PhD thesis will develop an individual-based modeling system 
to predict long-term trends in malaria epidemiology and evolution, in the context of different 
antimalarial treatment strategies.
This chapter, after a brief introduction to malaria, reviews what is currently known about 
mathematical modelling for malaria including compartmental and individual-based models, 
and lastly describes the rationale and objectives of the thesis.
1.1 Malaria
Malaria is a vector-borne disease that caused by Plasmodium parasites. There are five species 
of Plasmodium that cause disease in human, namely P. falciparum, P. vivax, P. ovale, P. 
malariae, and P. knowlesi. Among those species, P. falciparum is the deadliest one which 
accounted for more than half of symptomatic cases and 90% deaths from malaria as estimated 
in Africa 1993 22. According to the World Malaria Report 2015, P. falciparum is the most 
prevalent on the African continent, and is responsible for most deaths from malaria23.
P. falciparum is spread from human through human by female Anopheles mosquitoes 4. Within 
the host, the parasites proceed through a series of developmental stages. When an infectious 
mosquito bites a person to take a blood meal, the mosquito can inoculate sporozoites (a 
particular developmental stage of Plasmodium species) into human’s blood stream and these 
sporozoites invade the liver within half an hour. In the liver, they develop into around 30,000- 
40,000 merozoites over the duration of one to two weeks, after which they exit the liver cells 
to invade the red blood cells. Inside red blood cells, the merozoites continue to grow and divide, 
eventually reaching parasite population sizes approaching 1011 or 1012 parasites24. Some 
merozoites eventually develop into gametocytes, which are the only parasite stages that can be
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taken up by mosquitoes during blood meals. Inside the mosquito, the gametocytes undergo 
sexual reproduction (haploid to diploid to haploid) and then develop into sporozoites that enter 
the mosquito’s salivary glands after about ten days. At this point, the infected mosquitoes are 
infectious and the transmission cycle is re-initiated by biting a human and inoculating him or 
her with sporozoites.
During the transmission cycle, when asexual blood-stage parasites reach a total population size 
of around 108 or 109 25, the host will experience symptoms that include fever, muscle aches, 
sweats, chills and vomiting26. The WHO-recommended treatment for symptomatic or clinical 
malaria is artemisinin combination therapy (ACT), which currently would be one of artemether- 
lumefantrine, artesunate-amodiaquine, dihydroartemisinin-piperaquine, artesunate- 
mefloquine, or artesunate-SP27. If a naive patient does not receive any treatment or receives 
inadequate treatment, the infection can become severe and life-threatening. However, people 
who live in endemic areas acquire immunity through continuous natural exposure to malaria 
parasites, and this immunity can protect them from the severe effects of malaria or progression 
to symptoms28,29; the drawback of not experiencing symptoms is that these individuals are likely 
to not be treated and are thus likely to carry malaria parasites in their blood for prolonged 
periods30,31.
1.2 Malaria Control Strategies
1.2.1 Vector Control and Protection against M osquito Bites
To reduce the transmission between vectors and human, many attempts have been made to 
reduce the source of infection and to protect humans from infectious mosquito bites. The two 
most popular and effective methods in vector control are indoor residual spraying (IRS) and 
insecticide-treated bed nets (ITNs).
Indoor residual spraying is a widely used method that involves spraying insecticides on the wall 
inside a house. Mosquitoes usually rest on the wall after taking blood meal, so if the wall was
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surfaced by insecticides it can kill mosquitoes before they can bite another person, and thus 
reduce the transmission of malaria32. However, this method has its flaws. Mosquitoes can easily 
evolve to become resistant to chemical insecticides, and thus national malaria control programs 
have to perform entomological surveys and change the chemicals frequently to maintain the 
efficacy of IRS. In addition, due to the irritation caused by IRS, mosquitoes (and their 
subsequent generations) have adopted new behaviors, e.g. new time or place of blood meal or 
new host, to avoid the exposure to insecticides and maintain their reproduction33. For example, 
studies conducted in Senegal34 and Benin35 showed that A. gambiae changed their biting habits 
from after midnight to about before 10 p.m. when most people are not yet under a bed net. The 
studies from Benin also showed that, just one year after the large-scale introduction of ITNs, 
A.funestus, which used to bite inside people’s homes, began to take more frequent blood meals 
outdoors; the proportion of outside bites increased from 45% before intervention to >75% after 
the intervention35.
Mosquito nets help prevent mosquitoes biting people when they are sleeping, as A. gambiae, 
the major malaria vector species in Africa, usually have their blood meal at night 36,37. Hence, 
the use o f mosquito nets can reduce the transmissibility of infectious mosquito to human.. 
However, a simple net is not a sufficient shield from infection and it is often soaked with 
insecticide to kill mosquitoes when they land on the net. These insecticide-treated nets (ITNs) 
also have the advantage of also providing some protection to other people, including people in 
the same room but not under the net. The use of ITNs has been shown to be an effective method 
to prevent malaria in children and pregnant women. Under research study conditions, ITNs 
usage has been associated with significant reduction in malaria morbidity and all-cause child 
mortality38-41. However, due to the lack of knowledge of people living in the endemic areas, 
there are some concerns about the misuse of ITNs, i.e. using nets for window curtains, drying 
fish, or fishing, etc42,43. Those misuse may lead to a reduction in the efficacy of ITN control 
programs.
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1.2.2 Treatment Strategy in Individual-scaled and Population-scaled
Prophylaxis is a recommended method of malaria prevention for people that are going to travel 
to a malaria-endemic area. Due to the fact that Plasmodium species are resistant to one or more 
antimalarial drugs the choice of prophylaxis medications highly depends on location. Another 
possible prevention strategy is vaccination. Although malaria vaccines have been under 
continuous development for several decades and they still cannot offer lull protection from 
infection. As of mid 2015, there is no malaria vaccine that has been qualified or recommended 
by WHO.
Two traditional low-cost treatments for malaria are chloroquine (CQ) and sulphadoxine- 
pyrimethamine (SP). However, due to drug resistance, those drugs are ineffective in Asia and 
some parts of Africa for treatment of both P. falciparum and P. vivax infections15. These drugs 
have been replaced by artemisinin-based drugs over the past decade, and artemisinin derivatives 
have become standard treatment as WHO recommendation27. Although artemisinin is a 
powerful drug with very high parasite killing rate, it has a very short drug half-life. To improve 
the efficacy and to reduce the risk of resistance emerging to artemisinin, a combination of 
artermisinin with a longer half-life partner drugs is now recommended as the best use of 
artemisinin drugs. Some popular combinations that are used in many countries are Artemether 
Lumefantrine (AL), Dihydroartermisinin Piperaquine (DHA-PPQ), Artesunate Amodiaquine 
(ASAQ). Since 2006, ACTs have been globally recommended by WHO and artemisinin 
monotherapy has been actively discouraged44. However, partial resistance to artemisinin drugs 
has emerged as mentioned in the first reports coming from Southeast Asia in 2008 17,21’45>46. The 
genetic cause of this resistance appears to be K13-propeller gene mutations and these have been 
recently identified as being under positive selection 19.
One of the best known population-scale strategies to reduce and potentially eliminate malaria 
is mass drug administration (MDA)47. MDA is a strategy in which everybody in a population 
is treated during the same time period (a few days or a week, typically) with a curative dose 
regardless of whether the treated person is infected or symptomatic. However, there are some
Chapter 1. Introduction and Literature Review
concerns that using MDA may result in sub-therapeutic levels of drug in a large number of 
persons and thus increase the risk of developing drug resistance48. This strategy is currently 
being implemented in 11 villages in Southeast Asia in a clinical trial study known as “Targeted 
Malaria Elimination” (unpublished study).
One major concern for MDA strategies is that they may not be very effective in high 
transmission areas where individuals are very likely to be bitten and reinfected shortly after the 
MDA strategy has completed. A recent comparison of mathematical models by the World 
Health Organization 49 showed that MDA strategies can be effective in low transmission 
regions, but less so in high transmission regions as the application of MDA is normally followed 
by a rebound in prevalence. Historically, vector control has been viewed as the best-choice 
control strategy for high transmission regions50.
Another variation of the MDA strategy is a “mass screen and treat” strategy (M SAT)51. All 
people in a population are screened with a high-sensitivity malaria diagnostic test (normally 
RDT) and those with positive results will receive treatment. This intervention is based on the 
assumption that people who are gametocytaemic will have sufficient parasite density to be 
detected at the time of screening.
Another hypothetical population level intervention strategy is the deployment of multiple first- 
line therapies (MFT)52. While most national treatment policies recommend a single first-line 
therapy for uncomplicated malaria, an MFT policy would recommend the simultaneous 
deployment of different first-line therapies for different patients, as this type of public health 
policy may delay the emergence of resistance and thus result in a lower number of treatment 
failures52. This strategy is based on the concept that it is difficult for a pathogen to adapt to a 
constantly changing environment. Thus, in using MFT in a population, the parasites would 
experience difficulty evolving drug resistance as they have higher chance of encountering 
different drugs upon each successive new infection.
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1.3 Mathematical Model for Malaria
Many mathematical models have been developed to evaluate malaria public health policies. 
Some models focus on vector control and thus must have detailed vector dynamics in the model, 
while other models may evaluate treatment strategies and may be more focused on drug- 
resistance details, pharmacokinetics, and pharmacodynamics. This leads to two current trends 
in developing malaria models, those focused on vector interventions and those focused on drug- 
based interventions.
1.3.1 Compartmental Model
The very first mathematical model for malaria was developed by Ronald Ross in 1911 at the 
same time as his discovery that malaria parasites are transmitted by mosquitoes53. Ross wrote 
down many equations for the different parts of the malaria transmission cycle. His approach 
included both humans and mosquitoes and was centered around (1) a ‘happenings rate’ that 
described the frequency of occurrences of mosquito bites on humans and (2) a basic 
reproduction number that described, under static or equilibrium conditions, the number of 
secondary malaria infections generated by a single human case, as a function of the life course 
of the parasite in mosquitoes and humans. In Ross’s models that allowed for recovery, the 
happenings rate was accompanied by a recovery rate and the resulting system took the shape of 
a traditional Susceptible-Infected-Susceptible (SIS) model. Using these equations, Ross was 
able to show that reduction of the happenings rate below a certain threshold would stop 
transmission causing the parasite to die out (if the reduction were permanent). A reduction in 
the happenings rate could be achieved in multiple ways, for example by shortening the life of 
a mosquito or by increasing the recovery rate in humans and thus reducing the chance that an 
uninfected mosquito becomes infected after a bite. Ross’s approaches and methods have been 
reviewed in many places (e.g. Fine 1975 54, Smith and Mckenzie 2004 55) and his happenings 
rate still forms the basis of how dynamical epidemiological models are structured.
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Forty years later, Ronald Ross’s equations began to be modified by George Macdonald. 
Macdonald added an exposed state to the mosquito component56 and began fitting his EIR 
equation to field data 57. This modification was based on the knowledge of the parasite 
development period inside the mosquito. The results from this model implied that the crucial 
part of malaria transmission is the survival of the infected mosquito. Macdonald suggested that 
the worst conditions known in Africa could therefore be overcome by an increase in the daily 
mortality of the vector from about 5% to about 45%. This provided the rationale for a WHO- 
coordinated campaign that used DDT to kill mosquitoes in order to eliminate malaria in Africa 
58>59. Macdonald worked explicitly on elimination models looking at population growth rates 
in both P. falciparum and P. vivax 59, the observed and modeled rates of decline when 
transmission is interrupted60, and later stochastic computer models aimed at evaluating control 
strategies61.
Data collected through the global WHO malaria eradication program of the 1950s and 1960s 
led to many new analyses on basic malaria epidemiology and a second effort in the 1970s of 
controlling and understanding malaria in certain parts of West Africa (notably Garki, Nigeria). 
Dietz et a l 62 used periodic biting and prevalence surveys to fit a mathematical model to one 
year of malaria transmission data in Garki, and this work gave the community its first statistical 
estimates of recovery rates (infection duration) in a population where immunity to malaria could 
be gained and lost and could influence the rate of recovery. Bekessy et a l63, Cohen and Singer 
64, and Singer and Cohen 65 adopted an approach based on Markov models describing host 
states, and performed inference on the model’s transition probabilities. These analyses also used 
Garki data and were able to infer age-specific recovery rates. This level of inference was at the 
limits of what could be done, based on the data and computational methods available at the 
time.
The next natural step in the evolution of malaria models should have been the evaluation of 
interventions based on the well-parameterized models that emerged from the 1970s focus on 
detailed longitudinal studies. However, mathematical modeling was yet to mature into the
Chapter 1. Introduction and Literature Review
computation-intensive, connected, fast-moving field that it became at the beginning of the 21st 
century. Simplified models were still being used to evaluate things such as household-based 
intervention strategies 66. A theoretical focus on model analysis rather than data analysis put 
certain practical malaria intervention questions out of reach 67. And a lack of experience in 
drug treatment modeling caused some very useful intervention models to be overlooked 
because they were conceptually ahead of their tim e68 (Curtis and Otoo, 1986; 13 citations in its 
first 10 years after publication).
In 1983, Nedelman69 conducted a deeper investigation on the Dietz et al. model (1974) in order 
to achieve better understanding on the model’s assumptions, such as constraints on parameters, 
inoculation and recovery rates, and data-fitting methods. Nedelman assumed that the 
inoculation rate is proportional to the vector density and that the proportion depends on the 
following rationale, that the expected lifetime of a mosquito should be relatively short to both 
the human infectious duration and the expected time until a naive mosquito becomes infected. 
The fitting results showed some inconsistencies with Dietz et al. model, that could be due to 
the fact that Nedelman used a different approach in estimating the inoculation rate; instead of 
directly using the entomological data, Nedelman calculated the inoculation rate based on the 
estimation of human and mosquito susceptibility, using infant infection data and sporozoite rate 
data. The hypothesis that the inoculation rate is proportional to vector density was tested by 
the fitting ability of the new model. Although this approach provided a better understanding 
on the construction of the estimate of inoculation rate, Nedelman’s estimates resulted in poorer 
fits than the original Dietz estimates in some cases. Therefore, it is unclear which model is 
better at describing the mechanisms of malaria transmission.
In 1989, Halloran et al. 70, based on the Dietz’s model, developed the first malaria model to 
have the ability to evaluate the effect of malaria vaccine programs by introducing acquisition 
and loss of stage-specific immunity. As expected, the results showed that the prevalence of 
malaria wanes after implementing a vaccination program and increases if the program is 
stopped. If the vaccination program cannot eliminate malaria, the total transmission during the
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rebound phase overshoots the pre-program prevalence and the magnitude of the rebound 
increases as the proportion of the population vaccinated increases. Elimination of transmission 
could be achieved when the proportion of the vaccinated population reaches a certain threshold; 
however, it was difficult to have confidence in the exact value of the threshold vaccination level 
due to there being many assumptions about malaria immunity and the effect of the vaccine. 
One of the biggest drawbacks of this model is that the vaccines were assumed to be 100% 
effective, which is unrealistic, as through 2016 there is still no highly efficacious vaccine 
available.
Another mathematical model for vaccination and vector control was developed by Aron in 
198771. The analysis of this model showed that malaria elimination can be achieved by 
combining both vaccination and transmission control that reduce the R0 to below unity. When 
malaria control cannot eradicate the disease, this can lead to a perverse situation because the 
prevalence of symptomatic disease may increase. This is based on the assumption that the 
im m u n ity  is maintained by repeated exposure to infections; any intervention that affects or 
interrupts the transmission will reduce the immunity level in the population which leads to a 
change in the age distribution of clinical malaria, especially among adults. Aron also had a 
concern about the effects of the control program that would be sensitive to immunological 
assumptions made in the model, for example the relative contribution of immune individuals to 
the force of infection and the rates of waning and acquisition of immunity as the transmission 
setting changes.
Until 1991, there was no malaria mathematical model that included both population-level 
antimalarial treatment coverage and drug resistance (to the best of my knowledge). In 1991, 
Cross and Singer published a hybrid epidemiological and genetic model that allowed for the 
selection of resistant strains to occur based on the effectiveness of the drugs used72. The model 
was calibrated with the field data of pyrimethamine resistance in Tanzania73. The results from 
the model suggested that sparing use of new anti-malarial drugs is recommended to minimize 
the selective pressure on the parasite. However, due to the complexity of the model, some
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epidemiological features were omitted. The model did not take immunity acquisition or the 
resistant strain’s cost of resistance into account.
A latent period in humans was introduced to malaria models by Anderson and May in 1991 74. 
The model reconfirmed the conclusion by Macdonald 56 that an intervention that targets adult 
mosquitoes was more effective than the one that targets larval stages. These models also 
included age structure by considering the population density in the infectious class as a function 
of age. Then, the age-structured model was incorporated with a simple immunity model so that 
the model could reproduce the age-prevalence curve that was observed in data. However, this 
age dependence of infection approach did not make the model fit well when results showed a 
very long duration of infection. This was due to the limitation of the model which did not take” 
into account the interaction between age and immunity as well as some other epidemiological 
features.
The 1990s saw an increase in mathematical modeling publications relative to the 1980s. 
Although it was not yet possible to run large-scale individual-based simulations, numerical 
simulations for ordinary differential equation models could now be easily obtained and discrete­
time models could be implemented easily. Antibiotic resistance emerged as an area of focus 
for mathematical modelers, and in malaria the first drug-resistance models began to be 
published after Curtis and Otoo68. The initial approach to drug resistance in malaria was rooted 
in population genetics (Dye 1991 75, Dye and Williams 1997 76, Hastings 199777, Hastings and 
Mackinnon 1998 78, Mackinnon and Hastings 1998 79, Koella 1998 80) and the focus was on 
identifying mechanisms that were critical to understanding the evolutionary epidemiology of 
malaria drug resistance. From these papers, we learned about the importance of the cost of 
resistance, multi-clonality, linkage, recombination, immunity and the step-wise nature of 
mutation.
Most compartmental models are not able to have simple features in different heterogeneities in
the human population, e.g. age structure, immunity, within-host parasite density and diversity,
relative attractiveness to mosquitoes, or heterogeneity in the PK/PD model. The reason for this
11
Chapter 1. Introduction and Literature Review
is that those variables are most commonly modeled on the individual level but compartmental 
models are designed to look at groups of individuals. To meet these challenges, individual- 
based models are used to introduce heterogeneity at the individual level.
1.3.2 Individual-based Model
By the beginning of this century, computational power was sufficient to run both large-scale 
individual-based models and large compartmental models. The last decade and a half have seen 
a wide expansion in the use of mathematical models, as development and run-time have both 
become much shorter since 2000.
McKenzie developed a discrete-event simulation for malaria in 1998 and 200181. This model 
was developed in order to estimate the elimination probability of malaria in populations by 
utilizing computer techniques to extend classical compartmental models at the individual level. 
This can be considered as the first basic individual-based model for malaria. To simulate 
malaria transmission as well as the P. falciparum life cycle within hosts and vectors, a single 
“time-line” variable was used to schedule an event at a specific time. This model only keeps 
track of individual states, but not parasite density and it does not allow superinfections. There 
is no clinical or asymptomatic state in the model. An individual can be in one of four states: 
susceptible, infected/exposed, infectious and recovered with waning immunity. A simple 
immunity model was introduced into the simulation where individuals are at a certain 
probability of re-infection based on their current immunity level (ranging from zero to one). An 
individual has fully effective immunity at the beginning of an infection, and the level of 
immunity wanes exponentially to zero after the individual reaches the end of the infectious 
state.
Later in 1999, McKenzie extended his model to allow superinfection of multiple species, P. 
falciparum and P. vivax, in the transmission model82. The model shows that a misdiagnosis of 
a single P. vivax infection for a mixed-species infection can lead to a significant increase in P.
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falciparum parasite density after treatment for P. vivax. The number of individuals is 500 and 
the number of vector varies from 5000 to 50000 in their evaluations.
Another individual based model was developed in 2003 by Gu et.al83. Gu’s model included a 
simple immunity model and human immigration to consider the effect of importation of new 
cases in a scenario of malaria elimination. Multiple intervention strategies, from reducing 
transmission through bed net use to active case detection and treatment of diagnosed malaria 
infections, were employed. The results showed that local elimination could be achieved in a 
low transmission area. For high transmission areas, however, the probability for elimination 
was low even with a high coverage of whichever intervention strategy was used. In addition, 
the results also showed that a small level of immigration of new infections (>0.3% population 
size) would prevent local extinction of malaria. This model simulated both human and vector 
individuals and was based on an SIS model. The initial population size is 500 which is relatively 
small.
One of the most important models of the past fifteen years was developed by a team of 
researchers at the Swiss Tropical Institute; it is an individual-based model that is able to 
simulate the effect of different types of intervention strategies for malaria control 84-87. The 
model is called Open Malaria and its source code is available for free online access 88. Open 
Malaria is an individual-based model with a five-day time steps that looks at different aspects 
of the malaria transmission process in order to evaluate the impact of different types of 
vaccines. Each individual keeps track of within-host asexual parasite densities. This is an 
important feature which allows mathematical modelers to investigate the effects of parasite 
density on the transmission process. High parasite densities are predicted to be associated with 
clinical malaria, which helps to model the treatment seeking process and to extend the model 
to have severe and a malaria-induced mortality feature. The parasite densities determine the 
infectiousness of individuals to mosquitoes. The original version of the individual based model 
is the “non-vector” version, the vector component, which is a compartment model, was 
integrated into the original model later in 2008 to evaluate ITNs, IRS intervention strategy 86,89.
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By separating the model into different processes, the Open Malaria model can evaluate four 
types of vaccines. Pre-eiythrocytic vaccine acts on reducing the EIR experienced by individuals 
in the model. The asexual blood-stage vaccine can be simulated by a function that reduces the 
parasite densities. The transmission blocking vaccine can be modeled by modifying the 
individual infectivity function, and anti-toxic vaccine reduces the morbidity and mortality 
rate84.
For each epidemiological process, the model was validated/fitted with multiple different types 
of data. The model used the seasonal measured EIR from field data as the input to the 
transmission process 90. The malaria therapy data were used to fit the relationship between 
asexual parasite density and infectivity to vectors 91. Age-prevalence and incidence data from 
different sites in Africa were used to validate the immunity behavior of the model85. Due to the 
high computational demands and the complexity of the fitting process, different sub-models 
were fitted separately84.
The PK/PD model was introduced into the model in order to evaluate intermittent preventive 
treatment against malaria in infants (IPTi) using SP 92. Open Malaria also includes a drug 
resistance model but no evaluation has been published on this topic93. As of writing, the model; 
does not appear to simulate mutation or genetic recombination, hence it cannot simulate 
resistance evolution. The model does have heterogeneity in biting rate in individuals, as 
implemented via a differential biting rates according to age and body surface area. The 
computation cost for a simulation with 10,000 individuals with 1-day time step is said to be 
around 2 hours.
Another important individual-based model was developed over the past 7-8 years by modelers
at Imperial College in London. Based on a compartmental model developed by Filipe et.al.94,
that has both human and vector components, Griffin’s model used individual-based approach
to model the human components and a stochastic compartmental model to describe the vector
component95. The initial purpose of the model was to evaluate vector control interventions,
thus the vector model included 3 different species of mosquito, i.e. An.funestus, An. arabiensis,
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and An. gambiae. So that, the model has the flexibility to investigate different geographically 
location where the distribution of the species is different. The transmission rate of the model 
was controlled by the emergence rate of the mosquitoes which can vary the ratio of vectors to 
humans. However, there is literally no way to validate the fitted number of mosquitoes to match 
with the epidemiology data.
Turning into human component, the model implemented three different types of human 
immunity to malaria; i.e. infection-blocking immunity, clinical immunity, and parasite 
clearance immunity. Three different assumption on immunity acquisition functions were used 
in the model, namely that immunity increases with age only, immunity increase linearly with 
exposure, and immunity is acquired with exposure but limited to new infections. The immunity 
status of each individual is calculated based on transmission intensity, age, and relative biting 
rate of the individual, which means that individuals with the same age and the same relative 
biting rate will have the same immunity status. Thus, in the model, the individual does not 
directly acquire immunity through infections and the individual’s immunity status does not 
reflect the true infection history of an individual. For example, if there is a sudden drop in 
transmission rate that is caused by an intervention, the immunity will decrease immediately 
according to the transmission rate; this is implausible.
The model has heterogeneity in the biting rates which assigned to each individual following a 
log-normal distribution. However, the Griffin model does not have a clear discussion about the 
role of relative biting rates on the malaria transmission dynamic. In addition, the model does 
not explicitly keep track of the within host parasite density and thus will not provide an adequate 
evaluation on many treatment interventions.
The population size is assumed to be static overtime, which means that there is no age structure 
shifting in the simulation. There is no clear information on birth, death or age changing over 
time of an individual, which is an important feature where immunity in the model is 
implemented, as age-dependent immunity is said to be acquired immunity over the lifetime of 
an individual.
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The model’s parameters were fit with the age-stratified prevalence and clinical incidence data. 
The fitting results showed that the infection-blocking immunity is acquired with exposure bit 
limited to new infections and clinical immunity is acquired with exposure. The model can 
reproduce the log-linear relationship between EIR and prevalence in collected data. There is a 
close correlation between the posterior estimate of EIR and the measure EIR.
The model is a closed-source model, and a GUI software is available 96. However, the 
population size in the GUI software is fixed to 1,000 for faster performance. With a small 
population size, the disease tends to died out when population prevalence is less than 0.1%. 
Finally, I was not able to observe the performance of the model for higher population size, but 
is mentioned in other papers that the model takes a few hours to simulate 90 years with 100,000 
individuals97.
Improvements to the model were introduced in 2014 which included the improved fitting to the 
clinical incidence 98. There were modifications to the function of immunity to help the model 
fit to data, however there were no changes in the underlying mechanism in the model.
In summaiy, Griffin’s model is good at evaluating vector control interventions (e.g. ITNs or 
IRS) but not suitable for evaluating the action of antimalarials due to the lack of a within-host 
model, within host PK/PD heterogeneity and drug resistance mechanism.
A third important model developed over the past decade is the Epidemiological Modeling 
(EMOD) model or “kernel” developed by Institute of Disease Modelling in Seattle. The EMOD 
source code is freely available " . Initially, EMOD was an individual-based model that focused 
on simulating the mosquito life cycle and ecology 10°. The main purpose of the model was to 
evaluate the vector control interventions (e.g. ITNs, IRS). Thus, EMOD had many details on 
the mosquito life cycle that took into account different stages of vector development. To 
simulate the infection process to mosquito, a simplified human disease model was used, with 
22-day latent period from bite to infectiousness. The model allowed a maximum of five 
simultaneous infections within an individual. This model provides a flexible framework that is
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able to explore the effects of a combination of multiple vector control interventions on the 
dynamics of vector population and disease transmission.
Immunity to malaria was introduced in the human component in 2012 101. Instead of looking at 
age-dependent immune factors to fit with the age-pattem prevalence data, EMOD uses the 
parasite antigenic diversity to explain the age-trend data 102. The model has the ability to keep 
track of a population with different number of merozoites-surface antigens, PfEMP-1 variants, 
and minor antigenic epitopes associated with infected red blood cells. Thus, the clinical 
progression and parasitological immunity is determined by the adaptive immune response to 
specific antigens. This approach provides a better explanation on immunity acquisition through 
time compared to other models.
The PK/PD model was introduced to EMOD in 2015 in order to compare the used of DHA- 
PPQ and AL in a mass drug administration program 103. The results showed that MDA with an 
ACT which has a longer half-life partner drug would have resulted in better outcomes under 
high transmission with moderately high coverage. In addition, adding primaquine in MDA will 
have the largest effect in reducing prevalence when coupled with long-lasting prophylactic 
ACT. The PK model was described by a 2-compartment pharmacokinetic, fast decay rate for 
distribution phase and slow decay rate for elimination phase of the drug concentration; and the 
PD model followed the Hill equation 104.
According to the model’s document, EMOD uses a 24-bit barcodes to represent different 
parasite strains 105. It also has the recombination feature within mosquito when mosquito bites 
an infected individual carried more than one strain. However, in the current version, the parasite 
strains are only used to show the distribution of parasite strains in population across multiple 
transmission seasons. Different parasite strains have no effect on the antigenic presentation and 
drug action on resistance strains.
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In brief, the EMOD model should play an importance role in malaria eradication policy by 
having the ability to estimate the impact of ecology, vector behavior and the risk of re- 
introduction of disease from migrations to a location where elimination has been achieved .
In a recent publication, Open Malaria, Griffin and EMOD model were used to evaluate the 
public health impact and cost-effectiveness of the phase-3 malaria vaccine candidate called 
RTS,S/AS01 106. Basically, there is are no major differences in the underlying mechanisms of 
these models. These three models underwent a harmonization and validation exercise which 
illustrated their ability to represent similar patterns for some key features of malaria 
epidemiology, e.g. EIR-prevalence, prevalence-incidence, and age-incidence relationships. 
However, in all models, the human population was fixed as a non-growing static population 
with 100,000 individuals. This mean that the immunity status of an individual is determined by 
his age and the transmission setting, but not by the history infection of that individual. This way 
of implementation could be used to evaluate the short-term effects of a vaccination intervention 
but may not be the optimal way for evaluating long-term effects, due to the fact that any 
intervention that reduces exposure in children would shift the burden of malaria into older age 
groups.
As shown in a Lancet publication in September 2015, all three models were run with a 5-day 
time step 97. To simulate the dynamic of the malaria transmission, 5-day time step is an 
acceptable duration. However, to evaluate intervention that involves antimalarial acting and 
resistance, a smaller time-step, at least 1-day time step, is a must to maintain the realism of the 
simulation.
With a small population size, the outcomes have a wide range of variability. With larger
population size, results are more predictable and closer to their expected values. So far, the
number of individuals in the published individual-based model were set to be around 100,000
individuals to have a suitable running time for large scale analysis. Thus, there is a need for a
malaria simulation that can comfortably run with a larger number of individuals, with better
computational performance and equal or better epidemiological realism.
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In summary, the key projects in this area have been the OpenMalaria project run out of the 
Swiss Tropical Institute 84, the development of individual-based models by a team of 
researchers at Imperial College95, and the development of EMOD software (started in the year 
2011). None of these large projects have begun focusing on drug resistance (however, between 
2014 and 2016 this has begun to change), and for this reason during my PhD I set out to build 
an individual-based model similar to existing ones, but with a focus on drug resistance evolution 
and drug-resistance management strategies.
1.4 Rationale of the Thesis
It is clear that there are limitations of using mathematical models, for example, to predict the 
effects of antimalarial drugs on malaria transmission and host immunity due to the lack of 
knowledge on malaria immunology. As eradication plans are moving forward, a broad and 
sustainable policy is crucial to guarantee that reductions in malaria transmission are achieved 
and maintained. However, it is widely known that any long-term treatment policy with a high 
coverage would lead to rapid evolution of antimalarial resistance. Without the help of large- 
scale planning from mathematical models, we would be facing the risk of emerging and wide­
spread antimalarial drug resistance, or more specifically, the loss of artemisinin efficacy that 
would endanger the health of hundreds of millions of people where artemisinin combination 
therapy is still the primary treatment for malaria. Thus, despite of its limitation and caveats, 
mathematical models are important auxiliary tools in helping contain the risk of drug resistance. 
In addition, mathematical modeling is the only way to evaluate population-level treatment 
strategies since we cannot run a clinical trial for twenty years in order to compare long-term 
outcomes on drug resistance evolution.
Moreover, to evaluate the effects of individual heterogeneity, an individual-based model is the 
appropriate approach, when compared to compartmental models, because individual-based 
models keep track all different individuals in the population while compartmental models only 
keep track of groups of individuals who have similar characteristics.
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Because drug resistance mutations occur at the individual level, individual-based simulation is 
an appropriate method to capture the whole picture of resistance evolution and the spread of 
drug resistance in the population.
The compartmental model developed by Boni et.al. shows potential results for MFT which, 
according to that paper, is associated with a lower number of treatment failures compared to 
other strategies52. In this thesis, I aim to re-evaluate these results with an individual-based 
model.
1.5 Aims
The aims of this thesis are:
• to build and develop an individual-based modeling framework for Plasmodium 
falciparum malaria
• to compare the use of multiple first-line therapies (MFT) to the status quo strategies
• to determine if there is a benefit to using artemisinin combination therapies (ACT) in 
an MFT strategy, and if drug diversity in the partner drugs is sufficient to delay the 
onset of artemisinin resistance
• to experiment and combine other new treatment strategies (for instance, Multiple 
Courses of ACT for a single patient)
This thesis is focused on the following objectives:
• Firstly, an individual-based simulation is developed. This model should have not only 
high performance that can be run with millions individuals for 30 years, but also 
extensibility which would allow the model to adapt to changing requirements in later 
stage of development (Chapter 2 and Chapter 5).
• Secondly, this model has to be validated by acquiring parameter values directly from 
the real data or exhibiting key features of malaria epidemiology (Chapter 3).
• Thirdly, the model should be able to compare the benefit of using MFT to other
strategies (fixed-time cycling and sequential adaptive cycling) (Chapter 4).
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• And fourthly, the model should be upgraded to evaluate new treatment strategies where 
a dosing schedule can be lengthened or manipulated to allow the use of multiple ACTs 
in one course of treatment (Chapter 5 and Chapter 6).
The simulation is open-source and freely available at https://github.com/merlinvn/OUCRU- 
Malaria-Sim-v3.0.2
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Chapter 2 
Software Design for Malaria Simulation
2.1 Introduction
Software design and development play an important role in developing individual-based 
simulations for malaria or any other diseases. When simulations like these need to be run with 
millions of individuals that need to be updated regularly, the design of the system has to fulfill 
the following characteristics: robustness, extensibility, memory efficiency, and optimization for 
performance. This chapter will focus on the technical part of the model’s design.
First of all, the C++ programming language was chosen instead of Java or C# due to its features 
that can improve the performance of the simulation significantly. The C++ language allowed 
me to build a native executable machine code program which is by default two to four times 
faster than Java or C# programs that run in a virtual machine 107. Moreover, the individual- 
based model consists of millions of objects that need to be initiated and manipulated during 
running time, and C++ does not have extra computational overhead when creating objects and 
thus is more efficient in terms of its memory usage. C++ also allows the simulation to have its 
own manual resources and memory management; these features will be described in the 
following sections.
Section 2.2 provides an overview structure of the individual-based model. The whole model 
was broken down to multiple components in order to maintain the flexibility and robustness of 
the system.
Section 2.3 through 2.6 describe technical designs of some programming techniques and 
patterns that are crucial to develop a high performance simulation. Section 2.3 contains the 
description of a novel scheduler design where a combination of single time-step and discrete 
event scheduler was developed. Section 2.4 describes the design of parasite genotype that
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allowed the drug resistant evolution occurs in the simulation. Section 2.5 and 2.6 describe 
programming techniques about data structures and memory management that help improving 
the performance of the simulation significantly.
2.2 System Design
Individual-based models for infectious diseases attempt to mimic a complex system, and all the 
requirements of the model and the details of this system may not be known at the beginning. 
For example, in malaria, individuals that are negative in a blood-smear test may in fact be 
harboring parasites, but we may not know how likely this is; this could be a result from in test 
sensitivity, detection threshold of the microscopy technique or host infectivity, but we do not 
know precisely from the beginning and changes are likely to be introduced during model 
development. Thus, in order to maintain the robustness and flexibility of the system, the whole 
model is broken down to multiple components as shown in Figure 2.1, so that each component 
can focus on its own function. By separating components, changing internal behaviors of one 
component will not have any significant impact on other components in the system. In addition, 
by employing inheritance and polymorphism concepts in object-oriented programming, 
components are designed in a flexible and reusable way to allow the system to adapt easily to 
changes when the model evolves in later stages of development.
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Figure 2.1. Individual-based simulation system design.
2.2.1 Malaria M odel Com ponent
To connect all the components together, a centralized class called “Malaria Model” is used. 
This class is the centralized component that contains and controls other components o f the 
simulation. The main functionality o f the malaria model class is to initialize other components 
at the beginning o f the simulation and to act as a proxy or intermediary for other components 
o f the system to communicate with each other easily.
All properties and methods o f model class are shown in Figure 2.2. This central class has a 
lifetime that is the same as the lifetime o f the simulation and the flow activity o f this component 
is shown in Figure 2.3. A simulation is started by initiating a malaria model class, then setting 
options and parameters to the model object with the values that are read from the input file. The 
model object will call its “initialize” method that will set up other components with the initial 
values.
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c la s s  Model 7 1
Model
. MODEL: M odel*
- CONFIG: Confia*
- RANDOM: Random*
- SCHEDULER: Scheduler*
- STATISTIC: Statistic*
- POPULATION: Popula tion*
- PROPERTY_REF(std::vector<Reporter*>, reporters)
- PROPERTY_REF(long, in itia l_seed_num ber)
- PROPERTY_REF(std::string, con fig_filenam e)
- PROPERTY_REF(std::string, override_param eter_filenam e)
- PROPERTY_REF(int, override_param eterJine_num ber)
- PROPERTY_REF(int, gui_type)
- PROPERTY_REF(bool, is_farm_output)
+ M odel(in t&)
+ Model(M odel&)
+ ~Model()
+ initia lize(): void
+ in itia lize  ob iect DoolfintS): void
+ release_object_poolO: void
+ before_run(): void
+ run(): void
+ after_run(): void
+ release(): void
+ perform Jnfection_event(): void
+ report_end_of_time_step(): void
+ add_reporter(Reporter*): void
Figure 2.2. Model class diagram
instantiate 
centralized Model object
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Model's options and parameters
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Model object
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delete 
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Figure 2.3. Flow activity of a simulation
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2.2.2 Scheduler Component
In a naively constructed individual-based model, the model would have to loop through all 
individuals at each time step to determine if each particular individual needs to be updated 
during that time step, even if the only activities occurring at that time step are infections of only 
some specific individuals, e.g. find and infect ten new individuals. This process is both time 
consuming and inconvenient from a design perspective as the model becomes more complex 
and more different types of actions need to be performed. To solve this problem, the Discrete 
Event Simulation (DES) methodology has been applied to our individual-based model108. DES 
describes the system as a discrete sequence of events in time, where each event is associated 
with an object that will perform an action at a specific time point.
Hence, the Scheduler component is designed to keep track of the current simulation time and 
maintain a list of events which allows the events to be executed at a specific time point; in 
addition, this component schedules and cancels events in the future. The detail design of this 
component will be described in Section 2.3.
2.2.3 Random Generator Component
The Random Generator component is a utility class that provides a simpler way to draw random 
numbers by using functions in the Gnu Scientific Library (GSL)109. Here, the random generator 
algorithm gsl_mg_mtl9937 or Mersenne-Twister-19937 is used in the simulation and the seed 
number is converted from the current time, or it can be manually set from the command line. 
The class design diagram of Random Generator component is shown in Figure 2.4.
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c la s s  Random
Random
+ G_RNG: gsl_m g*
. VIRTUAL_PROPERTY(unsigned int, seed)
- READ_ONLY_PROPERTY_REF(Bitting Level Generator, b itting_ leve l_genera tor)
- READ_ONLY_PROPERTY_REF(Bitting Level Generator, m oving_level_generator)
- READ_ONLY_PROPERTY_REF(Bitting Level Generator, extem al_popu la tion_m oving_ leve l_genera to r)
- POINTER_PROPERTY(Model, m odel)
+ Random (M odel*, gsl_rng*)
+ ~RandomQ
+ in itia lize(unsigned int&): void
+ release(): void
+ random _poisson(double&): int
+ random_uniform(int&): int
+ random_uniform(int&, int&): in t
+ random_uniform(): double
+ random_normal(double&: double&): double
+ random_normal_tnjncated(double& , double&): double
+ random_normal(int&, int&): int
+ random_normal_truncated(int&, int&): int
+ random _beta(double& , double&): double
+ random _ganma(double& , double&): doub le
+ cdf_gam m a_distribution(double&, double&, double&): double
+ cdf_gam m a_distn'bution_inverse(double& : doubte& : double&): double
+ random_flat(double&: double&): double
+ random_multinomial(int&, unsigned& , d oub le , unsigned): void
+ random _shuffle(void*: size_t, size_t): void
+ random _biting_level(): int
+ random_moving_level(): int
+ random _extem al_popu la tion_m oving jevel(): int
+ cdf_standard_normal_distribution(double& ): doub le
+ random_binomial(double&, int&): int
- good_seed(): unsigned in t
Figure 2.4 Random class diagram.
2.2 .4  Configuration Com ponent
The main function o f the Configuration component is to store all parameters and initial 
conditions that will be used later by other components in the simulation. For the ease o f use, all 
initial parameters and initial conditions are stored in a text file with YAML format n0, and read 
to memory when the Configuration component is initialized by the main Model component. 
Here, the YAML format is used instead o f XML or ini format due to its human readability, 
standardization, and portability across multiple programming languages. The detail design o f  
the Configuration class is described in Figure 2.6. Example o f YAML-format input file is 
shown in the Figure 2.5.
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# t o t a l  days the simulation i s  run, including the burn-in period
# where the system goes to  equilibrium  
to ta l_ t im e : 11300
# length o f  burn-in period 
start_treatment_day: 4000
# probabil ity  that a person receives treatment 
p_treatment: 0.8000
#comments
number_of_locations: 1 
number_of_age_classes: 15
# THE MAIN TRANSMISSION PARAMETER THAT DETERMINES R0 AND EIR
# i f  there i s  more than 1 locat ion  ju st  separate by a comma 
#beta: [2 .5  , 0 .1  , 0 .2 ,  0.0015]
beta: [0 .4  , 1 .4  , 1 .4 ,  1 .4 ,  1]
seasonal_beta:
a: [0, 0 .25 , 0 .25, 0 .25]  
phi: [200, 200, 200, 200]
# population s iz e  by locat ion
# th i s  i s  only population o f  su scep tib le  ind iv iduals!  
population_size_by_location: [1000000, 1000 , 1000, 1000, 500]
#probability  for an in fe c t io u s  b ite  to make an in fec t io n
#maybe range from 0 .1  to  0 . 3 . . .
p_infection_from _an_infectious_bite: 0 .1
# ageStructure
age_structure: [1, 2, 3, 4, 5, 6, 7, 8, 9 ,1 0 ,11 ,  15, 20, 60, 100] 
# [0 ,1 )  [1 ,2 )  .........
ageStructureReport: [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 14, 19, 60, 100] 
Figure 2.5. Example YAML-fonuat input file.
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class Config y /
Config
- P O IN T E R _P R O P E R T Y (M od el, m o d e l)
- V IR T U A L _P R O P E R T Y _R E F (in t, to ta l J i  m e)
- V IR T U A L _PR O P E R T Y _R E F(in t, sta r t_ trea tm en t_ d a y )
- V IR T U A L _PR O P E R T Y _R E F(in t, s ta r t_ c o lle c t_ d a ta _ d a y )
- V IR T U A L _P R O P E R T Y _R E F (d ou b le , p j r e a t m e n t )
- V IR T U A L _PR O P E R T Y _R E F(in t, n u m b e r _ o f_ lo c a tio n s )
- V IR T U A L _PR O P E R T Y _R E F(in t, n u m b e r _ o f_ a g e _ c la ss e s )
V IR T U A L _PR O P E R T Y _R E F (in t, n u m b e r _ o f_ p a ra s ite _ ty p e s)
- V IR T U A L _P R O P E R T Y _R E F (std ::vector< d ou b le> , b e ta )
- V IR T U A L _P R O P E R T Y _R E F (S eason a lity , s e a s o n a l_ b e ta )
V IR T U A L _P R O P E R T Y _R E F (d ou b le , p _ in fec t io n _ fr o m _ a n  _ in fe c t io u s _ b ite )
- V IR T U A L _P R O P E R T Y _R E F(std ::vector< int> , a g e_ stru c tu re )
- V IR T U A L _PR O P E R T Y _R E F (std ::vector< int> , in it ia l_ a g e_ stru ctu re )
- V IR T U A L _PR O P E R T Y _R E F(std ::vector< int> , p o p u la t io n _ s iz e _ b y J o c a t io n )
V IR T U A L _P R O P E R T Y _R E F (std ::vector< std ::vector<d ou b le>  >, a g e _ d is tr ib u tio n _ b y _ lo c a tio n )
- V IR T U A L _P R O P E R T Y _R E F (d ou b le , b irth_rate)
- V IR T U A L _P R O P E R T Y _R E F (std ::vector< d ou b le> , d e a th _ r a te _ b y _ a g e )
- V IR T U A L _PR O P E R T Y _R E F(in t, n u m b er_ o f_ tra ck in g _ d a y s)  
V IR T U A L _P R O P E R T Y _R E F (std ::vector< d ou b le> , m o rta lity _ w h e n _ tr e a tm e n t_ fa il_ b y _ a g e _ c la ss )  
V IR T U A L _P R O P E R T Y _R E F (P arasiteD en sityL evel, lo g _ p a r a s ite _ d e n s ity _ le v e l)
V IR T U A L _P R O P E R T Y _R E F (lm m u n eS ystem In form ation , im m u n e _ sy ste m _ in fo r m a tio n )
- V IR T U A L _P R O P E R T Y _R E F (R ela tiveB ittin gIn form ation , r e la tiv e_ b ittin g _ in fo rm a tio n )
- V IR T U A L _P R O P E R T Y _R E F (R ela tive ln fectiv ity , r e la t iv e jn fe c t iv ity )
- P O IN T E R _P R O P E R T Y (S trategy , strategy)
- P O IN T E R _P R O P E R T Y (D ru gD atab ase , d ru g_d b )
P O IN T E R _ P R O P E R T Y (P a ra siteD a ta b a se , p a r a s ite _ d b )
- V IR T U A L _P R O P E R T Y _R E F (std ::vector< ln itia lP arasiteln fo> , in it ia l_ p a r a s ite _ in fo )
- V IR T U A L _PR O P E R T Y _R E F(in t, d a y s _ to _ c lin ic a l_ u n d e r _ fiv e )
- V lR T U A L _P R O PE R T Y _R E F(int, d a y s _ to _ c lin ic a l_ o v e r _ f iv e )
- V IR T U A L _PR O P E R T Y _R E F(in t, d a y s _ m a tu r e _ g a m e to c y te _ u n d e r _ fiv e )  
V IR T U A L _PR O P E R T Y _R E F (in t, d a y s _ m a tu r e _ g a m e to c y te _ o v e r _ f iv e )
- V IR T U A L _P R O P E R T Y _R E F (d ou b le , p _ c o m p lia n c e )
- V IR T U A L _PR O P E R T Y _R E F(int, m in _ d o s in g _ d a y s )
V IR T U A L _P R O P E R T Y _R E F (d ou b le, g a m e to c y te _ le v e l_ u n d e r _ a r te m is in in _ a c t io n )
- V IR T U A L _P R O P E R T Y _R E F (d ou b le , p _ r e la p se )
- V IR T U A L _PR O P E R T Y _R E F(in t, re la p se_ d u ra tio n )
V IR T U A L _P R O P E R T Y _R E F (b ool, a llo w _ n e w _ c o in fe c t io n _ to _ c a u s e _ s y m to m s )
- V IR T U A L _PR O P E R T Y _R E F(in t, u p d a te _ fre q u en cy )
- V IR T U A L _P R O P E R T Y _R E F (in t, rep ort_ freq u en cy)  
V IR T U A L _P R O P E R T Y _R E F (R ela tiveM ovin g ln form ation , s p a t ia lJ n fo r m a t io n )
V IR T U A L _P R O P E R T Y _R E F (E xtem al P o p u la t io n  Inform ation . s p a t ia l_ e x te m a l_ p o p u la t io n _ in fo r m a tio n )
- V IR T U A L _P R O P E R T Y _R E F (d ou b le , T F _rate)
- V IR T U A L _PR O P E R T Y _R E F(T M E Info, t m e j n f o )
P O IN T E R _P R O P E R T Y (Strategy , tm e _ stra te g y )
V IR T U A L _P R O P E R T Y _R E F (d ou b le . m o d if ie d _ c o s t_ o f_ r e s is ta n c e )
V IR T U A L _P R O P E R T Y _R E F (d ou b le, m o d ified _ m u ta tio n _ fa c to r )
- V IR T U A L _P R O P E R T Y _R E F (d ou b le. m o d ified _ d r u g _ h a lf_ I ife )
V IR T U A L _P R O P E R T Y _R E F (bool, u s in g _ fr e e _ r e c o m b in a tio n )
+ C o n fig (M o d eP )
+ ~ConfigQ
+ read_from _file(std::string& ): void
+ rea d _ im m u n e_ sy stem _ in fo rm a tio n (Y A M L ::N o d e& ): void  
+ rea d _ p a ra site_ d en sity _ lev e l(Y A M L ::N o d e& ): void  
+ read _stra teg y _ th era p y _ a n d _ d ru g _ in fo rm a tio n (Y A M L ::N o d e& ): vo id  
+ read _rela tiv e_ b itin g _ ra te_ in fo (Y A M L ::N o d e& ): void  
+ ca lc u la te_ r e la tiv e _ b it in g _ d e n s ity O : void  
+ read _spatia l_ in fo(Y A M L ::N od e& ): void  
+ r e a d _ sp a tia l_ ex tern a l_ p o p u la tio n _ in fo (Y A M L ::N o d e& ): void  
+ read _ in itia l_p arasite_ in fo (Y A M L ::N od e& ): void  
+ read_rela tive_m fectiv ity_ in fo (Y A M L ::N od e& ): vo id  
+ read_strategy(Y A M L ::N ode& , YA M L::N ode& , std::string&): S trategy*
+ read_th erapy(Y A M L ::N ode& , int&): Th erapy*
+ read_drugtype(Y A M L ::N ode& , int&, int&): D rugT ype*
+ override_param eters(std::string& . int&): void  
+ o v errid e_1_p aram eter(std ::str in g& , std::string&): void  
+ b u ild _drug_db(Y A M L ::N ode& , std::set<int>& , int&): void  
+ b u ild _p aras'te_d b (in t& ): vo id  
+ b u ild _d ru g_an d _p arasite_d b (Y A M L ::N od e& ): vo id  
+ seaso n a lity (in t& , dou b le& , dou b le& ): d o u b le
Figure 2.6. Configuration Component class diagram
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2.2.5 Statistic and Data Collection Component
The main function of the Statistic and Data Collection (SDC) component is to keep track and 
analyze all the data that are generated during the simulation running time. For instance, when 
an individual was bitten by a mosquito in the simulation, the SDC records it by adding one in 
a variable called totaljiumber_ofJbites that is used later to calculate the EIR.
The analyzed data are mainly used by the Reporting component to generate the model output.
2.2.6 Reporting Component
Due to the requirements that the model needs to be able to generate multiple types of output, 
e.g. output to file, console, GUI or a group of processors on a farm, the Reporting component 
was designed in a way that allows the flexibility to add new reporting types as well as allows 
multiple type of Reporters to work at the same time without interfering with each other. The 
design of Reporter class and subclasses are shown in Figure 2.7.
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1 1 1 ! ! !
Figure 2.7. Reporter class diagram.
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2.2.7 Human Population Component
The Human Population Component (HPC) organizes and keeps track of all individuals in the 
simulation. By employing the Object Index technique (described in Section 2.5), the HPC can 
classify individuals into different groups based on the characteristic of the individual, e.g. 
grouping by location, host-state, or age-class. Moreover, by having multiple nested groups, the 
HPC can query individuals with specific information. For example, the HPC can directly access 
a list of symptomatic individuals who live in location 0, and are aged between 15 and 20, 
without having to scan all individuals in the population and pick out the ones that satisfy these 
criteria.
Individual information
An individual in the simulation is represented by a Person class and has heterogeneous 
characteristics. Each individual will have a different age, age-class, birthday, attractiveness to 
mosquitoes, and other features; this will allow us to evaluate the effect of different age-pattems 
or biting patterns on the outcome of the model. The detail design of Person class is shown in 
Figure 2.8.
Each individual has a variable that describes his or her current infection status with malaria. 
The following states are used in the simulation: Susceptible, Exposed (having liver-stage 
parasites), Symptomatic, and Asymptomatic.
Individuals in the simulation have their own immune system. The details of the immune system 
will be described in Section 3.9.
Each individual has a list of asexual parasite populations. The purpose of this list is to allow a
person to have multiple malaria infections (i.e. coinfection). Each infection or “clone” or
“parasite population” is a genetically identical clonal population, and each person can be
infected with multiple clonal populations that differ from each other by genotype and parasite
density. Thus, each asexual parasite population will keep track of all the information about
parasite density and genotype. The resistant genotype representation will be described in
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Section 2.4. This way o f implementation also allows multiplicity o f infections to occur in the
simulation.
Each individual has a set o f drug concentrations to represent multiple different drug levels that
are circulating within host. Theses drug concentration levels will be used in the PK/PD model
(described in Section 3.8)
c la ss  Person
D ispa tche r  
P e rso n  h d e x A l I H a n d le r  
P e rs o n ln d e x B y L o c a tio n B ittin g L e v e l H a n d le r  
P e rs o n h d e x B y L o c a tio n E x te m a lP o p u la tio n M o v in g L e v e lH a n d le r  
P e rs o n h d e x B y L o c a tio n M o v in g L e v e lH a n d le r  
P e rs o n h d e x B y L o c a tio n S ta te A g e C la s s H a n d le r
Person
+ O B J E C T P O O L (P e rso n )
+ D IS A L L O W _ C O P Y _ A N D _ A S S lG N _  (P e rso n )
+ P O ! N T E R _ P R O P E R T Y (P o p u ia t io n : p o p u la t io n )
+  P R O P E R T Y _ H E A D E R ( in t! lo c a t io n )
+ P R O P E R T Y _ R E F (in t,  r e s id e n c e _ lo c a t io n )
+ P R O P E R T Y _ H E A D E R (H o s tS ta te s , h o s t_ s ta te )
+ P R O P E R T Y _ H E A D E R (in t, a g e )
+ P R O P E R T Y _ H E A D E R (in t, a g e _ c la s s )
+ P R O P E R T Y _ R E F (in t,  b ir th d a y )
+  P O I N T E R _ P R O P E R T Y _ H E A D E R (lm m u n e S y s te m , im m u n e _ s y s t e m )
+ P O I N T E R _ P R O P E R T Y (P a r a s 'te P o p u la t i o n .  p a ra s i te _ p o p u la t io n )
+ V IR T U A L _ P R O P E R T Y _ R E F (in t, l a te s t_ u p d a t e _ t i m e )
+ P R O P E R T Y _ H E A D E R (in t! b i t t in g _ le v e l)
+ P R O P E R T Y _ H E A D E R (in t. m o v in g _ le v e l)
+ P R O P E R T Y _ H E A D E R (in t, e x te m a l_ p o p u la t io n _ m o v in g _ le v e l )
+ P O IN T E R _ P R O P E R T Y (D m g s ln B lo o d . d r u g s _ in _ b lo o d )
+ P O !N T E R _ P R O P E R T Y (ln tG e n o ty p e , I iv e r _ p a ra 3 te _ ty p e )
+ P O IN T E R _ P R O P E R T Y (ln tV e c to r , t o d a y j n f e c t i o n s )
+ P O IN T E R _ P R O P E R T Y (ln tV e c to r . to d a y _ ta r g e t_ lo c a t io n s )
+ P R O P E R T Y _ R E F (in t, n u m b e r _ o f _ t im e s _ b i t te n )
+ P R O P E R T Y _ R E F (in t.  I a s t_ th e r a p y _ id )
+ P R O P E R T Y _ R E F (b o o i ,  i s _ m o v in g _ to _ e x te m a l_ p o p u la t io n )
+ P e rso n Q  
+ - PersonQ  
+ in it() : v o id
+ N o tif y C h a n g e ( P e r s o n ::P e r s o n P r o p e r t ie s & , v o id* , vo id*): v o id  
+ inc rea se _ a g e _ b y_ 1 _ ye a r(): vo id  
+ is_ in fa n t( in t& ): b o o l
+ a d d _ n e w _ p a r a s 't e _ to _ b lo o d ( ln tG e n o ty p e * ) :  B l o o d P a r a s te *
+ n o tify _ c h a n g e _ in _ fo rc e _ o f_ in fe c tio n (d o u b le & . in t& . d o u b le & . d o u b le d ): v o id  
+ g e t_ b it in g _ le v e l_ v a iu e () : d o u b le  
+ re la t iv e _ in fe c t iv ity (d o u b le & ). d o u b le  
+ g e t_ p ro b a b ility _ p ro g re s s _ to _ c lin ic a l( ): d o u b le  
+ v .'iU _ p rog re ss_ to_d ea th _w he n_ rece ive _n o_ trea tn ie n t(): b o o l 
+ w ili_ p ro g re ss_ to _ d e a th _ w h e n _ re c ie ve _ tre a tm e n t(): b o o l 
+ c a n c e l_ a l I _ o th e r _ p r o g re s s _ to _ c ! in ic a l_ e v e n ts _ e x c e p t( E v e n t* ) :  v o id  
+ c a n c e l_ a l l_ e v e n ts _ e x c e p t ( E v e n t* ) :  vo id
+ r e c o rd _ t re a tm e n t_ f a i lu r e _ f o r_ t e s t_ t re a tm e n t_ fa i lu r e _ e v e n t s O :  v o id
+ c h a n g e _ a I I _ p a r a s te _ u p d a t e _ f u n c t i o n ( P a r a s i te U p d a te F u n c t io n * ,  P a r a s i te U p d a te F u n c tio n * ) :  v o id  
+ c o m p l ie d _ d o s n g _ d a y s ( in t& ) :  in t 
+ r e c e iv e _ th e r a p y ( T h e r a p y \  int& ): v o id  
+ a d d _ d ru g _ to _ b io o d (D r u g T y p e * . int& ): vo id  
+ s c h e d u le _ p r o g r e s s _ to _ c l in ic a l_ e v e n t_ b y (B lo o d P a r a s i te * ) :  v o id  
+ s c h e d u le _ e n d _ c l in i c a l_ d u e _ to _ d r u g _ r e s i s ta n c e _ e v e n t ( B lo o d P a r a s i te * ) :  vo id  
+ s c h e d u le _ te s t_ t r e a tm e n t_ f a i l u r e _ e v e n t ( B lo o d P a r a s te * : int& . b o o l& , int& ): v o id  
+ s c h e d u le _ u p d a te _ b y _ d r u g _ e v e n t ( B lo o d P a r a s i te * ) :  v o id  
+ s c h e d u ie _ e n d _ c l in i c a l_ e v e n t ( B lo o d P a r a s te * ) :  v o id  
+ s c h e d u le _ e n d _ c l in i c a l_ b y _ n o _ t r e a tm e n t_ e v e n t ( B lo o d P a r a a 't e * ) :  v o id  
+ s c h e d u le _ r e la p s e _ e v e n t ( B lo o d P a r a s i t e * .  int& ): v o id  
+ s c h e d u le _ m o v e _ p a r a a t e _ to _ b lo o d ( in tG e n o t y p e ’ , int& ): vo id  
+ s c h e d u le _ m a tu r e _ g a m e to c y te _ e v e n t ( B lo o d P a r a s i te * ) :  v o id  
+ s c h e d u I e _ u p d a te _ e v e ry _ K _ d a y s _ e v e n t( in t& ) :  v o id  
+ c h a n g e _ s t a t e _ w h e n _ n o _ p a r a s i t e J n _ b i o o d O :  v o id  
+ d e t e r m in e _ r e la p s e _ o r _ n o t ( B lo o d P a r a s te * ) :  v o id  
+  d e t e r m in e _ c l in ic a l_ o r _ n o t ( B lo o d P a r a s te ‘ ): v o id  
♦  upda teQ : vo id  
+ u p d a te _ c u r r e n t_ s ta te O : v o id  
+ r a n d o m  ly _ c h o o s e _ p a r a s f te ( ) :  v o id  
+ in fe c te d _ b y (in t& ) : vo id  
+ r a n d o m iy _ c h o o s e _ ta r g e t_ lo c a t io n { ) :  vo id  
+ s c h e d u le _ m o v e _ to _ ta rg e t_ lo c a t io n _ n e x t_ d a y _ e v e n t ( in t& ) :  v o id  
+  h a s _ re tu m _ to _ r e s id e n c e _ e v e n tO :  b o o i 
+ c a n c e i_ a l l_ r e tu m _ to _ r e s id e n c e _ e v e n ts O :  vo id  
t  h a s _ d e te c t a b le _ p a r a s 'te O :  b o o l 
+ in c re a s e _ n u m b e r_ o f _ t im e s _ b i t te n O '.  vo id  
+ m o v e _ to _ e x te m a l_ p o p u la t io n O :  v o id  
+  r e tu m _ to _ n o rm a l_ p o p u la t i o n ( ) :  v o id  
+ m o v e _ to _ p o p u la t io n ( P o p u la t io n * ) :  vo id  
+ i s _ i n _ e x te m a l_ p o p u la t io n O : b o o l
Figure 2.8. Person class diagram.
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2.3 The Combination of Time-Step and Discrete-Event Simulation 
(details of scheduler and event)
The simulation is required to allow some daily activities that can apply to the whole population, 
i.e. potential infection activity, birth and death activity, importation, migration. In addition, the 
system also has activities that act independently on each individual, i.e. introducing parasites 
to the blood from the liver, progressing to a symptomatic clinical state, or the maturation of 
gametocytes. To fulfill these requirements, a modified discrete-event simulation (DES) is 
developed by combining designs of time-step model, that performs executions at each time 
step, and discrete-event simulation to allow the simulation to have a quick and convenient way 
to schedule and update both daily and time-specific activities.
The heart of a discrete-event system is the scheduler that is used to schedule and perform an 
event at a specific time point. In other discrete-event systems, the scheduler is implemented by 
using single-dimension vector (or a priority queue) because those systems do not have a fixed 
time step. However, in malaria simulation, all of the individual-related events are independent 
and the simulation has a fixed daily time step. Hence, to improve the performance, a modified 
event lists in the scheduler is used to achieve the feature that allows both daily behaviors and 
time-specific activities to be scheduled and executed in advance. Here, a two-dimensional 
vector is used to arrange generic event pointers at multiple time-points, as shown in Figure 
2.10. The length of the first dimension of this vector is equal to the total number of days that 
the simulation will be run and the index of the first dimension represents a single day in the 
simulation. The second dimension of the vector is used to store all the events that will occur on 
the same day. Figure 2.9 shows all different events that will occur in the simulation.
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Figure 2.9. Event class hierarchy.
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Figure 2.10. Overall view of the Scheduler. Scheduler was implemented by a two-dimensional vector of 
Event pointer. The vertical dimension represents for days (time step) in the simulations while the 
horizontal dimension represents all the events that will occur in a particular day.
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2.4 Parasite and Drug Resistant Genotype design
Each clonal parasite population within individual, described in Section 2.2.7, is associated with 
a specific genotype. A proper design for genotype representation will not only allow the 
occurrence of the mutations but also improve the performance of the simulation.
To model drug-resistant genotypes, a bit-string data structure from the C++ Boost library has 
been used111. Each position in the bit-string represents a particular drug that is used in the 
simulation, and the values represent the resistance mutation to that drug that have occurred or 
not (0 means non-mutant and 1 means mutated).
Example of resistant genotypes when using three different drugs:
• Naive strain genotype: [0,0,0]
• Single resistant genotypes: [0,0,1], [0,1,0], [1,0,0]
• Double resistant genotypes: [0,1,1], [1,0,1], [1,1,0]
• Triple resistant genotypes: [1,1,1]
If the parasite becomes resistant to a particular drug, the drug will have no efficacy on the 
treated patients that carry the resistant parasite. The genotype representation will be modified 
to allow partial resistance in Section 5.2.
36
^napici z.. ounwaic iui iviaiana oimuiauuii
2.5 Object Index for Faster Calculation and Reducing Memory Usage
In the traditional way of counting how many individuals have symptoms at a specific time 
point, the simulation has to loop through all individuals in the population and increase the 
counter for each individual that is in a symptomatic state. This process would be time 
consuming when it needs to be done at each time step during the infection event for the whole 
population. However, at every time point, the simulation only needs to update the state of 
individual carrying parasites. Hence, a convenient way to group individuals into separated 
groups could improve the performance of the simulation significantly.
In the model, I use a technique called “object indexing” that utilizes multi-dimensional array of 
pointers in order to group individuals having similar properties; such as states, age classes, or 
biting level. For each object index in the simulation, an individual will have a separate member 
variable that is associated with that index. This variable stores the position of the individual 
pointer in the deepest nested vector of the index. This variable is used when the simulation 
wants to randomly access an individual through the object index and it also helps improve the 
performance in adding and removing pointer in the index.
To add a new object pointer to the object index, the program just adds the object pointer at the 
end'of the object index. To remove an object pointer at a specific position in the object index, 
the object index swaps that object pointer with the last pointer in the index, then removes the 
last pointer. With the “swap and remove last” technique, the performance improves 
significantly in comparison with the method that removes and shifts left all objects from the 
removed position to the last position: 0(1) vs. 0(n) in term of computational complexity. C++ 
code to add and remove object pointer in the object index is shown in Figure 2.12.
Here, a technique called the “Observer” design pattern 112 is used to allow the object index 
classes to automatically update the multidimensional array pointer whenever a change occurs 
to the individual. For example, in a model that has multiple different object indexes, when an 
individual changes his state from susceptible to exposed, the individual object makes a signal
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to inform all object indexes in the model; the object index that is responsible for grouping by 
host state will capture that change and update the underneath pointer array. There are currently 
three different objects indexes in the simulation: AllObjects, IndexedByBitingLevel, and 
IndexedByStageAgeCIass, shown in Figure 2.11. The AllObjects index object manages all 
individuals in the model. The IndexedByBitingLevel index object, which uses a one­
dimensional array pointer, groups individuals by each individual’s biting level (i.e. how likely 
a mosquito is to bite that particular individual because o f his or her innate attractiveness to 
mosquitoes), and it is used at every time step to distribute new malaria cases. The 
IndexedByStageAgeCIass index object used two-dimensional array to group individuals into 
stage and age class. An example usage o f this index object is to count how many symptomatic 
individuals there are in age class 5, or to select randomly three individuals that are susceptible 
in age class 2.
Object Index
All Objects
Indexed By 
Biting Level
Indexed By 
State - Age 
Class
Figure 2.11. Person Index Hierarchy
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void  Person lndexB yL ocat ionB itt in gL eve l: :add(P erson*  p, c o n s t  int& lo c a t i o n ,  c o n s t  int& b i t t i n g _ l e v e l ) {
vPerson [ l o c a t i o n ] [ b i t t i n g _ l e v e l ] . push_back(p);
p->PersonIndexByLocat ionBitt ingL evelH andler: : s et_ index(vP erso i  [ l o c a t i o n ] [ b i t t i n g _ l e v e l ]
}
s i z e ( )  - 1 ) ;
void  P e rso n ln d ex B y L o ca t io n B it t in g L e v e l: :remove_without_set_index(Person* p) {
vPerson_[ p - > l o c a t i o n ( ) ] [ p - > b i t t i n g _ l e v e l ( ) ] . b a c k Q ->
Person lndexB yL ocat ionB itt in gLeve lH and ler : : s e t _ in d ex(p -> P e rson !n d exB yL ocat ion B it t in gL eve lH an d ler : : in d e x ( ) ) ;
v P e r so n _ [p - > lo c a t io n ( ) ] [p -> b i t t in g _ le v e l ( ) ] [p -> P e r s o n I n d e x B y l_ o c a t io n B i t t in g L e v e lH a n d le r : in d e x Q ] =
vPet'sqn [ p - > l o c a t i o n ( ) ] [ p - > b i t t i n g _ l e v e l ( ) ] . back();
vPerson [ p - > l o c a t i o n ( ) ] [ p - > b i t t i n g _ l e v e l ( ) ] . pop_back();
>
Figure 2.12. Example C++ code for adding and removing a person pointer of the 
PersonlndexedByBittingLevel object.
2.6 Memory Management with Object Pool
Throughout the lifetime o f the simulation, a large number o f short-lived objects are created and 
deleted; e.g. parasite population objects, event objects, person objects. When creating an object, 
the program has to allocate a free memory location for this new object; when the program 
deletes this object, the memory will be deallocated. The processes o f allocating and deallocating 
memory are time consuming, especially when millions o f  objects are spawned and released. To 
improve the performance, a technique called “Object Pools” is used. The pools create objects 
at the beginning o f the simulation. Whenever the program needs to allocate an object, it asks 
the corresponding pool for one. When the program is done with the object, it returns the object 
to the pool. The object pools automatically increase their size when the number o f using objects 
excesses the number o f pre-created objects in the pools.
A dedicated Object Pool object, shown in Figure 2.13, is assigned to each class that needs to 
apply the object pools technique, e.g. the parasite object pool object is only used to manage 
parasite objects. All the created objects are stored in the AllObjects, a vector o f pointer arrays, 
and all o f the ready-to-use objects are stored in f i ’eeList, a vector o f pointers. Each time the 
simulation requests an object, the pool gives the last object pointer in the freeList vector, and 
pushes back the object when the simulation returns it to the pool. Basically, the pool does not 
explicitly keep track o f objects that are in use and the program has to return objects correctly 
to the pool when the simulation finishes with them. In a simple program which constantly
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creates and deletes 10,000 individuals 10,000 times, the object-pool version achieves five to
six times faster computation than a version with ad hoc memory allocation and freeing.
c la ss  O bjectPool J
T : c la ss
O bjectPool
- e x p a n s io n S iz e :  in t 
a l lO b je c ts :  s td : :v e c to r< T * >
- f re e L is t:  s td : :v e c to r< T * >
+ O b je c tP o o l ( s iz e _ t& )
+ - O b j e c tP o o l O  
+ A llocO : T*
+ F re e fT * ): v o id
E x p a n d F r e e L is tQ : vo id
Figure 2.13. Object Pool class diagram
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Chapter 3
Model Construction and Model Validation
This chapter is an expanded version of the supplementary appendix to a manuscript titled 
“Optimal population-level deployment of artemisinin combination therapies.” This manuscript 
was published on Lancet Global Health in November 2015. In order, the authors on this 
manuscript are myself, Piero Olliaro, Arjen Dondorp, J Kevin Baird, Ha Minh Lam, Jeremy 
Farrar, Guy E Thwaites, Nicholas J White, and Maciej F Boni.
The first section of the chapter contains a description of the biology and epidemiology 
implementation of the individual-based model (“microsimulation”); this description includes 
details on the mechanisms and assumptions in the model that are related to transmission, clinical 
progression, immunology, pharmacokinetics and pharmacodynamics, evolution, and 
demography.
Sections 3.2 through 3.8 contain descriptions of model parameters where model inputs can be 
directly obtained from field or clinical data.
Sections 3.9 through 3.15 describe model validations for behaviors that cannot be input directly 
into the model. For example, clinical episodes decrease with age more quickly in high- 
transmission settings than in low-transmission settings, but the model cannot be forced to 
exhibit this behavior; this behavior is a consequence of the interaction between population-level 
immunity and entomological inoculation rate (EIR). In the sections below we validate that 
these qualitative features of malaria epidemiology are observed in our model.
Due to the complexity and high computational requirement of the individual-based simulation,
I do not do rigorous model fitting, but instead I used model calibration, through visual
comparison of data and model outputs, to find suitable ranges for unknown parameters. The
model is then validated against collected data by showing that the model, with these ‘calibrated’
parameters, can illustrate key epidemiological features of malaria.
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3.1 Model Description
The model is an individual-based stochastic microsimulation developed in C++ using a daily 
time-step and asynchronous updating. Individuals in the model carry certain basic attributes 
such as age, attractiveness to mosquitoes, presence/absence of malaria symptoms, level of 
parasitaemia (possibly none), the number of independent clonal parasite populations circulating 
in their blood, the presence/absence of parasites in the liver (before a blood-stage infection), 
level of acquired immunity to malaria, and drug levels in the blood. These are described in 
more detail below. The population size in the model is set to one million, as larger population 
sizes showed no difference in qualitative dynamics. Typical simulations for our present analysis 
were run to equilibrium with no treatment, which was done so that all simulations would settle 
to the same endemic equilibrium before the application of any treatment strategy, allowing for 
a fair comparison of the different strategies. After treatment was initiated -  for a fraction /  of 
symptomatic malaria cases (known as the “treatment coverage”) — the simulations were run for 
another twenty years. The treatment coverage parameter/ was varied between 0.5 and 0.9 in 
the simulations. Asymptomatic cases were not treated in our simulations. The microsimulation 
is meant to model the dynamics of Plasmodium falciparum.
Blood-stage Parasitaemia. Each host i is associated with an asexual parasite density A , which 
is the sum of the densities of the individual clonal parasite populations in that host. If there are 
Ci clonal parasite populations inside host i, then we le t/=  1,..., a  index these clonal populations. 
We let R j  be the resistance profile of clonal population j ,  where R j  is the set of drugs to which 
the corresponding parasite population carries resistance (using the index-set notation of 
Andreasen et a l 113). As an example, R3 -  0 indicates that the third clonal population in this 
host does not carry any drug resistance genes, and R4  — (1, 2} indicates that the fourth clonal 
population in this host carries resistance to drugs 1 and 2. The parasite density inside host i is 
then described by the equation 1.
Pi = 'Z%1wRjSjliYj,i (1)
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where wR. is the relative fitness of a resistant parasite with resistance profile R/, the fitness of a
sensitive parasite is defined as W0 = 1. The quantity Sp is the parasite density of clone j  in host 
/, and jjj is the relative gametocyte production of clone j ,  with one corresponding to normal 
production and zero to no production. Typically, yp is set to zero for the first four (children) or 
six (adults) days of an infection, and then fixed at one after gametocytes begin to be produced; 
this is slightly earlier than true gametocyte production, the reason being that we do not model 
the tail-end of a cured infection when asexual parasitaemia is zero but gametocytaemia stays 
positive for one week or more 114. Essentially, the model shifts the gametocytaemic period to 
be several days earlier so that infected hosts have the same number of transmissible days as 
they would for real infections. This adjustment does not affect our simulations as we do not 
model gametocytocidal drugs such as primaquine. The force of infection of resistant type R at 
time t, denoted asT l^ , is calculated from equation 2.
,  _  (wxZiRj=xsi.ini\
^ t,R  ~  P  S a il hosts i d  (P i)  ’ ^ p ; J ( 2 )
where bt is the biting attractiveness of host i (drawn from a gamma distribution with coefficient 
of variation equal to 2.0 115), the function g  describes the saturation of transmission probability 
with increasing parasite density 91 (see Section 3.2), and./? is a scaling factor that we vary to 
obtain a particular entomological inoculation rate (EIR) in a given simulation. The parameter /? 
does not represent any particular epidemiological quantity such as biting or mosquito 
population size; it is a non-dimensional quantity that allows us to scale the force of infection to 
get a particular prevalence or EIR. Recombination can occur when a mosquito bites a host with 
multiple clonal infections. We assume that interrupted feeding on multiple hosts does not occur; 
the frequency of interrupted feeding by non-infected mosquitoes has been estimated to be as 
high as 10% 80,116,117 but our previous modeling analysis 52 indicated a weak relationship 
between outcrossing rate the evaluation criteria we measure here. It is assumed that drug 
resistance genes are located on different chromosomes. The parasite densities in the above
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equation already take into account a single generation of segregation and recombination that 
occurs inside the mosquito.
Parasitaemia levels are set to 20,000 parasites per microliter at the beginning of a symptomatic 
episode of malaria (this is relaxed in Chapter 5). Asymptomatic cases have their parasitaemia 
levels initialized at 1000 parasites per microliter, after which the parasite population size is 
slowly reduced by the immune system; the minimum and maximum durations of asymptomatic 
parasitaemia observed in the model are 60 days and 281 days 85,118,119, and this varies with the 
host’s immune status. The progression of an asymptomatic case to a clinical case is determined 
by the host’s immune status, the details of and justifications for this process are described in 
section 3.9. For a multi-clonal infection presenting with clinical malaria, symptoms are caused 
by one clonal parasite population (typically, the most recent bite) reaching a density of 20,000 
parasites per microliter, while the other parasite population sizes stay at levels of <1000 
parasites per microliter.
Transmission model. Genotype-specific forces of infection are stored in the simulation for 11 
days, and new infections are generated by drawing a Poisson number of hosts based on each 
genotype’s force of infection 11 days ago (this 11-day lag mimics the course of parasite 
development in the mosquito 12CM22). Once this number has been drawn, the specific hosts to 
be infected are chosen with replacement relative to their biting weights bi, and seven days later, 
after growth and development of liver-stage parasites, these hosts will have a newly emerged 
blood-stage parasite population (50,000 total parasites).
Immunity Model. We implement an immunity model in each host that describes the general 
level of acquired immunity that a host has to P. falciparum malaria; specific immunity is not 
modeled. This model’s immunity variable M  ranges from zero to one, and it is meant to be 
interpreted on a relative scale. Its two biological effects are that a higher level of immunity 
increases parasite clearance rate and decreases the chances that a new infectious bite leads to a
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clinical episode of malaria, similar to Filipe et a l94. The immunity-dependent parasite clearance 
rate is defined by the equation 3.
P t+ K  ~  W R ~  ^ t )  c m a x  ‘ ^ t \  ' (^ )
where P t is the parasite density at time t ,  w r  is the fitness of the given strain (1 for the drug- 
sensitive strain, 1 -  c r  for a single-drug resistant strain; see drug-resistance description below), 
and (1—cmax) and (1 — cmin) are the daily immunity parasite reducing rate for fully-immune 
and non-immune individual respectively. The values of cminand cmax are calculated as the 
equation 4 and 5.
log10{parasite density  assymptomatuO-logujCparasite density cured)
Cm ax =  1 0  duration o f infection fo r  fu lly  immune individuals =  0 . 9 5 7 2  ( 4 )
logio(Parasite density assym ptom atic)-\og10(parasite density cured)
Cm in  =  10 “  duration o f infection fo r  immunologically naive individuals = 0.8036 (5)
The parasite density is typically updated asynchronously every seven days (K=l) in the 
simulation; validations were done to ensure this is not very different from daily updating. If an 
individual has another event occurring (e.g. new infection, clearance of a different parasite 
clone) then the parasite density is updated earlier than the scheduled 7-day interval. The 
parameters in this equation are calibrated so that infections are a maximum of 281 days and 
minimum of 60 days. Details of this calibration are presented in Section 3.3. The effect of 
immunity of symptoms development is described in Sections 3.9 and 3.10.
Clinical/Symptomatic Malaria. When an individual in the model acquires a new malaria 
infection, that host will progress to clinical or symptomatic malaria with probability P cim. This 
probability is immunity dependent and will be described in detail in Sections 3.9.
Pharmacokinetics and pharmacodynamics (PK/PD). Drug action was modeled with a
standard concentration-effect curve, and drug clearance was modeled with a standard
exponential decay (Section 3.8). Daily killing rates, or parasite reduction ratios, were obtained
from past PK/PD studies 123_132. Variable drug absorption was included so that different
individuals had different starting concentrations of drug (this allowed treatment to fail
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sometimes); the coefficient of variation of the starting drug concentration was varied between 
0.1 to 0.4. This coefficient of variation and the slope of the concentration-effect curve were 
varied for each specific therapy, to obtain a desired efficacy at 28 days. As an example, the 
maximum daily killing rates for artemether, artesunate, and dihydroartemisinin were set to 
99.9% per day. For artemisinin combination therapies, the standard deviation for the initial 
concentration of both drug components was set to 0.4, resulting in an efficacy of 95%, and these 
parameters were used for ACTs in the simulations presented here.
Drug resistance evolution. Evolution in clonal parasite populations is modeled by allowing a 
parasite population to mutate from sensitive to resistant to drug x, only in the presence of drug 
x; as in previous modeling studies, this model behavior really represents the fixation of a new 
mutant, but we keep the terminology of a “mutation rate” to be consistent with past modeling 
literature. In the simulation, mutation occurs on a daily basis with a certain daily probability. 
For the majority of drugs, these probabilities are unknown. Hence, the probabilities in the 
model are set so that resistance evolves, under high drug coverage, during the 20-year time span 
that the model is run. These mutation parameters were set to be the same for all resistant 
genotypes, including those encoding resistance to the partner drugs, as the relative magnitudes 
of these mutation rates are unknown. In the model version presented in Chapter 3 and Chapter 
4, drug-resistant genotypes are completely resistant to the action of the drugs they are resistant 
to.
Mutation rates from drug-sensitive to drug-resistant genotypes are a function of the drug 
concentration. When the drug concentration is zero, the mutation rate is set to zero. When the 
drug concentration is a full dose, the mutation probability is //. We introduce a parameter k  to 
determine whether the probability of drug resistance emerging and fixing is higher or lower at 
intermediate drug concentrations. Under a simple linear model, the mutation probability falls 
linearly with drug concentration (&=0.5) so that the mutation rate is fill at half concentration. 
We also test a model where the mutation probability is twice as high at half-concentration than
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at full concentration (&=2), and another where the mutation probability is four times as high at 
half-concentration (k=4).
Each resistant genotype is assigned a fitness cost c r  (that varies between 0.1% and 1.0%), and 
for multiple-resistant genotypes fitnesses are multiplicative. The fitness component in the force 
of infection (showed in equation 2) is defined as equation 6.
W r  =  1 -  Cr  (6)
3.2 Gametocytaemia and Infectivity
Ross and colleagues developed a statistical model that described the relationship between host 
infectivity to mosquitoes and asexual parasite density and fit that model with data from 392 
neurosyphilis patients treated with malaria therapy91. In their model, the relationship between 
gametocyte density and asexual parasite density was described as equation 7.
lnf e )  ~ NormalQnip?), ag) (7)
where yg is the density of functional female gametocytes in an individual, P is the asexual 
parasite density, p is the parameter that tells us the proportion of asexual parasites that have 
developed into gametocytes, and og is the standard deviation. Then the probability that at least 
one functional gametocyte is taken up is defined as equation 8.
PrO s >  Vs) = *
ln (p P )- ln (y j ty
L <*g
(8)
where yg is the gametocyte density (per microliter) required for a mosquito to take up at least 
one functional gametocyte during one blood meal; <f> is cumulative distribution function (CDF)
of the standard normal distribution and p* = if  the volume of the blood meal is
'9
assumed to be 3 p i133 then yg =  j .  And, if the sex ratio between male and female gametocytes
is 1:1 then the probability that a mosquito is infected by taking up both male and female
gametocytes is Pr(y5 > yg) . According to the results from Ross et al.’s study 91, p =
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0.00031 ( 95% Cl: 0.00027 -  0.0036) and ag =  3.91 (95% Cl: 3.72 -  4.10) were the 
statistically fitted values to the neurosyphilis dataset.
In our simulation, we use this Ross et al (2006) function Pr(y^ >  y j ) 2 =  “
1.7852])2 as g(P) function that used in equation 2 to describe the per-bite infectivity of an
individual with an asexual parasite density Y. An individual with a parasite density of 10/jil 
will have approximately a 1% chance of infecting a mosquito. An individual with a parasite 
density of 1000/pl will have approximately a 25% chance of infecting a mosquito.
3.3 Duration of Infection
The duration of infection is the amount of time that it takes for an untreated individual to clear 
all blood-stage parasites. This duration is dependent on how high or low an individual’s 
immunity is. Finding a plausible range for the duration of infection is crucial to a malaria 
model.
Using the malaria therapy data, Maire et a l85 computed the duration of an untreated infection. 
Of patients whose infection duration was longer than two months, the log-mean of the untreated 
infection durations for 47 patients was 5.13 (o=0.80), which corresponds to a mean of 169 days 
(± la  range: 76 -  376). Eyles and Young 118 described the course of malaria infection in 22 
neurosyphilitic patients with malaria therapy and presented an average duration of infection of 
222 ±117 days for patients where the entire course of continuous and intermittent parasitaemia 
was followed until they were defined as cured or cleared (6 months of zero parasitaemia). For 
a larger group of 38 patients, the initial course of continuous parasitaemia was calculated as 
121 ± 58 days. These patients were normally untreated and occasionally received quinine 
treatment during clinical episodes.
In the World Health Organization’s Garki Project Report 119, the daily clearance rate ranged
from 0.002 to 0.018 (approximately, according to the Figure 31 of the report), corresponding
to an infection duration between 55 and 500 days (in the absence of interventions). This graph
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also shows an increasing clearance rate with age which is likely due to the development of 
immunity in older individuals.
In our simulation, we define the duration of infection as the number of days that an untreated 
or inadequately treated individual clears all blood-stage parasites (by action of the immune 
system only). By comparing and combining all 3 references above85,118,119, we select 60 days 
and 300 days as the suitable lower and upper limits for infection duration, for fully immune and 
immunologically naive individuals, respectively (see Section 3.9 for the immunity model in the 
simulation). Because immunologically nai've individuals acquire some level of immune 
protection during the course of a malaria infection, a 300-day parasitaemia is never observed. 
The maximum observed parasitaemia in the simulation is 281 days for a naive 1-year-old child 
and 197 days for a naive 20-year-old individual.
3.4 Probability that an Infectious Bite Causes an Infection
From February 1986 to October 1987, Beire et al conducted an epidemiological and 
entomological investigation of malaria incidence in 809 children in Saradidi (western Kenya) 
to investigate the relationship between P. falciparum incidence and EIR 134. Using clinical 
incidence reports and EIR measurements from household vector studies, the authors found that 
7.5% (1 in 13) of sporozoite inoculations produced new infections in children in Saradidi. The 
measured EIR during this period was 0.75 infective bites per person per night or 273 bites per 
person per year.
A parallel study in Saradidi135 indicated that adults were less susceptible to malaria compared 
to children given the same level of exposure. In the same village during a high-transmission 
period, 57 of 62 children (92%) experienced parasitaemia within 56 days and all children 
developed parasitaemia by day 84, while only 16% (day 56) and 58% (day 84) of adults 
developed parasitaemia. All participants received radical cure at the beginning of the study. 
Thus, the probability of developing parasitaemia after receiving an infectious bite likely
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depends on an individual’s level of immunity (possibly sporozoite-blocking immunity, but this 
is not known).
In our simulation, we use a single parameter to define the probability that an infectious bite 
causes a new infection, as there are still not enough data to accurately measure the age 
dependence of this parameter. We keep this probability constant at 10% across all age groups.
From experiments, changing this probability mainly affects the association between EIR and 
prevalence and the MOI distribution. With high probabilities, the model failed to replicate the 
log-linear relationship between EIR and prevalence as well as the MOI pattern describe in the 
Section 3.12 and 3.14. In later analysis in Section 4.4.10, this probability is modified to be age- 
dependent and this modification does not have any impacts on the main results.
3.5 Age-specific All-cause and Malaria Mortality
Considering DSS data from seven sites in sub-Saharan Africa from 2001-2005 I36, malaria 
mortality ranged from 2.5 to 8.2 deaths per 1000 children per year. Age-specific mortality rates 
are shown in Figure 1 of this paper. Extracting these numbers from the graphs and averaging 
across sites, we obtain the table 3.1.
Combining this with a longitudinal data set on 60,000 individuals in Burkina Faso from 1999 
to 2003 137, we summarize age-specific all-cause mortality and age-specific malaria mortality 
in the table 3.2.
With these two datasets, we construct an age-specific mortality pattern (table 3.3) (malaria 
attributable and non-malaria attributable) that we would expect to observe in a high- 
transmission region.
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Age All-cause
M ortality
M alaria M ortality
0.1 170.2 27.4
0.3 58.7 23.8
0.6 60.6 28.3
0.9 62.4 31.5
1.1 52.3 23.4
1.4 43.7 19.6
1.6 37.8 16.2
1.9 31.4 13.4
2.6 21.3 19.2
3.5 10.1 9.6
4.4 5.0 4.2
5.4 4.9 2.7
6.5 3.8 1.9
7.5 3.0 1.2
8.5 2.7 1.8
9.4 2.9 1.7
10.4 2.2 1.0
11.5 2.1 1.5
12.5 2.2 1.6
13.4 2.3 0.9
14.4 1.8 0.8
Table 3.1. Averaged age-specific mortality (per 1000 person-years) from seven sites in Burkina Faso, 
Ghana, Kenya, Tanzania, and Mozambique
<1 year | 1-4 years 5-14 years | 15-59 
! years
> 60 years Reference
All-cause m ortality 60.5 ! 23.6 2.8 ! 5.9 54.7 Becher et al
M alaria m ortality 23.4 1 10.4 0.7 ! 0.4 10.2 Becher et al
All-cause m ortality 80.84 | 28.79
i
2.98 j No data
1!
No data Abdullah et 
al
M alaria m ortality 26.86 | 15.09
\
1.77 j No data No data Abdullah et 
al
Table 3.2. Annual mortality (per 1000) by age group, data extracted from Becher et al 137 and Abdullah 
et a l 136.
Age-Group 0-1 ! 1-2i
| 2-3
1 3"4 i 4-5\ 5-6 j 6-7i ] 7-8i | 8-9i j 9-105 10-15 i i5 -  1 20 20-60 | >60
All-cause
M ortality
80.84 [ 37.29
iI
1 20.94 | 12.14 j 6.65
1
4.54 ! 3.88
1
| 3.16 j 2.88 ! 2.60 
|
2.25 ! 5-9 5.9 1 54.7
Malaria
M ortality
26.86 j 18.36
\I
14.07 11.02 j 5.51
I
2.93 i 1.92
I
j 1.63 1 1.59
!
1 1.5313
1.27 j 0.4
!i
0.4 10.20
Non-Malaria
M ortality
53.98 [ 18.94
i
| 6.87 | 1.12 i i . i4
i
1.61 1 1.95
I
| 1.53 | 1.30
1
| 1.07
|
0.98 | 5.5
1
5.5 | 44.5
Table 3.3. Expected age-specific mortality per 1000 persons per year in a high-transmission region.
51
VChapter 3. Model Construction and Model Validation
The mortality not attributable to malaria is input directly into the demographic part of the 
simulation; however, malaria mortality depends on transmission and must be input as a per- 
case probability of death. In the simulation, we count failed treatments and non-treatments, but 
we do not distinguish between severe malaria and uncomplicated malaria in these cases. Using 
summary information from the WHO 138, we assume that the percentage of symptomatic 
malaria cases that progresses to severity is 5% for the 0-5 age group and 1% for individuals 
over five years of age.
In a meta-analysis of malaria clinical trials conducted through 2002, Myint et al summarized 
the mortality rates for uncomplicated and severe malaria, for which the probabilities of death 
were 0.03% and 13.9%, respectively 139. These numbers are for treated patients. The 
assumptions in Goodman et a l 138 have the under-five case fatality for severe malaria at 19.2% 
if  treated and 50% if untreated; the over-five case fatalities used are 10% for treated patients 
and 25% for untreated patients. Depending on how many of the treated patients were receiving 
failing treatments and how many would progress to severe malaria under these circumstances, 
the malaria mortality for a “treated patient population” should be, approximately, between 0.1% 
and L0% of all malaria cases. For untreated patients, the total malaria mortality rate could be 
as high as 2.5% in under-fives and 0.5% in over-fives.
In our simulation we set the mortality rate for untreated malaria to 4% for age group 0-1, 2% 
for age-group 2-5, 0.4% for age-group 6-10, and 0.1% for older age groups. Successfully 
treated cases in our simulation result in zero mortality, and unsuccessfully treated cases have 
the same mortality profile as untreated cases. It is important to remember that mortality rates in 
south Asia, southeast Asia, and the Americas may differ from the parameterized values here 
using African data, due to different clinical setting and different levels of familiarity with 
malaria and malaria case management. When evaluating our comparison criteria (Section 4.2.2) 
we decided not to include mortality as one of the reported measures, as the mortality measure 
correlated very closely to our 'failed treatment measure’ (NTF).
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3.6 Age Structure
The current implementation of our individual-based simulation is not intended to represent any 
particular country; however, we must choose a population age structure for the simulation. In 
the current implementation, we use the population age structure of Tanzania, obtained from the 
web site of the Tanzanian National Bureau of Statistics (see table 3.4). The initial population 
size for each age 0 to 14 will be calculated based on these numbers; for other ages, the 
population size for each one-year age band is obtained by equally dividing the age classes 
below.
Age j Population
|
%  of Total 
Population
Age G roup Population %  of Total 
Population
0 1,499,389 3.34% 15-24 8,562,875 19.06%
1 1,349,091 3.00% 25-34 6,302,172 14.03%
2 1,477,998 3.29% 35-44 4,340,066 9.66%
3 1,456,609 3.24% 45-54 2,716,946 6.05%
4 1,490,745 3.32% 55-64 1,544,557 3.44%
5 1,412,917 3.14% >65 1,736,851 3.87%
6 1,420,161 3.16% •
7. 1,394,553 3.10%
8 1,279,389 2.85%
9 1,152,017 2.56%
10 1,340,272 2.98%
11 951,527 2.12%
12 1,443,723 3.21%
13 1,022,836 2.28%
14 1,034,229 2.30%
Table 3.4. Population distribution of Tanzania
In 2013, the birth rate of Tanzania is estimated at 37.25 births per 1000 population per year. 
Note that with a birth rate of 37.25 births per 1000 population and the death rate as described 
in Section 3.5, the population size of the simulation will double after 30 years.
As in the Griffin papers 95, Tanzania was chosen as a malaria-endemic country with a 
representative population structure as Tanzania is neither small nor isolated (e.g. Equatorial 
Guinea, Comoros), is not severely overpopulated (Nigeria, Bangladesh), and has a mixture of 
rural and urban areas.
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3.7 Parasite Density Levels
3.7.1 Asymptomatic Hosts
In a study of 314 asymptomatic children in Kampala, Uganda, Nsobya et a l 140 showed that, at 
the enrollment point of the study when all children were asymptomatic, the asexual parasite 
densities had a range between 16 and 71840 parasites per microliter, with a geometric mean 
parasite density (GMPD) of 2630 parasites per microliter.'
In a study from Gabon in 1995, 10 children aged from 5 to 11 with positive thick-film blood 
smears for P. falciparum and no symptoms for at least 5 days were followed daily for 7 days 
and then every 2 to 3 days until symptoms appeared 141. The duration of the asymptomatic state 
for the 10 children ranged from 7 to 38 days and parasitaemia remained low (ranging from 10 
to 10,000 parasites per microliter) during the asymptomatic state and usually increased with the 
appearance of symptoms (in 8 of 10 children). However, some children had more than 2500 
parasites per microliter for several days without developing symptoms. The appearance of 
symptoms, in all 10 children, was coupled with the occurrence of a new parasite genotype. An 
immunological hypothesis consistent with this observation is that the children had a moderate 
amount o f specific immunity to their resident parasites, but this immunity was not strong 
enough to prevent a clinical episode caused by a newly acquired parasite. The short duration of 
asymptomatic parasitaemia in this study is likely due to the fact that the study was conducted 
in a high EIR area (EIR -5 0 )  where new infectious bites occur frequently.
Data from a study conducted in Madagascar from 1996 to 2005 show age-stratified histograms 
of parasite density among 541 asymptomatic P. falciparum malaria patients (Figure 5 in their 
paper) 142. Across all age groups, the majority of asymptomatic cases had parasite densities 
lower than 500. A relatively high parasite density (>5OOparasites/pi) was observed in ~50% of 
children under ten and -25% of individuals older than ten. A very high asymptomatic 
parasitaemia (>5000 parasites/pl) was observed in -15% of under-tens and <2% of individuals 
over the age of ten.
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In our simulation, we use 1000 parasites/pl as the initial parasite density for an asymptomatic 
individual. During the asymptomatic phase, parasite density decreases according to the host’s 
level of immunity until it reaches 0.002 parasites per microliter which we define as the “cure 
level” where parasitaemia in the simulation is set to zero.
3.7.2 Symptomatic Hosts
It is generally accepted that the total parasite burden for a symptomatic patient varies from 1010 
to 1012 parasites24. Hence, for symptomatic adults and children we set the initial parasite density 
at 20,000 parasites/microliter (1011 total parasites), assuming that an adult individual has 5 liters 
of blood. For children the total parasite burden will be lower than 1011 parasites per 
symptomatic infection.
3.7.3 Detection Level of Microscopy
A review of malaria diagnostic tools shows that the detection limit of microscopy has been 
estimated to be 4-20 parasites/microliter; however, in field conditions, a detection level of 
around 50-100 parasites/microliter is more realistic 143. In our simulation, the detectable 
parasite density is chosen as 10 parasites/microliter and this threshold is used to determine the 
blood-slide prevalence, as show in Figure 4.1.
3.8 Pharmacokinetics / Pharmacodynamics
Each individual is assigned a relative drug concentration value (relative to the initial 
concentration) for each drug that he or she has received during a treatment. We use a basic 
pharmacodynamic (PD) model (showed in equation 9) to describe the exponential waning of 
drug concentration144:
C=C0 ■ e~klt (9)
where t is time in days, k\ is the elimination rate constant, and C0 is the maximum initial
concentration after dosing. When an individual is treated, the initial drug concentration C0 will
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be drawn from a normal distribution with mean of one and standard deviation ranging from 0.1 
to 0.4; C0 will be constrained to be within the range [l-3*sd, 1+3 *sd]. The variation in CO 
mimics patient variability in drug absorption and/or patient variability in body size. By 
adjusting the value of the standard deviation, we can vary the efficacy of a particular drug 
(explained below).
The relationship between k\ and drug half-life is given by the equation 10.
where t* is the half-life of the drug.
To formulate the pharmacokinetic (PK) model, a modified version of the standard Michaelis- 
Menton equation (which is known as Hill’s equation ) was used 145>146:
p ( 0  =  P m ax  ■ ( c n+ £ r n )  ( 1 1 )
is the fraction of parasites that are killed in a given day. The value C is the current drug 
concentration, pmax is the maximum fraction of parasites that can be removed by a drug in one 
day, EC50 is the concentration level corresponding to 50% effect, and n is the slope of the 
concentration-effect curve. In the simulation, the parasite density is updated according to the 
equation 12.
p ( t)  = ( i - p ( C ) ) - P ( t - i )  (12)
We can consider the term (1 — p(C ))-1 as the parasite reduction ratio and (1 — pmax) _1 as
the initial parasite reduction ratio. In the simulation, estimated in vivo PRR values of different
drugs, as shown in Table 3.5, correspond to the following pmax values for antimalarial drugs.
A ntim alarial drugs PRR/day 1 P m ax
Artemnisinin, artesunate, 10A2 - 1 0 A2.5 1 0.99 -  0.9968; see also 147
artemether 1 for a higher estimate
4-Aminoquinoline (Cholorquine, 
Amodaquine), halofantrine
o1o ! 0 .9 -0 .9 9
i
!
Quinine, mefloquine, sulfadoxine- 
pyrimethamine
i/"i<o1ino<o j 0 .6 8 -0 .9684
j
56
Chapter 3. Model Construction and Model Validation
1 Antimalarial antibiotics I 10A0.35 -  10A0.5 0 .55-0 .6838
j (doxycycline, clindamycin), 1
j desferrioxamine |
Table 3.5. Maximum parasite killing rates for different antimalarial drugs123.
Intuitively, one would expect to vary the pharmacodynamic parameters p max, EC5 0 , and n to 
vary the efficacy. However, the PD process outlined in equation (12) is very deterministic as 
parasite numbers are very high; i.e. there is very little variability in outcomes when equation 
(12) is simulated forward stochastically. Therefore, the 7-day efficacy, 14-day efficacy, 28- 
day efficacy measures will all be either 0% or 100%, regardless of how the three PD parameters 
are varied. As another option for introducing variability, we may like to draw the parameters 
Pmax, EC5 0 , and n from a distribution to introduce some variation, but estimates of these 
parameters (i.e. means) are already difficult to obtain from data and choosing/estimating the 
right distributions is difficult. The simplest choice is to introduce stochasticity into the 
parameter Co, as it is known that patients have different body sizes and different absorption 
rates. By choosing Co randomly for each patient and simulating 10,000 patient treatments, we 
can measure the x-day efficacy, for any x, of a particular set of PD parameters. If Co were to 
remain fixed, all of the efficacy measurement from a 10,000-patient simulation would be 0% 
or 100%.
Drug half-life values were obtained from a 2001 WHO Report on antimalarial drug use 148 and 
several other sources (shown in the table 3.6).
! D rug Half-life (**)
! C hloroquine 10 days
I A m odiaquine 9 (7-12) days 149
! Sulfadoxine 8 days
! Pyrim etham ine 4 days
1 Proguanil 16 hrs
i Quinine, quinidine 10-12 hrs
1 M efloquine 10-40 days
j H alofantrine 1-6 days
1 Artem isinin derivatives 4-11 hrs (DHA: 11-12 hrs)
I Lum efantrine 3-6 days 150
| P iperaquine 33 days 151
Table 3.6. Half-lives of antimalarial drugs.
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To find specific values of n and EC50 for a particular drug or drug combinations, we fixed the 
drug half-life and pmax value which are known, and we adjusted n (ranging from 10 to 25 with 
step equals 1), EC50 (ranging from 0.4 -  0.6 with step equals 0.1), and the standard deviation 
of the initial drug concentration (ranging from 0.1 to 0.4 with step equals 0.1) until the PK/PD 
profile of that drug (for 10,000 treatments) or combination corresponded to the treatment 
efficacy measured from clinical trials. For example, for artemether-lumefantrine, we set a half- 
life of zero days (i.e. drug is completely out of the system on the following day), n=25, 
EC5o=0 .6 , /?max=0.999 147 for artemether, and a half-life = 4.5 days, n=21, EC50-O .6 , /w -0 .9 9  
for lumefantrine. This corresponded to a treatment efficacy of 94.9%, when using a standard 
deviation of 0.4 for Co.
Note that the one-day time step in the simulation is a major limitation for modeling the 
clearance artemisinin and its metabolites, as these molecules are cleared from the system very 
quickly. The model essentially approximates the action of artemisinin derivatives for one day, 
and then assumes that the compound is completely absent from the system in the next time step 
if the patient is not dosed again.
3.9 Model of Immunity and Symptoms
Using M as the variable describing the general immune level (0 < M <  1), the equation for 
immune acquisition while a host maintains a blood-stage infection is defined in equation 13.
1 -  m (t2) =  ( l  -  M (ti)) (13)
where the rate of immune acquisition {ai) increases with age. We model this age dependency 
by allowing the rate aj to increase by 1% every year for hosts over the age of ten. For hosts 
under the age of ten, we use a convex function to describe the slower immune acquisition 
observed in children. For children under ten (1 < a < 10), the age-specific immunity acquisition 
rate is defined by equation 14.
a2(a) =  (a /1 0 )K x (1.01)a x 0.00125, (14)
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where a  is treated as an integer and k  determines the convexity of the function (this is fit from 
Figure 3.1 and Figure 3.2 below). Individuals younger than six months have maternal immunity 
(see below) with no immune acquisition; individuals between 6 and 12 months no longer have 
maternal immunity and acquire immunity when infected at a rate ai that is half as fast as the 
rate for one-year olds. The parameter k  sets the convexity age-specific immune acquisition -  
for low k  the immune-acquisition rate of children quickly reaches the normal level observed in 
adults, and for high values of k  children will have slow immune acquisition rates until they 
reach an age of nine or ten. We varied k  between 0.1 and 5.0 to determine how it affected rates 
of clinical presentation, and in our simulations we use k  = 1.0.
For individuals older than ten, the immune acquisition rate is defined by equation 15.
a2(a) =  (1.01)a- 10 x 0.0013809 (15)
Using these parameters, a naive ten-year old child would reach a state of 80% immunity
(M=0.8) in about three years. A naive 30-year old adult would reach this state after about 2.5
years. Assuming k =  1.0, a persistently infected two-year old would reach 80% immunity by 
age nine, and a persistently infected five-year old would reach 80% immunity by age ten. 
Figure 3.1 shows the immune acquisition by age under different kappas.
Immunity wanes according to the equation 16.
M (t2) =  M (ti) e - aiV2-ti) (16)
where a \  is set to 0.0025. This corresponds to 90% immune loss after 2.5 years94. Newborns 
are given maternal immunity (M= 1) which wanes linearly over six months and is then set to 
zero.
The level of immunity M  determines the duration of parasitaemia (see Section 3.3) and the 
probability that a new infectious bite leads to symptomatic/clinical malaria. Our model most 
closely resembles the immunity model in Filipe et a l.94, which describes two types of immunity 
in individuals that are acquired and lost at different rates. In our model, there is a single
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immunity variable but this variable M  determines two clinical phenotypes (probability of 
developing symptoms and rate of parasite clearance) that are acquired and lost at different rates 
as they are non-linear functions of M.
Note that the behavior and structure of our immunity model will not exactly mirror that of the 
2007 Filipe model, as their model is compartmental and immunity is modeled as a population- 
level variable. For example, in our model a na'ive individual can become infected and acquire 
a higher degree of immunity, associated with faster clearance, over the 6-month duration that 
he/she is clearing parasites; but in a compartmental model with a population-level immunity 
variable this host would remain naive and a slow-clearer as long as the EIR and prevalence in 
the population remained low.
The probability of progression to symptoms, as a function of M, is modeled as equation 17.
p‘‘< » = T T o % b F  ( l7)
The value 0.99 is the maximum probability when an individual is immunologically naive; the 
parameter z  describes the relationship between the level of immunity and the likelihood of 
developing symptoms, and z  is varied between 2.0 and 8.0 to determine its effects on patterns 
of clinical malaria; we set Mmid to 0.4 as in the Filipe paper94. Figure 3.2 shows the probability 
of progressing to clinical disease after in infectious bite, based on host’s immune level and the 
parameter z.
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Figure 3.1. Immune acquisition by age under different kappas. The y-axis shows a child’s relative 
immune acquisition rate when compared to a ten-year old. Ten different lines are drawn for different 
values of the k  parameter ranging from 0.1 to 5.0.
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Figure 3.2. The probability of progressing to clinical disease after in infectious bite, based on host’s 
immune level and the parameter z.
3.10 Incidence of Clinical Episodes by Age
Because there is no single measure o f immunity, and because some o f the unknown parameters 
from Section.3.9 (a\, z, and k) are impossible to measure directly, we perform a model 
calibration to determine suitable parameter values so as the age-stratified annual incidence o f  
clinical episodes in the simulation matches what is observed in the field.
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If immune acquisition is rapid and if immunity has a strong effect on protecting individuals 
from severity/symptoms, then the age distribution of clinical cases should have a spike in the 
younger age groups with a rapid drop off as age increases. If immune acquisition is slow with 
weak effects of symptoms prevention, the age-distribution of clinical cases would look flat in 
low-transmission areas and nearly-flat (slowly decreasing with age) in higher transmission 
areas. Essentially, as EIR increases children acquire immunity more quickly, and a larger 
fraction of clinical episodes should be observed in the younger age classes.
We use eight sites (from five publications) that report incidence patterns of clinical episodes by 
age for varying levels of EIR. The table below shows the annual incidence of clinical malaria 
episodes for 2-year olds, 10-year olds, and 17-year olds for these eight sites. These age groups 
were chosen for convenience based on the available data. The numbers in the table 3.7 are 
approximations as it is only necessary to see roughly how the age-specific clinical episodes 
change relative to one another when the EIR is changed.
Clinical Episodes Per Year
Age
Study Reference EIR 2 10 17
Mwangi et al152 10 1.60 0.50 0.35
Saute et a l153 18 0.42 0.13 no data
Trap and Rogier 154 30 2.10 2.70 1.20
Mwangi et a l152 37.5 1.55 0.30 0.25
Guinovart et al155 38 0.87 0.28 no data
Trap and Rogier 154 200 5.00 0.60 0.30
Table 3.7. EIR and clinical episodes/year by for ages 2, 10, and 17, extracted from 4 referenced studies. 
Figure 3.3 and Figure 3.4 show the ratio, from the table above, of clinical episodes in 2-year
olds to clinical episodes in 10-year olds. These data are compared to our simulation output.
Simulation results show that the ratio of clinical episodes in age-group 2 to age-group 10 has a 
positive log-linear relationship with EIR. The square distance between the model output 
(selected EIR values only) and the field data with k  = 1 and z = 4 is at a minimum when/  = 0.0 
(figure 3.3) and this is the third best among 40 other K-and-z combinations whenf -  0.5 (figure 
3.4). With/  = 0.5, the best 3 minimum square distances are 24.2, 24.3 and 25.11 with the three
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combinations k  = 0.4 and z = 4; k  = 0.5 and z = 4; and k  = 1 and z = 4, respectively. Thus, we 
chose the combination k  = 1 and 2 = 4 as the closest match to the data points shown in the last 
panel of Figure 3.3 and Figure 3.4, and we fix k  = 1 and 2 = 4 in our simulations.
We also verified that the EIR-prevalence relationship (Section 3.12) and EIR-multiplicity of 
infection relationship (Section 3.14) were not sensitive to the values of 2 and k .
After choosing a particular immune acquisition behavior for our model (tc= 1 and 2 = 4), we 
test whether the model reproduces the expected age-specific clinical pattern under different 
transmission scenarios. The burden of clinical disease should shift from the older age-group to 
the younger age-groups as transmission rate increases, and this is indeed what we observe in 
Figure 3.5 (no treatment) and Figure 3.6 (50% treatment coverage).
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3.11 Prevalence of Symptoms and Blood-Slide Prevalence {(p value)
For all age classes, we are interested in the ratio of symptomatic cases over all infected cases 
(what we call the “(p value”) as this will give us a measure of the selection pressure on the 
parasite population as only symptomatic cases are treated. We would expect that for (p 
decreases as EIR increases, as in the model described by Boni et a l52. Very few data exist on 
this measurement. A recent review on asymptomatic parasitaemia and transmission showed 
that (p ranges from 0.40 to 0.01, as prevalence increases from 1% to 85% 156. Yekutiel reports 
(p as being between 0.06 and 0.17 157. In two other studies, it appears to be below 0.20 158’159. 
Note that this ratio is very sensitive to the denominator, which is very sensitive to the detection 
method used in each study.
In our simulations, the range of (p does stay below 0.20, and <p decreases with EIR. However, 
we also observe a complicated interaction between (p and age. As shown in Figure 3.7 and 
Figure 3.8 below, the ^-value for younger age groups (<10) increases as EIR increases; the 
explanation for this is that in high transmission areas, children are bitten more often and 
experience symptoms more often.
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3.12 Relationship between EIR and Malaria Prevalence
It is well known that the relationship between the entomological inoculation rate (EIR) and 
malaria prevalence (PR) should be non-linear, as prevalence will saturate close to 100% as EIR 
increases. Beier et al (1999) reviewed data from 31 sites in Africa and suggested a linear 
relationship between log(EIR) and prevalence (their Figure 1) 160. Similarly, Hay et al 161 
analyzed data from 22 countries across Africa between 1980 and 2004 and also found the log- 
linear relationship between EIR and PR. Figure 3.9 and Figure 3.10 show this relationship for 
our model. Saturation at high EIR is seen as expected, and a general log-linear relationship 
(bottom panel) is seen between EIR and prevalence.
As a second validation, we consider an EIR-PR relationship (showed in equation 18), proposed 
by Smith et al (2005), which includes biting rate heterogeneity 115.
P f i=  (18)
where s is EIR, b is the probability that an infectious bite results in an infection, r is the host’s 
clearance rate, and l/k  is the variance of a unit-mean gamma distribution describing 
heterogeneity in biting rates. This model fit the data 161 better than five other models they 
proposed.
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3.13 Prevalence by Age
As discussed in previous sections, it is believed that immunity is acquired slowly in the 2-10 
age group, with individuals over the age of ten acquiring immunity (as a result of parasitaemia) 
at approximately the same rate. A result of this assumption is that older age groups should have 
faster clearance rate and lower prevalence compared to younger age groups, as is observed in 
the field119. A decrease in transmission or prevalence may lead to a shift in peak risk of malaria 
infection to older age groups I62_164. Age-specific prevalence data, summarized by Smith et al 
165, show the shift in peak prevalence from older age groups to younger age groups as 
transmission increases. In a hypoendemic area, the prevalence appeared to be distributed 
equally across all the age groups. Our model exhibits the expected age-specific prevalence 
patterns as shown in Figure 3.11 and Figure 3.12.
3.14 Multiplicity of Infection
The multiplicity of infection (MOI) data from Owusu-Agyei et al 166 is used to validate the 
distribution of the number of parasite clones within each host. The EIR in the Owusu-Agyei 
study is estimated at approximately 300 bites per person year. We generate two model 
scenarios with this high level of transmission (Figure 3.13 and Figure 3.14) and plot the 
multiplicity of infection (MOI) distribution from the equilibria reached in these simulations, 
alongside the data from the Owusu-Agyei paper (green squares below).
The shape of MOI distribution depends on the transmission intensity. In a low-transmission 
setting, most infected individuals have a single parasite clone present in their blood, while in 
high-transmission areas the majority of individuals have multiple clones present. Amot 167 
showed a relationship between EIR and the average number of malaria parasite clones per 
infection with a positive linear association on a log-log scale. Our model output shows a similar 
pattern (not shown here), but there are simply too few data points from the field on the EIR- 
MOI relationship to determine what the null shape of this distribution should be.
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Number of Clones
Figure 3.13. Distribution of number of clones per infection. The bar graph shows the output from our 
simulation with EIR = 290 while the dashed line (green squares) represents the data from Owusu-Agyei’s 
study with EIR approximately 300 ( k  = 1, z = 4 , /  = 0.0).
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Figure 3.14. Distribution of number of clones per infection. The bar graph shows the output from our 
simulation with EIR = 335 while the dashed line (green squares) represents the data from Owusu-Agyei’s 
study with EIR approximately 300 ( k  =  1, z = 4, /  = 0.5, with a single 7-day half-life drug of 
approximately 80% efficacy).
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3.15 Biting-Rate Heterogeneity and Prevalence
Heterogeneity in transmission was modeled by assigning a relative biting level (&,) to each host, 
which describes that host’s relative attractiveness to mosquitoes. The higher an individual’s 
relative biting level, the more frequently mosquitoes will bite that individual. A convenient 
and classic formulation of transmission heterogeneity is the “20/80 rule” 168 which states that 
in many epidemiological scenarios with transmission heterogeneity 20% of the population is 
responsible for approximately 80% of transmission.
The relative biting levels (&,) in our simulation follow a gamma distribution. In the Smith et al 
paper115, the inferred coefficient of variation (mean 1, variance 4.2) is approximately 2.05, and 
we set this coefficient of variation as our default. Sensitivity analyses (Section 4.4.3) are 
conducted with coefficients of variation set to 1.0 and 2.0.
The effect of the standard deviation on the 20/80 rule is shown in the figure 3.15 and 3.16.
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Chapter 4 
Optimal Population-Level Deployment of 
Artemisinin-Combination Therapies
This chapter is an expanded version of the main text of a manuscript titled “Optimal population- 
level deployment of artemisinin combination therapies.” This manuscript was published on 
Lancet Global Health in November 2015. In order, the authors on this manuscript are myself, 
Piero Olliaro, Arjen Dondorp, J Kevin Baird, Ha Minh Lam, Jeremy Farrar, Guy E Thwaites, 
Nicholas J White, and Maciej F Boni.
In this chapter, the individual-based individual is used to evaluate which population-level 
approaches to distributing ACTs are most effective at (1) reducing the cumulative number o f 
treatment failures over twenty years and (2) minimizing the risk that a novel artemisinin- 
resistant genotype emerges.
Section 4.2.1 describes drugs and strategies that are used to compare in the simulation, while 
Section 4.2.2 describes four evaluation criteria that are used.
Section 4.4.1 shows the results of the compared strategies.
Section 4.4.3 shows the sensitivity analyses. These sensitivity analyses were performed to 
determine the effects of differences in transmission setting, treatment coverage, partner-drug 
half-life, the fitness cost of drug resistance, and the relationship between drug concentration 
and resistance evolution. Sensitivity analyses were carried out with populations of 500,000 
individuals (for quicker simulation runs).
4.1 Introduction
Over the next decade, significant public health effort and financial resources will be expended 
to eliminate malaria in as many parts of the world as possible169. In this endeavor, multiple
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antimalarial tools will be used, including antimalarial treatment for clinically acute cases, 
antimalarial chemoprophylaxis in at-risk populations, insecticide treated nets (ITN), household 
insecticide use, improved diagnostics, and expansion of health service delivery170. For some of 
these interventions, we will need to be concerned with long-term diminishing returns as drug 
or insecticide resistance emerges and as mosquitoes adapt their behavior to ITN use and 
insecticide application. Efforts to maximize the effects of elimination campaigns are important, 
and so too are those aimed at minimizing the chances of an emergent drug or insecticide 
resistance phenomenon occurring during this period171. Such an event would seriously 
undermine the ambition and progress of any malaria elimination program.
Since 2005, the World Health Organization (WHO) has strongly endorsed first-line use of 
artemisinin-based combination therapies (ACTs) for uncomplicated falciparum malaria 
because of their safety and rapid action against asexual blood stages including some 
transmission stages27,172. In addition, the WHO discouraged artemisinin monotherapy to reduce 
recrudescence rates and to decrease the probability of de novo artemisinin resistance emerging 
in individual patients. The partner drug in a coformulated ACT always has slower elimination 
than the rapidly eliminated artemisinin derivatives, offering protection during the course of 
treatment against the de novo emergence of an artemisinin-resistant genotype. For artemisinin 
resistance to emerge, a parasite must be capable of surviving exposure to both artemisinin and 
the partner drug -  a highly improbable event unless the infecting parasite population already 
carries resistance genes to the partner drug.
Despite these precautions aimed at preserving the efficacy of artemisinin-based therapies, the
dangers of artemisinin resistance still warrant serious concern. A partially-resistant, slow-
clearing P. falciparum phenotype emerged in Cambodia in the 1980s or 1990s17,19. This same
phenotype was later observed on the border between Thailand and Myanmar45, in southern
Vietnam near the Cambodian border173,174, and is now established in much of mainland
Southeast Asia174,175. Slow parasite clearance is now strongly associated with a group of
polymorphisms in the P. falciparum kelch propeller domain19,174. In devising strategies to
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contain or extinguish this resistant genotype, we must also consider the potential for future 
resistance and that a fully artemisinin-resistant genotype could emerge in the next decade.
Artemisinin pressure on parasites is likely to increase over the next decade as (/) ACTs will 
remain the most commonly used antimalarial therapies, (ii) existing partner-drug resistance is 
likely to spread to areas where the corresponding ACTs are used, and (iii) artemisinin 
monotherapies are still likely to be used to some extent in contravention of strong WHO and 
national-level health policy recommendations. In addition, in individual patients, underdosing 
with artemisinin-based drugs may be a concern as subtherapeutic doses create an environment 
favorable to the fixation of drug-resistant genotypes176. Underdosing may occur as a result of 
substandard drugs177, insufficient absorption, poor adherence practices, or the prescription of 
subtherapeutic doses especially in hyperparasitaemic cases (who require higher doses than 
patients with lower parasite densities) and young children or pregnant women (who have lower 
drug exposures)176,178. For these reasons, additional measures should be taken to ensure that 
the evolutionary selection pressure for artemisinin-resistant genotypes is as low as possible for 
as long as possible.
A key biological principle underpinning potential strategies for slowing down the evolution and
spread of a novel mutant is that evolution occurs more slowly in heterogeneous or variable
environments179. Combination therapy takes advantage of this principle by introducing drug
heterogeneity into a pathogen’s environment and forcing the pathogen population to adapt to
multiple new environmental features simultaneously. This same principle can be applied at the
population level, by having a parasite encounter different drugs in different individuals. The
two commonly explored approaches to achieving this effect are drug cycling -  where a single
therapy is used population-wide for a certain amount of time before it is replaced with a
different therapy -  and the simultaneous distribution of multiple therapies in a population. Both
of these strategies have been evaluated with mathematical models for bacteria180-182 and
malaria52,183-185, and the strategy of simultaneous distribution is generally found to be more
effective at delaying resistance evolution and keeping prevalence low for a longer period. One
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of the reasons is that under a strategy of simultaneous distribution of different drugs the 
parasite’s environment is more variable52,182. In this scenario, even if a de novo resistant 
parasite were to emerge in a single host, it would have difficulty establishing itself in the 
population as there would be at least a 50% chance that the parasite’s next host would not be 
treated with the same drug. Under a drug cycling strategy, this effect would be as strong only 
if the drugs were being cycled in and out very rapidly, on the order of the generation time of 
the infection.
Here, we evaluate the optimal distribution of ACTs at the population level (see evaluation 
criteria in section 4.2.2), specifically focusing on a strategy of multiple first-line therapies52 
(MFT) -  in which therapies are simultaneously recommended as first-line and are prescribed 
to individual patients according to some random factor (e.g. day of week, true randomization) 
-  and comparing it to strategies of cycling or sequentially deploying single first-line ACTs. 
The optimal strategy in this chapter is simply the best strategy among the three presented; these 
three were chosen as they are all relatively simple strategies that could be implemented on a 
large scale. We developed and validated (Chapter 2 and Chapter 3) an individual-based 
microsimulation to answer this question, and our model represents an advance over previous 
efforts to address this question, as it accounts for key features of malaria epidemiology that 
affect patterns of resistance evolution: age-specific immune acquisition, biting rate 
heterogeneity, drug pharmacokinetics and pharmacodynamics, asexual parasite density, 
multiplicity of infection, and recombination.
4.2 Strategy Comparison and Evaluation Criteria
Assuming that three ACTs with different partner drugs are available for treatment, three 
population-level treatment strategies were compared in the simulations. The half-lives and 
efficacies of the therapies in the simulation were set to mimic the characteristics of artesunate- 
amodiaquine (ASAQ), artemether-lumefantrine (AL), and dihydroartemisinin-piperaquine 
(DHA-PPQ) 148~151.
78
Chapter 4. Optimal Population-Level Deployment of ACTs
4.2.1 Strategies
Multiple first-line therapies (MFT). In a strategy of multiple first-line therapies, one-third of 
individuals are treated with one ACT, one third with a different ACT, and the final third with 
the remaining ACT. If the treatment coverage parameter i s / =  0.6, this means that 40% of 
individuals would not be treated for a symptomatic malaria infection (due to lack of access, 
inability to pay, not reporting to a clinic or pharmacy, etc.). The model would then assign 20% 
of individuals to be treated with the first ACT, 20% to the second ACT, 20% to the third ACT, 
and 40% to no treatment.
Five-year cycling. In a 5-year cycling strategy, a single ACT is used in the population at any 
one time and the ACTs are rotated out and switched every five years. We compared several 
cycling strategies in a previous publication 52 (2-year cycling, 3-year cycling, etc). Here, we 
choose five years as a feasible schedule which could be implemented at a national level in an 
endemic country. Shorter cycling periods are of course associated with improved outcomes, as 
they create more variability for the parasite population and slow down the pace of resistance 
evolution. The shorter the cycling period, the closer this strategy approximates an MFT 
strategy.
Sequential Deployment. The third strategy is meant to mimic the status quo approach of 
rotating therapies out when they begin to fail. We call this ‘sequential deployment’, and under 
this strategy switches occur when the treatment failure rate (using a 60-day moving average) 
reaches 10%, the WHO criterion for replacing first-line therapies27; a one-year delay is built in 
to this strategy as it is known that switching first-line drugs at the national level can take a 
significant amount of time and effort186. This is optimistic, but we used this one-year delay to 
compare the best possible sequential deployment strategy against the two alternatives. In a 
previous publication, this strategy was called ‘adaptive cycling’ 52.
Multiple first-line therapies with one non-ACT component. For the Figure 4.6, we 
evaluated an MFT strategy with two ACTs (ASAQ and AL) and one non-ACT therapy. The
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non-ACT component in this strategy was a combination therapy whose components have 7-day 
and 10-day half-lives, mimicking the pharmacodynamics of chloroquine and sulfadoxine- 
pyremethamine.
4.2.2 Evaluation Criteria 
Four evaluation criteria are used:
NTF. The number of treatment failures per 100 individuals per year over the 20-year course 
of the simulation. This measure is discounted with a 3% annual discounting rate. Non­
treatments are counted as treatment failures; if this were not done, then policies with low 
coverage if) would appear optimal as they would treat the fewest people and drive resistance 
evolution at the slowest rate.
AMU. Artemisinin monotherapy use is a risk measure describing how exposed to resistance 
evolution the artemisinins are under a particular strategy. “Exposed” in this context means “not 
protected by the partner drug”. To compute the AMU measure, we run a separate set of 
simulations with the artemisinin-resistance mutation parameter set to zero, and we count all 
treated cases in which an individual with parasites resistant to partner-drug x  is treated with an 
ACT containing the same partner drug x. We call this type of treatement de facto  artemisinin 
monotherapy use because only the artemisinin component is acting in this situation. AMU is 
simply an absolute count of all cases of de facto artemisinin monotherapy use during a 20-year 
simulation.
We reported three types of AMU measures in our simulation: by person, by parasite clone, and 
by person but weighted by the number of parasite clones. Consider an individual with 5 clonal 
P. falciparum infections in the blood, two of which carry amodiaquine resistance. If this person 
were treated with ASAQ, then we could count this as 1 AMU (‘by person’ measure), 2 AMU 
(‘by parasite clone’), or 2/5 AMU (weighted measure). All three measures had similar
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behaviors when comparing treatment strategies. In Figure 4.5, we present the weighted 
measure.
We do not discount the AMU measure as we are trying to compare the relative probabilities 
across treatment strategies that, over a 20-year period, a novel artemisinin-resistance genotype 
could emerge and establish itself. Alternatively, AMU can be thought of as the total amount of 
“selection pressure via artemisinin monotherapy” present during a 20-year period. Comparisons 
using a discounted AMU measure were qualitatively identical to those shown in Figure 4.5.
UTL. In an MFT strategy, this is the time until the treatment failure rate reaches 10%. 
Treatment failure is computed in all simulations as a moving average over the past 60 days as 
this is what is likely to be picked up by surveillance systems. For the cycling and sequential 
strategies, the UTL is defined as the total time during the 20-year simulation that the treatment 
failure rate is below 10%. Note that the treatment failure rate computed in the simulation 
includes the usual expected treatment failure even when the parasite population is drug- 
sensitive. For this reason, the UTL would not be a useful measure for a drug or therapy with 
91% efficacy as 10% treatment failure could be reached very quickly.
Tm . The time at which the “genotype frequency of resistant alleles” reaches 1% in the 
population. If four drugs are being used in the population, then each parasite can be a single- 
resistant, a double-resistant, a triple-resistant or a quadruple-resistant. Ifpi is the frequency of 
single-resistant genotypes, p i the frequency of double-resistant genotypes, etc., then the 
“genotype frequency of resistant alleles” is defined as equation 19.
^ P l + ^ P 2 + ^ P 3 + P 4  (19)
The frequencies are calculated across parasite clones. This quantity is equivalent to the 
probability that if a parasite genotype is chosen at random and a drug is chosen at random, that 
the parasite will carry resistance to that drug.
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When comparing two strategies, we test statistically for rank differences in the outcome 
measures (Mann-Whitney Test) as well as differences between the medians, 25th percentiles, 
and 75th percentiles (Mood’s Test). To summarize, we present the maximum of these four p- 
values, unless stated otherwise.
4.3 Ecological Rationale for MFT
Basic ecological and evolutionary theory has demonstrated the rationale for using multiple first- 
line therapies. First, as described by Bergstrom et al 182, deploying multiple drugs 
simultaneously creates a more variable environment for the pathogen and makes any specific 
type of resistance evolution more difficult. Second, as described in Boni et al 52, cycling 
strategies have a particular detrimental effect on driving drug resistance, because each 
individual cycle drives the evolution of a particular resistant genotype. Hence, at the end of a 
cycle, we may observer one resistant genotype at a very high frequency in the population. 
When the second “drug cycle” begins and when the second drug-resistant type emerges, this 
newly emerged genotype will only have to outcompete resistants that have persisted from the 
previous treatment period. This is an easier evolutionary competition to win than one where 
drug-resistant genotypes have to outcompete wild-types. Cycling strategies, therefore, make 
resistance evolution (for all resistant types) easier by strongly driving the evolution of the first 
drug-resistant genotype. Third, as we will show later in this chapter, cycling strategies are 
susceptible to epidemiological rebounds and MFT strategies are not. Figure 4.1 shows what 
occurs at the end stages of each cycle: prevalence increases above the expected level at endemic 
equilibrium because of a temporary excess of susceptibles in the population. Epidemiological 
rebounds can occur under many disease dynamic scenarios. For malaria, they can be associated 
with a substantial increase in morbidity and mortality, and they should be avoided if possible.
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4.4 Results
4.4.1 Strategy Comparisons.
The deployment of multiple first-line therapies (MFT) had consistently better population-level 
outcomes than either cycling strategy, and the superior performance of MFT was robust to a 
variety of transmission, clinical, and evolutionary settings. As noted in previous modeling 
efforts52,182, an MFT strategy creates a more variable environment for the malaria parasite, 
which results in delayed resistance emergence and slower drug-resistance evolution. This is 
true even when allowing for free recombination among resistance loci, which was previously 
raised as a potential concern when evaluating the benefits and drawbacks of MFT strategies187. 
Figure 4.1 shows typical evolutionary-epidemiological trajectories for malaria under the three 
treatment scenarios we evaluated.
A strategy comparison in a low-transmission setting corresponding to an EIR of 1.3 infectious 
bites per person per year (Figure 4.3) shows significant variation, due to the stochastic nature 
of the model, in the number of treatment failures (NTF) and the time until resistance emergence 
(T01); note that in some high-coverage settings treatment drives the parasite population to a 
'sticky elimination’188. When resistance does evolve (0.5 < / <  0.7), MFT strategies have 
median NTF values that are between 16% and 41% lower (p < .003; Mood’s test) than either 
sequential or cycling strategy; this difference is larger for higher costs of resistance. In addition, 
elimination was observed more often under MFT strategies as these strategies preserve full drug 
efficacy for longer than either cycling strategy. Figure 4.4 shows that low NTF values are 
closely associated with longer times to emergence. MFT strategies exhibit a higher mean and 
more variation in their associated time-to-emergence (an expected outcome from a waiting 
process), resulting in a higher proportion of simulations in which resistance emerges very late 
or not at all during the 20-year model simulation.
Because these model simulations rely partially on the prediction of rare events (the emergence
of artemisinin resistance), we ran a separate set of simulations to quantify the risk of artemisinin
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resistance using the AMU criterion: the total number of cases during the 20-year simulation 
where a partner-drug resistant infection was treated with an ACT (Figure 4.5). Excluding one 
comparison set in this figure, the median AMU outcomes for MFT strategies were between 
28% and 78% lower (p < 10'5; Mood’s test) than for either cycling strategy, suggesting that 
MFT strategies may carry a much lower risk of selecting for de novo artemisinin resistance. 
Essentially, MFT strategies delay and decelerate partner-drug resistance evolution, thus 
prolonging the time that artemisinin-based drugs are used as combination therapies with both 
components effective.
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Figure 4.1. Expected paths of drug-resistance evolution and corresponding malaria prevalence under 
three different treatment regimes. One hundred stochastic simulations were run in a population of one 
million individuals, in a low transmission setting (EIR=1.3) with 60% treatment coverage and an 
assumed cost of resistance of 0.5% for all resistant genotypes. The mutation rate is assumed to be highest 
for intermediate drug concentrations. The black line shows the median prevalence across 100 
simulations, and the teal areas show the interquartile and 90% ranges. The media number treatment 
failures (NTF) with interquartile ranges are shown in each panel ( p <  10"6 when comparing MFT to the 
other two strategies). The dashed line shows 5% prevalence. For the cycling/sequential strategies, after 
the emergence of a novel drug-resistant type, an epidemiological rebound sometimes causes the 
prevalence to reach higher-than expected levels (here, >6%) for short periods.
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Figure 4.2. As Figure 4.1, 70 stochastic simulations were run in a population of one million individuals, 
in a high transmission setting (EIR=18) with 60% treatment coverage and an assumed cost of resistance 
of 0.5% for all resistant genotypes.
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Figure 4.3. Comparisons o f  MFT, five-year cycling, and sequential deployment. Figure shows the N TF- 
values -  the annual number o f combined treatment failures and non-treatments, per 100 individuals -  for 
different strategies, different costs o f resistance ( c r ) ,  and different treatm ent coverages (/). Each row 
shows the NTF results o f  100 model simulations with the colored bars spanning the interquartile range. 
NTF values are lower under multiple first-line therapies; all p  < 10'4 except for the com parisons m arked 
a and b where p  < .01. For / >  0.7, the NTF distributions had a bimodal shape with N TF < 0.5 
corresponding to simulations that achieved extinction or near-extinction; the numbers on the left-hand 
side o f  each boxplot show the counts o f  these (near)-extinctions, and the interquartile ranges are plotted 
only for simulations that did not result in extinction. Simulations assume that three ACTs with 95%  
efficacy are available and that the three partner drugs have 4.5-day, 9-day, and 28-day half-lives 
(corresponding to lumefantrine, am odiaquine, and piperaquine, respectively). Simulations are done in a 
low transm ission setting with EIR=1.3. Drug-resistance mutations have their highest probability o f 
fixation at intermediate drug concentrations. Figure 4.15 shows the results for the case when m utation 
is proportional to drug concentration.
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Figure 4.4. As Figure 4.3, figure shows NTF values from the same simulations that are plotted against 
the time it takes the average resistance level to reach 1% frequency in the population. Note that the 
variance in time-to-emergence is greater for MFT strategies, resulting in a subset of simulations with 
long emergence times. Simulations are done in a low transmission setting with EIR=1.3. Drug-resistance 
mutations have their highest probability of fixation at intermediate drug concentrations.
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Figure 4.5. Comparisons of artemisinin monotherapy use (AMU) for MFT, five-year cycling, and 
sequential deployment. AMU-values are shown for different costs of resistance (cr), and different 
treatment coverages (/). Each row shows the AMU results of 100 model simulations with the colored 
bars spanning the interquartile range; AMU values are lower under multiple first-line therapies (all p  < 
.001) except for the two comparisons corresponding to a. Simulations assume that three ACTs with 95% 
efficacy are available and that the three partner drugs have 4.5-day, 9-day, and 28-day half-lives. 
Simulations are done in a moderate transmission setting (EIR=1.3). Partner-drug resistance mutations 
have their highest probability of fixation at intermediate drug concentrations. AMU decreases with 
treatment coverage because prevalence is lower when more individuals are treated. Figure 4.16 shows 
the results for the case when mutation is proportional to drug concentration.
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4.4.2 Further Options for Artemisinin Conservation.
In addition to deploying multiple first-line ACTs, we considered other possibilities that would 
allow us to preserve the efficacy of artemisinin-based drugs for as long as possible. From the 
analyses presented here and basic evolutionary theory, it is apparent that alleviating the 
parasites from artemisinin drug pressure should slow down artemisinin-resistance evolution. 
Employing a non-ACT alongside two artemisinin-based drugs in an MFT treatment strategy 
should have this effect. Clearly, the major consideration for such a strategy will be whether the 
non-ACT component is as effective and safe as an ACT. If this individual-level acceptability 
criterion is met, an MFT strategy with a single non-ACT therapy189 could have significant 
benefits in extending the lifespan of artemisinins. Figure 4.6 shows the lower NTF values and 
longer UTLs that would be associated with this strategy, the lower NTF being a direct result of 
a longer time-to-emergence for artemisinin resistance. In these simulations, the treatment 
coverage is 60%; thus, even in the worst-case scenario of 75% efficacy for a non-ACT therapy, 
only 4% of individuals in the model experienced a failing treatment as a result of not receiving 
an ACT. In the six scenarios in Figure 4.6, the median time-to-emergence for a strategy 
employing a non-ACT was between 43% and 71 % longer (p < .001; Mood’s test) than a strategy 
using three ACTs. With a mix of two ACTs and one non-ACTs, a third ACT would be 
preserved in case one of the partner drugs began failing early.
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Figure 4.6. Comparison using a non-ACT drug included in MFT strategy. Comparisons between MFT 
strategies with three ACT components and MFT strategies where one of the components of the treatment 
strategy is not an artemisinin-based therapy. Results of one hundred simulations for each strategy are 
summarized as normal distributions for NTF (shown in green out to ±2a), and as gamma distributions 
for the time until the frequency of artemisinin resistance reaches 1% (central 90% of distribution shown 
in green). The top panels use a standard mutation model (&=0.5) where the mutation rate is proportional 
to the drug concentration. The bottom panels show simulation results when the mutation rate increases 
at intermediate concentrations (k=4). Simulations assume that three ACTs with 95% efficacy are 
available and that the three partner drugs have 4.5-day, 9-day, and 28-day half-lives. In the simulations 
with 2 ACTs, the 4.5-day and 9-day halflife ACTs were used (minimizing selection pressure), and the 
non-ACT therapy is assumed to be a combination therapy whose components have 7-day and 10-day 
halflives. Treatment coverage isy=0.6.
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4.4.3 Sensitivity Analysis
To perform a sensitivity analysis to certain epidemiological, pharmacological, evolutionary 
parts of our model, a comprehensive set of simulations was done in order to vary the 
transmission setting, biting rate heterogeneity, treatment coverage, the relationship between 
drug concentration and mutation, drug half-life, and the fitness cost of resistance. The ranging 
values of the parameters are described below.
First we varied the transmission setting by varying the transmission coefficient /? (four different 
values) as well as the coefficient of variation in the biting rate (two different values). The 
equilibrium behaviors of these eight scenarios are described below. In these test scenarios, we 
assume that 50% of clinical cases are treated with a drug of 80% efficacy and a 7-day half-life.
Transm ission 
Coefficient ( f i)
| Coefficient of V ariation j 
j in Biting R ate j
Prevalence a t 
Equilibrium
A nnual E IR  a t 
Equilibrium
0.50 ! 2.0 [ 18.7% 18.0
0.50 1 1-0 1 23.1% 20.3
0.25 1 2.0 ! 9.17% 6.20
0.25 1 i.o i ... 9.20% 5.43
0.20 i 2.0 ! 6.56% 4.07
0.20 ! i.o i 4.88% 2.36
0.14 ! 2.0 i 2.70% 1.33
0.14 I i.o . j 0.01% <0.01
Table 4.1. Varying transmission intensity in sensitivity analysis.
Because the last scenario in the table above resulted in frequent extinction, this transmission 
setting was not used in the sensitivity analysis. Only the first seven transmission settings were 
used. Note that in the simulations, a different EIR will be observed as ACTs are used in our 
simulated scenarios and the equilibrium prevalence and EIR are lower than in the table reported 
above. The table above can be thought of as the “pre-ACT era” transmission setting.
The treatment coverage was varied across the five values f -  0.5, 0.6, 0.7, 0.8, and 0.9. It is 
important to remember that 80% coverage or 90% coverage are very high estimates for many 
malaria-endemic countries. In part, these high-coverage scenarios are being run to compare 
strategies in the hypothetical situation that coverage and access improve over the next decade.
The cost of resistance was varied across the three values c r  = 0.001, 0.005, and 0.010.
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To vary the effect of the drug concentration in the probability of drug-resistance evolution we 
varied the parameter k  (see “Drug Resistance Evolution” heading in Section 3.1). Three values 
are used, k = 0.5,2.0, and 4.0.
The drug half-lives were varied to test four different scenarios: (a) all three partner drugs have 
a half-life of 4.5 days, (b) all three partner drugs have a half-life of 9 days, (c) all three partner 
drugs have a half-life of 28 days, (d) the three partner drugs have three different half-lives of 
4.5 days (corresponding to lumefantrine), 9 days (corresponding to amodiaquine), and 28 days 
(corresponding to piperaquine).
In each of the above scenarios, it was assumed that three ACTs were available, and three 
strategies were evaluated: MFT, 5-Year Cycling, and Sequential Deployment.
Thus, a total of 3780 scenarios are simulated. This requires approximately 4-5 days of 
computation time on a modem 70-core computer cluster. A total of five complete sensitivity ■ 
analyses were run (18,900 simulations), and the results are summarized below.
Excluding extinctions, MFT was associated with the lowest NTF values in 86.2% of 
simulations; extinctions were also more common under MFT. The median reduction in 
treatment failures achieved by MFT was 10.6% (IQR: 2.9% - 20.0%; p  < 10'12) when compared 
to a 5-year cycling strategy and 9.6% (IQR: 3.0% - 18.6%; p  < 10'11) when compared to a 
strategy of sequential deployment.
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Figure 4.7. This boxplot shows the percent reduction in NTF achieved by using an MFT policy, when 
compared to sequential deployment (orange) and five-year cycling (red), across all parameter 
combinations in the sensitivity analysis. The boxes show interquartile ranges, stratified by different 
transmission intensities. For each parameter combination in the comparison, only scenarios with no 
extinction (NTF>0.25) are included in the calculation of interquartile ranges. The numbers at the top 
and bottom of each boxplot show the number of comparisons for which one strategy caused extinction 
but the comparator strategy did not. The green numbers indicate the number of simulations for which 
MFT resulted in extinction but the cycling/sequential strategy did not, while the red and orange numbers 
show the number of simulations when the cycling (red) or sequential (orange) strategies reached 
extinction but MFT did not. There are fewer extinction under E1R=4.07 than EIR=5.43, because the 
former is associated with a higher coefficient of variation in the mosquito biting rate. Across the different 
transmission settings and counting all simulations (including those that did and did not lead to extinction) 
NTF numbers are lower for MFT than other strategies (all p  < .002; Mann-Whitney).
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Figure 4.8. This boxplot shows the percent reduction in NTF achieved by using an MFT policy, when 
compared to sequential deployment (orange) and five-year cycling (red), across all parameter 
combinations in the sensitivity analysis. The boxes show interquartile ranges, stratified by different costs 
of resistance. For each parameter combination in the comparison, only scenarios with no extinction 
(NTF>0.25) are included in the calculation of interquartile ranges. The numbers at the top and bottom 
of each boxplot show the number of comparisons for which one strategy caused extinction but the 
comparator strategy did not. The green numbers indicate the number of simulations for which MFT 
resulted in extinction but the cycling/sequential strategy did not, while the red and orange numbers show 
the number of simulations when the cycling (red) or sequential (orange) strategies reached extinction but 
MFT did not. For the three different costs of resistance, and using all simulations (including those that 
did and did not lead to extinction), NTF numbers are lower for MFT than other strategies (all p  <  10-6; 
Mann-Whitney).
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Figure 4.9. As Figure 4.7 and Figure 4.8, stratified by EIR and partner drug half-life. For the higher 
transmission scenarios (top five rows), NTF numbers are lower for MFT than other strategies (p < 10'4; 
Mann-Whitney, for each boxplot). For the bottom two rows, the main qualitative feature of these 
comparisons is the number of total extinctions in the simulations (approximately 50%) and not a 
comparison of medians or ranks. MFT caused more extinctions than Cycling or Sequential Deployment 
in all of these comparisons; for simulations that did not result in extinction the NTF values for MFT were 
lower (p  <  .002; Mann-Whitney, for each boxplot).
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4.4.4 Comparison to Results in Antao-Hastings (2012)
In a 2012 paper in Malaria Journal, Antao and Hastings [66] performed comparisons between 
MFT and Sequential Deployment strategies. For certain parameter combinations (0.4 < /<  0.6; 
MOI = 2 or 4; c r  = 0.10), they observed that MFT strategies resulted in a quicker time to the 
10%-treatment-failure milestone and were thus associated with shorter useful therapeutic lives 
(UTL).
In this section, we attempt to recreate the conditions that led to these outcomes in the Antao- 
Hastings analysis. However, several important caveats need to be stated and some differences 
between the models need to be underlined. The differences between the model constructions 
are substantial, and the comparison presented in this section is approximate.
(a) The Antao-Hastings model (called ogaraK) does not explicitly model a population of 
humans. It only tracks gene frequencies of malaria parasites (as in a traditional population 
genetics framework). Therefore, some key aspects of malaria epidemiology are missing in this 
model and are not able to be compared to our model. For example, malaria prevalence cannot 
be tracked in ogaraK, and as resistance evolves in ogaraK it is not known if prevalence increases 
or by how much; hence, we cannot compare a prevalence trajectory from our model and the 
Antao-Hastings model. Likewise, ogaraK does not track clinical/symptomatic cases, age- 
structure of malaria cases, or MOI distribution, so these general epidemiological measures of 
malaria cannot be compared.
(b) UTLs can be compared between the two models, but NTF values cannot be compared, as 
a purely population-genetic model cannot track the total number of treatment failures in a single 
model simulation. We will present the NTF and UTL comparisons from our model below, but 
it is important to remember that the total number of treatment failures is the more appropriate 
health outcome measure for policy comparison, as this represents the number of individuals 
that will receive a failing/ineffective therapy during a fixed time period (in our model, 20 years).
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(c) OgaraK uses a fixed “generation time” of approximately 50 days, meaning that the model 
assumes that it takes about 50 days for one malaria infection to generate a second malaria 
infection. The generation time in our model is variable and dependent on symptoms, age, 
parasitaemia, biting rate, and current prevalence. The relationship between prevalence and 
generation time is especially important because at low prevalence the generation time will be 
longer, resulting in slower evolution in general; at high prevalence, mosquito bites are more 
common and the generation time is shorter, resulting in a faster process of positive selection or 
negative selection if either of these is occurring.
(d) OgaraK fixes its MOI distribution. The MOI distribution in our model is dependent on 
prevalence. At high prevalence, individuals get bitten more often by infectious mosquitoes and 
the number o f clonal parasite populations carried by each individual will generally be higher. 
The ogaraK simulations were run with MOI set to either 2 or 4 for all individuals. Because we 
cannot calibrate our model so that each host has exactly 2 or 4 clonal parasite populations, we 
chose prevalence levels where the mean MOI was equal to 2 or 4.
(e) There are other model differences that will affect the results. Our simulation has a model 
of immunity, within-host parasitaemia, immunity-mediated symptoms, immunity-mediated 
parasitaemia, and a transmission cycle that depends on parasite density levels, 
pharmacokinetics, pharmacodynamics, and biting rate heterogeneity. All of these features will 
affect the epidemiology and evolution in the simulation to some degree.
First, we attempted to calibrate the transmission setting in our model to mimic the MOI levels 
in the Antao-Hastings paper. We used these two transmission settings:
| Transm ission 
| Coefficient (/?)
Coefficient of 
V ariation in 
Biting R ate
Prevalence a t 
Equilibrium
A nnual E IR  at 
Equilibrium
M ean of M O I 
distribution
| 1.50 2.0 44.0% 94 2.12
j 8.00 2.0 83.8% 791 4.01
Table 4.2. Transmission settings used to compare with Antao-Hasting model.
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However, after running these at/ =  0.6 and c r =  0.10, we could not compare results because, in 
our model, a 60% coverage and a 10% cost of resistance do not generate sufficient selection 
pressure for rapid resistance evolution (note that both our model and the Antao-Hastings model 
use a multiplicative fitness model for cost of resistance in multi-drug resistant genotypes). Very 
little resistance evolution was seen in about 500 model runs, and the useful therapeutic lives of 
both strategies (MFT and Sequential) were equal to 20 years for a 20-year model simulation. 
This was not a consequence of the mutation rate or of the introduction/non-introduction of 
resistant mutants at the beginning of the simulation (we tested both hypotheses). This was 
simply a consequence of the resistant types experiencing a weak selective environment, which 
resulted in very slow resistance evolution.
Therefore, we set the cost of resistance to c r  = 0.025 in the MOI = 2 scenario, and we set the 
cost of resistance to c r  = 0.010 in the MOI = 4 scenario, in order to get resistance evolution 
times that were close to those seen in Figures 1 and 3 of the Antao-Hastings paper. Below we 
present the comparisons between an MFT strategy and a Sequential Deployment strategy under 
these conditions. For sequential deployment, normally the drugs are deployed as AL first, then 
AS-AQ, then DHA-PPQ, so that shorter half-life ACTs are used first to minimize drug pressure. 
For these comparisons, we also tested the inverse order (“Seq Depl Inv”), as the UTLs were 
quite long in most cases and using the long-half life drug first sometimes minimized prevalence 
and NTF.
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For MOI = 2, the comparisons between MFT and Sequential Deployment were:
Seq Depl Inv
Seq Depl
MFT +
33 34 35 36
NTF
37 38
Figure 4.10. Comparison of MFT and Sequential Deployment (one hundred simulations for each 
strategy) under the Antao-Hastings scenario of MOI = 2. Cost of resistance in this figure is c r  = 0.025. 
Treatment coverage is/ =  0.6. Drug-resistance mutations are more likely at intermediate concentrations 
(k = 4). All p  < 10‘15 when comparing MFT to other strategies.
Seq Depl Inv
Seq Depl
MFT
16 18
UTL
20
Figure 4.11. Useful therapeutic lives (UTLs) of drug strategies from Figure 4.10. All p  < 10'15 when 
comparing MFT to other strategies.
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For MOI = 4, the comparisons between MFT and Sequential Deployment were:
Seq Depl Inv
Seq Depl
MFT
40 42 44 46 48 50
NTF
Figure 4.12. Comparison of MFT and Sequential Deployment (one hundred simulations for each 
strategy) under the Antao-Hastings scenario of MOI = 4. Cost of resistance in this figure is cR = 0.010. 
Treatment coverage is f  = 0.6. Drug-resistance mutations are more likely at intermediate concentrations 
(k = 4). All p < 10-15 when comparing MFT to other strategies.
- K
________ l________________________________L
Seq Depl Inv
Seq Depl
MFT
' 1
0 2 4 6 8
UTL
Figure 4.13. Useful therapeutic lives (UTLs) of drug strategies from Figure 4.12. All p  <  10'15 when 
comparing MFT to other strategies. Drug resistance evolution occurs more quickly in this scenarios than 
for MOI = 2 because the costs of resistance are different for the two figures. No resistance evolution 
was observed in the MOI = 4 scenario when c r  = 0.025.
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4.4.5 A ge-targeting Distribution
We investigated the possibility o f targeting different age groups with different ACTs. We found 
no simple method o f optimizing either o f these strategies. A specific challenge with an age- 
based treatment strategy is the changing age-profile o f symptomatic infections as transmission 
intensity decreases over time. Previous studies32,77,190 have described selection pressure for 
drug resistance increasing with lower transmission. However, our age-structured model shows 
that this effect has a strong interaction with age, with younger age groups exerting less selective 
pressure as transmission falls and older age groups exerting more selection pressure as 
transmission falls (Figure 3.7 and Figure 3.8).
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Figure 4.14. Age-specific relationship between EIR and the fraction of infected hosts that are 
symptomatic. The gray dots in the figure show what fraction (pa of all malaria infections are symptomatic 
infections in a specific age group (red lines are medians). Assuming that infections are treated equally 
among age groups, the quantity cpa is a proxy for the evolutionary pressure placed on malaria parasites 
via treatment of symptomatic cases. For example, when EIR is between 10 and 20, a median of 1.3% of 
all malaria infections will occur as symptomatic cases in 0-4 year-olds. In adults, (pa decreases with EIR 
because immunity in adults increases with EIR increasing the likelihood of asymptomatic infections. In 
children aged 0 to 4, (pa increases with EIR because and frequent biting, frequent clinical episodes, and 
none or low acquired immunity. Simulations were run with treatment coverage j= 0 .5. The fraction cp of 
all symptomatic cases among all cases decreases from 5.8% when EIR < 3.0 to 3.0% for EIR > 100.
101
Chapter 4. Optimal Population-Level Deployment o f ACTs
4.4.6 Varying the Parameter K  Which Describes the Relationship between 
Drug Concentration and Mutation Probability
f ~  0-5 J =  0 6 / =  0.7 / =  0.8 / =  0 4
Cycling \ ~ m - 98 98
Seq Depl {*" - 96 98 100
MFT f * « ~ 96 100 100
Cycling + 66—L i­ 98 96
Seq Depl -------- —  — as 98 100
MFT f ~ t 96 ; 98 100
Cycling . ~ * ~ - 72 • • V  |  . |  - - 98 98
Seq Depl - - - - - 66 |  - - - - 96 98
MFT 1 - H K - - 7« “ 98 98
0 1 2 3 4 5 6 7 8
NTF
0 1 2 3 4  5 6  7 8  
NTF
0 1 2 3 4 5 6 7 8
NTF
0 1 2 3 4 5 6 7 8
NTF
0 1 2 3 4 5 6 7 8
NTF
F i g u r e  4 .1 5 .  As Figure 4.3, but with k = 0.5; i.e. the probability of a drug-resistance mutation is 
proportional to drug concentration. Fifty simulations are shown for each strategy, drug coverage (/), and 
cost of resistance ( c r )  combination. NTF values exhibited a bimodal distribution corresponding to 
simulation runs that did or did not result in extinction. Box plots show NTF interquartile ranges for 
simulations with no extinctions. The numbers on the left-hand side of each plot show the percentage of 
simulations that resulted in extinction. Mutations accumulate more slowly for k= 0.5 (this figure) than for 
k= 4.0 (Figure 4.3), and for this reason extinction is more likely for £=0.5 when treatment coverage is 
very high. For/ =  0.5 and/ =  0.6, NTF values were lower under MFT (p=0.02; except for comparison 
a).
/ =  0.5 / =  0.6 f=  0.7 / =  0.8 / =  0.9
Cycling f * Y ................ U .............. - Q Z 3 -  -
c„= 01 Seq Depl ..........  — — - ....................... -  —  -
MFT ■ b • • I h 1
Cycling —
cK = .005 Seq Depl — L .................. -
MFT f h 1 ............................. b i -
Cycling -i .........  a ~t X "T'T' • * a {  r r  " ............... - - 8 3 3 1  —
cR = .001 Seq Depl _ ----- —r|- _ — . _ ............... _IT 1. . ...
MFT • # " *  •• » -  • • t - f
50 100 150 0
AMU
50 100 150 0
AMU
0.5
AMU
1 0 0.1 0.2 
AMU
0 0.05 0.1
AMU
(thousands of c a ses )  (thousands of c a se s )  (thousands of c a s e s )  (thousands of c a se s )  (thousands of c a s e s )
F i g u r e  4 .1 6 .  As Figure 4.5, but with k = 0.5; i.e. the probability of a drug-resistance mutation is 
proportional to drug concentration. Fifty simulations are shown for each strategy, drug coverage (/), and 
cost of resistance ( c r )  combination. AMU values did not exhibit a bimodal distribution, and interquartile 
AMU ranges are shown as boxplots for all fifty simulations. For/ >  0.7, AMU values were lower under 
MFT (p < 0.003). For/ <  0.6, AMU values were lower under MFT (p < 0.01, except for those labeled 
a); note that in these three cases it was only the 25th percentiles were not statistically different.
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4.4.7 Varying the Transmission Setting
Under different transmission settings, ranging from moderate to high, the results from Figure 
4.17 and Figure 4.18 show that MFT strategies are associated with lower number o f treatment 
failures compare to other cycling strategies.
/= os
Cycling 
£>=.01 Seq Depl 
MFT
Cycling 
cF = .005 Seq Depl 
MFT
Cycling 
cR = .001 Seq Depl 
MFT
/= 0 6 / -  0.7 / =  0.8 /= 09
*
8 10 12 14 16 
NTF
10 12 14 16 
NTF
10 12 14 16 
NTF
10 12 14 16
NTF
10 12 .14 16 
NTF
F i g u r e  4 . 1 7 .  As Figure 4.3 but in a moderate transmission setting corresponding to the fifth scenario 
listed in the Table 4.1. Annual EIR is 4.07. All p  < 10'10 when comparing MFT to other strategies. 
Each boxplot corresponds to 100 simulations.
f -  0.5 / =  0.6 / =  0.7 / =  0.8 / =  0.9
Cycling I + Hh Hh +
cR = .01 Seq Depl T — +■ + +"
MFT 1 f f- *4—
Cycling -t- -1- Hh 4-
cR = .005 Seq Depl - f + + - i t fr
MFT f -S~ + +
Cycling 4 + f +
cs = .001 Seq Depl -§• j- 4 - +•
MFT + 4~ + f
16 20 24 28 32 16 20 24 28 32 16 20 24 28 32 16 20 24 28 32 16 20 24 28 32
NTF NTF NTF NTF NTF
F i g u r e  4 .1 8 .  As Figure 4.3 of the main text but in a high transmission setting corresponding to the first 
scenario listed in Table 4.1. Annual EIR is 18.0. All p  < 10’11 when comparing MFT to other strategies. 
Each boxplot corresponds to 100 simulations.
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4.4.8 Changing Distribution Based On Drug Half-Life
We also experimented changing usage frequencies for ACTs according to the partner drug half- 
life. The results show that adjusting the distribution strategy according to half-life also had no 
noticeable effect on long-term treatment outcomes (Figure 4.19 and Figure 4.20).
/ =  0.5 f= 0 6
MFT235 + - •41— 62- H * - 98 | 98 j
<— .01 MFT532 4h 7 * » ~ - 95M * 99
MFT 1 ~ H l — H B * 9 7 - B 100
MFT235 H h -4 b - 49-»- 9 2 * B B “ 98 B
c„ -  .005 MFT532 4b — ■ — 5 * H B ~ 88- -iU- 98 •
MFT 4b H B - - ea-BBh 69 M ~ 98 I
MFT235 “I-  a -4b  a 3-3------- 92 |  • 90 1
C* = .001 MFT532 •4b- B • a 36----  i------ 69 • 1 - 95 Bfl-
MFT HK • —Bb 40—- H ------ 91 ' f r 94HI-
0 1 2 3 4 5 6 7 8
NTF
0 1 2 3 4 5 6 7 8
NTF
0 1 2 3 4 5 6 7 8
NTF
0 1 2 3 4 5 6 7 8
NTF
0 1 2 3 4 5 6 7 8
NTF
/ =  0.7 f= 0.8 f=  0.9
Figure 4.19. As Figure 4.3, but two new strategies are added: MFT235 and MFT532. In MFT235 the 
proportion of patients that are treated with AL, ASAQ, and DHA-PPQ are 20%, 30%, and 50%, 
respectively. In MFT532 the proportion of patients that are treated with AL, ASAQ, and DHA-PPQ are 
50%, 30%, and 20%, respectively. These simulations were run in a low-transmission scenario, and it 
does not appear that altering the distribution of therapies according to half-life has a consistent effect on 
patterns of resistance evolution. One hundred simulations are shown for each scenario. For/  = 0.5 and/  
= 0.6, MFT has a lower NTF distribution (p < .004, except for the comparisons labeled a), but the 
magnitudes of the differences are small. For / >  0.7, the number of extinctions is quite high and a 
statistical comparison of NTF ranges is not done. Mutation rate is highest at intermediate drug 
concentrations (k = 4).
/=  0.5 / =  0 6 f ~  0.7 /=  0.8
MFT235 h i - -  • 100 100
cs =0I MFT532 b 1 - « 9 6 i  • 100 100
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Figure 4.20. As Figure 4.19, but the mutation rate is proportional to drug concentration (k = 0.5). Fifty 
simulations are shown for each scenario, but note the small number of simulations plotted for f >  0.7 as 
the majority of simulations in these scenarios reached extinction. For f  = 0.5 and f  = 0.6, MFT has a 
lower NTF distribution (p < .01, except for the comparisons labeled a), but the magnitudes of the 
differences are small.
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4.4.9 Variation in the Surveillance Window That Detennines The 10% 
Treatment Threshold
N onnally, we simulate a sequential deployment strategy by assuming that the treatment failure 
rate is computed by analyzing the successful and failing treatments over the past 60 days 
(“ws60”). Here, we look at the differences if  the past 120 days (“ws 120”) or past 180 (“ws 180”) 
days are used.
ws180 
cfi=.01 ws120
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ws180 
ce -  .005 ws120 
ws60
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cB — .001 ws120 
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f - 0.5 f=  0.6
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Figure 4.21. Epidemiological scenario from Figure 4.3. Sensitivity analysis for the sequential 
deployment strategy aimed at investigating if the method of computing the 10% treatment-failure 
threshold will have a large effect on the strategy’s long-term outcomes. Here, we look at the differences 
if the past 120 days or past 180 days are used. For 0.5 < /<  0.7, there are no statistical differences when 
“ws60” is compared to either “ws 120” or “ws 180” (all p  > 0.05) except for the comparison (a) where the 
25th quantiles of these distributions are statistically different at p  = 0.022. For/ >  0.8, the majority of 
these simulations resulted in extinction (numbers plotted to the left hand side of these panels) and 
statistical comparison among these distributions is not meaningful. Each boxplot corresponds to 100 
model simulations.
4.4.10 Robustness of the Biting Model
Here, the frequency with which a host is bitten by mosquitoes is associated with w eight in 
kilograms. This relationship is motivated by the findings o f Port et al 116 and the analysis 
presented in Smith et al 90. Weight is taken to be directly proportional to likelihood o f  biting 
and age-for-weight measures are taken from WHO 191. Figure 4.22 shows the comparisons 
between strategies when applied the age-weighted biting probability.
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Figure 4.22. Epidemiological scenario from Figure 4.3. Each boxplot corresponds to 50 simulations, and 
for /  < 0.8 all p  <  l O'3 when comparing MFT to other strategies except (a) and (b) where the 25th 
percentiles of these ‘Seq Depl’ NTF-distributions are not statistically different from MFT. For/ =  0.9, 
statistical comparisons among interquartile ranges were not done as the majority behavior in these 
simulations was extinction.
Here, the probability o f an infectious bite causing an infection is proportional to a host’s relative 
level o f immunity (which normally depends on age). The data in Hoffman et al [35] suggest 
that there may be a five-fold or six-fold difference in this probability between children and 
adults (not accounting for size, weight, or immunity), and in the comparisons presented in the 
figure 4.23 we let this infection probability vary from 0.04 to 0.16 according to Prob = 0.04 + 
0.12x(l -  ImmuneLevel). The moderate transmission scenario from Figure 4.17 was chosen 
for this comparison so that there would be more variation in host immunity in the population.
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Figure 4.23. Epidemiological scenario from Figure 4.17. Each boxplot corresponds to 50 simulations, 
and all p <  10'5 when comparing MFT to other strategies.
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4.4.11 Smaller Population Size
As can be seen from Figure 4.24, reducing population size to 500,000 does not have any 
unexpected effects on the benefit o f  MFT to other cycling strategies.
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Figure 4.24. As Figure 4.3 (with cost of resistance fixed at cr = 0.005), and population size is varied 
here to see if there are any unexpected effects at small population size. The major observed effect is more 
frequent extinctions observed at small population sizes, which is expected. Each boxplot corresponds to 
100 simulations, and the numbers at the left of each panel show what percentage of those simulations 
reached extinction. For/ =  0.5 and/ =  0.6, all p  < 10"6 when comparing MFT to other strategies. For/ >  
0.7 the predominant behavior is extinction, and in all cases MFT is associated with more frequent 
extinction events than either cycling strategy.
4.5 Conclusions
The main conclusions reached in this chapter were that the deployment o f  multiple first-line 
artemisinin combination therapies has better population-level outcomes than cycling ACTs 
through the population one by one. An MFT strategy is associated with delayed resistance 
emergence, slower resistance evolution, and as a result, a smaller number o f negative outcomes 
for patients which in this chapter are described as “treatment failures.” This result has proven 
to be robust to a variety o f epidemiological, pharamacological, and entomological scenarios, 
and it is also robust to model structure as past analyses on antimalarial drug resistance and 
antibiotic resistance have come to the same conclusion. It seems that recommending the 
deployment o f MFT at the level o f national malaria control programs would be beneficial both 
for those counties and their neighbours. However, implementation challenges loom around the
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comer. In Chapter 7 ,1 discuss the urgency of a global malaria policy aimed at stemming the 
spread of artemisinin resistance, the future challenges of MFT implementation, and certain 
model caveats that should keep us on guard for situations where model-based predictions may 
not be in line with real epidemiological scenarios,
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Chapter 5 
Introducing New Biological Features
In general, developing a mathematical model, especially an individual-based model, involves a 
trade-off between simplicity and realism (or accuracy) of the model. Occam’s razor principle 
is often used as a heuristic technique to develop theoretical models; it states that we should 
prefer a simpler model over a complex one when those models have similar predictive power 
192. In other words, adding complexity can improve the realism of a model, however, it can 
make the model more difficult to understand and analyze, especially for model-fitting and 
validation. Furthermore, increasing the complexity can also pose new computational problems. 
In contrast, Thomas Kuhn argued that during scientific progression, scientists tend to enlarge 
the central paradigm by adding more complexity to their explanations before a paradigm shift 
offers a radical simplification or a new theory 193.1 would not be bold enough to say that we 
are near a paradigm shift for malaria epidemiology, but in modifying my individual-based 
simulation I will consider each additional change carefully, looking both at its potential to 
improve the model’s realism and to improve our understanding of malaria.
With these two principles in mind, the version of the model in Chapter 2 (version 3.0.2, as it 
will be called when it is released on GitHub in August 2015) has balance in the complexity by 
simplifying components of the model to a certain level in order to maintain not only the 
computational performance but biological meaning in analysis. For instance, the resistant 
genotype representation is modelled as just a single value for each resistance locus (sensitive 
or resistant), and we do not explicitly keep track of gametocyteamia but instead use a formula 
describing the relationship between asexual parasite density and gametocyteamia.
As the analysis moves forward, in order to evaluate MFT strategies in many more complex 
situations, new biological features will be required and implemented. Based on the fact that 
drug resistance can be associated with multiple alleles at different loci 76)194 and different alleles
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at a single locus can be associates with different degrees of resistance 13,195, , a new genotype 
presentation is introduced in this chapter to fulfill this requirement (Section 5.1). In addition, 
each genotype will be associated with a particular drug EC50 that allows partial resistance in 
the model (Section 5.2).
Not all antimalarial drugs are gametocytocidal, and patients are observed to be gametocyte 
carriers for up to 28 days after radical cure with an ACT 196,197. Hence, some modifications in 
the infectivity function and the asexual parasite density value at which parasites are considered 
“removed” from the individual are introduced (Section 5.3).
Finally, in this new model version I also allow for variation in the initial clinical parasite density 
(previously set to 1011 parasites per individual) as it is known that different individuals exhibit 
different parasite burdens at peak parasitaemia (Section 5.4).
5.1 New Genotype Representation
Instead of using bit strings to represent genotypes, an integer vector is used to express the
genome structure of a parasite. Each position in the vector represents one locus and a particular 
integer value codes for a specific allele. The ancestral allele (i.e. the drug-sensitive allele) is 
coded with value 0.
Examples of genotypes with 3 loci, where each locus has 3 different alleles (values 0, 1, and 2 
are shown below, but any positive integer value is possible):
• Ancestral sensitive genotype: [0,0,0]
• Single mutation at 1 locus: [0,0,1], [0,1,0], [1,0,0]
• Multiple mutations at 1 locus: [0,0,2], [0,2,0], [2,0,0]
• Multiple mutations at multiple loci: [0,1,1], [0,2,1], [0,2,2],...
To implement the resistance evolution feature, two new classes Allele and Locus are created to 
store all necessary information and their class diagrams are shown in the Figure 5.1. This 
flexible allele class will allow us to model multiple copies of the pdmdrl gene without requiring
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an explicit representation o f the genome. Each Locus object stores all predefined alleles in an 
allele vector, their positions in the genotype expression and the cost o f  resistance.
c la ss  Locus
« struct* 
Locus
+ alleles: std::vector<Allele>  
+ position: int 
+ cost of resistance: double
« s truct*  
Allele
+ value: int
+ m utation_value_up: IntVector 
+ m utation_value_down: IntVector 
+ m utation_values: IntVector 
+ mutation level: int
Figure 5.1. Class diagrams of Allele and Locus class.
The evolution pathway o f an allele is stored in an integer vector and these numbers represent 
the new values that a particular allele can mutate to. The mutations only occur under drug 
pressure, and the mutation is allowed to occur when it reduces drug efficacy. The 
implementation o f the mutation process is described in Figure 5.2.
For each mono drug i  that i s  c ircu la t in g  in an individual  
I f  mutation under drug i  pressure occurs
Mutation_locus <- s e l e c t  randomly locus from a f f e c t in g  lo c i  o f  drug i ;  
New_mutation_allele < -s e le c t  randomly new mutation a l l e l e  (both up and down) 
I f  drug i  has lower e f f ic a c y  to  the new genotype
Allow mutation by replacing the old genotype by the new genotype
Else
Discard mutation 
End i f  
End i f  
End for
Figure 5.2. Pseudo code describes the drug resistance mutation process
The value stored in the mutation level o f an allele object determines how far that allele is to the 
ancestral allele, i.e. 0 means ancestral, or 2 means 2 mutations away; this value is also used to 
calculate the cost o f resistance for a particular genotype (Figure 5.3).
re la t ive_ f i tn e s s_ m u lt ip le_ in fec t io n _  = 1;
for ( in t  i  = 0; i  < number o f  l o c i  in gene expression; i++) {
re la t iv e_ f itn e s s_ m u lt ip le_ in fec t io n _  *= (1 -  de novo cost_of_res istan ce  o f  locus i )  A
mutation_level o f a l l e l e  at posi t io n  i ;
>
Figure 5.3. Pseudo code to calculate the cost of resistance for a genotype
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Total number o f genotypes that can be used in the simulation is calculated by the equation 20.
Il?=1 num ber  o f  alleles a t  locus i (20)
A database o f all genotypes is generated at the beginning o f the simulation, and each generated 
genotype is assigned its own ID. During the ID assignment, the genotype string is generated 
according to the following pseudocode:
in t temp = id;
fon ( in t  i = 0; i  < number of l o c i ;  i++) {
a l l e l e at locus i  = temp d iv  w e ig h t[ i] ;
temp = temp mod w e ig h t[ i] ;
>
Figure 5.4. Pseudo code to generate genotype string from a given ID. 
The weight vector is calculated from the equation 21.
weighti  \jY-=i+1num ber  o f  available alleles a t  locus j , i < n  
where n is the number o f predefined loci in the simulation.
In reverse, to get an ID o f a particular gene string, equation 22 is used.
ID = £ f =1 w eight; x  allelei (22)
5.2 Partial Resistance
In the previous version o f the model (Chapter 3), the drug had no efficacy on a resistant parasite 
type. To implement the partial resistance feature in this new version, each genotype is 
associated with an EC50 for each drug used in the simulation. By adjusting the EC50, the 
efficacy o f a drug to a specific parasite strain can vary between 0% and 100%.
An EC50 matrix is used to define the relationship between a genotype and EC50 o f a single 
drug. Each row of the matrix represents one genotype and the row number is the ID o f  the
genotype. The columns o f the matrix represent single drugs that are used in the model and the
column number is the id o f the drug.
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An example of an EC50 matrix with three mono drugs is shown in the Table 5.1.
Genotype ID I Drugl
j
| EC50 (efficacy)
|
Drug2 
EC50 (efficacy)
Drug3 
EC50 (efficacy)
0-[0,0,0] | 0.65 (80%)1
i
0.65 (80%) 0.65 (80%)
1 - [0,0,1] | 0.65 (80%)
1|
0.65 (80%) 1.3 (30%)
2-[0,1,0] | 0.65 (80%)
\1
1.3 (30%) 0.65 (80%)
3-[0,1,1] | 0.65 (80%)
1i
1.3 (30%) 1.3 (30%)
4-[1,0,0] | 1.3(30%)
1}
0.65 (80%) 0.65 (80%)
5-[1,0,1] ! 1.3(30%)
|
0.65 (80%) 1.3 (30%)
6-[1,1,0] 1 1.3 (30%)
j\
1.3 (30%) 0.65 (80%)
7-[1,1,1] I 1.3(30%)
i
i
1.3(30%) 1.3(30%)
Table 5.1. Example of EC50 matrix for 3 mono drugs (with 7 days half-life), the mutation position is 
associated with the drug ID, i.e. mutation at locus 1 cause resistance to drug 1, and each locus have 2 
alleles (naive is 0 and mutation is 1).
5.3 Change in Infectivity Function and parasite zero level to 100 
Total Parasites (2 x 10'5/pl)
In the previous model version, the infectivity to mosquito of an individual was calculated based 
on the current asexual parasite density using the formula in Ross et.al.91 (described in Section 
3.2). When the parasite density declines, the infectivity to mosquitoes will also decrease; 
however, when the parasite is cleared by a successful treatment, the infectivity is immediately 
set to zero. In the new version, after the parasite density drops to zero, the infectivity to 
mosquitoes will remain stable at a very low level (1%) for a couple of weeks (14 days) before 
dropping down to zero. The rationale for this is that the proportion of gametocyte carriers at 
day 28, after radical cure, was observed to range from 0.3% to 3% 197. It is impossible to 
compare these numbers directly as the former describes successful transmission to mosquitoes, 
but the latter describes the observation of gametocytes on blood slides.
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To fulfill these requirements, two adjustments have been made. Firstly, the infectivity curve is 
shifted up by 1%, so that the minimum infectivity at all time during an infection is 1%. 
Secondly, the parasite density level at which the parasite will be cleared from blood is set to 
100 total parasites (or 2x1 O'5 parasites/pl). Figure 5.5 shows the change in infectivity o f an 
individual from the previous version to the current version. These changes are very small, but 
they are made to improve the realism o f  the model.
5.4 Variation in Maximum Parasitaemia
For each individual who progresses to symptoms, the model will now assign a random parasite 
density level drawn from a uniform distribution (logscale) between 2,000 to 200,000 
parasites/pl (i.e. the actual draw is from U \3.3, 5.3]). This range was chosen to have the similar 
range with the initial parasite density o f  the recruited patients to clinical trials 198~200.
0 8
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g
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>
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10"
Asexual parasite density per microliter
Figure 5.5. Change in infectivity function. Red line shows the curve for the old version and the blue one 
represents the curve for the new version.
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5.5 Validation
A low transmission scenario is chosen to compare with the results from Chapter 4. Here we 
simulate with the same three ACTs used in the previous chapter, however with the new partial 
resistance feature, the cure rate of an ACT for patients with single resistant strain is around 75% 
(artemisinin resistance) or 80% (partner drug resistance). The efficacy wanes to 30% for a 
double-resistant parasite as shown in Table 5.2.
Genotype ID ASMQ AL DHA-PPQ
0 - [0,0,0,0] 95% 95% 95%
1 - [0,0,0,1] 80% 95% 95%
2-[0,0,1,0] 95% 80% 95%
3-[0,0,1,1] 80% 80% 95%
4-[0,1,0,0] 95% 95% 80%
5-[0,1,0,1] 80% 95% 80%
6-[0,1,1,0] 95% 80% 80%
7-[0,1,1,1] 80% 80% 80%
8 -  [1,0,0,0] 75% 75% 75%
9-[1,0,0,1] 30% 75% 75%
10-[1,0,1,0] 75% 30% 75%
11-[1,0,1,1] 30% 30% 75%
12-[1,1,0,0] 75% 75% 30%
1 'h* © 30% 75% 30%
14-[1,1,1,0] 75% 30% 30%
15-[1,1,1,1] 30% 30% 30%
Table 5.2. Efficacies of 3 ACTs on the different genotypes
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Here, the MFT strategy still has a lower number treatment failures compared to other strategies. 
However, the MFT results have a lower effect compared to the previous model version; this 
was due to the effect of the partial resistance as drugs still have 30% efficacy when being used 
by patients infected with a double-resistant strain; thus drug resistance evolves more slowly for 
a single-drug strategy than was observed in chapter 4.
Figure 5.6 can be compared to Figure 4.1. The main difference between these two figures is 
that the 5-year cycling strategy shown in Figure 5.6 appears to be largely a successful strategy 
as opposed to the simulations shown in Figure 4.1, where both 5-year cycling and sequential 
deployment fare very poorly when compared to MFT. The reason for this difference is 
essentially that drug resistance is not as bad in the new model (v3.1, Chapters 5 and 6) as it was 
in the old model (v3.0.2, Chapters 3 and 4). In the new model, drug-resistant parasites still 
have a chance to be cleared by ACTs, and thus, even though the 5-year cycling strategy 
generates more drug resistance than the MFT strategy, the consequences (higher prevalence, 
more treatment failures) are minor as 75%-80% of the single-resistants and 30% of the double- 
resistants are still able to be cleared by the currently used therapies.
Due to the changes introduced in this chapter, the dynamics of the system have changed, and I 
did not notice the extent of these differences until after all of the simulations had run (a time- 
consuming process). For example, in the base scenario in Figure 4.1, the EIR is 1.4, but in 
Figure 5.6 the EIR is 1.7. When publishing these results, I will try to match the EIRs exactly 
so that the results can be comparable to the results published in my first paper in Lancet Global 
Health.
The sequential deployment strategy is the worst of the three in Figure 5.6; approximately 25% 
of simulations of sequential deployment reached prevalence levels above 4% by year 12. 
Remember that the sequential deployment strategy has a 1-year delay built in between policy 
changes, and it is likely that these accumulated delays over the first decade allowed drug 
resistance to establish. Again, however, note that MFT’s relative advantage over sequential
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deployment in this scenario is smaller than the advantage shown in Figure 4.1 where drug 
resistance is modeled as “100% fully resistant”.
One key parameter that has not been discussed so far is the mutation rate. In treatment strategy 
modeling comparisons for drug-resistance management, if the mutation rate is set too low, all 
treatment strategies will appear to be equal as drug resistance will be very unlikely to emerge 
during each 20-year simulation run. Likewise, if the mutation rate is set too high, all strategies 
will appear equal as the multidrug resistance will appear very early in the simulation, and 
widespread multidrug resistance also ensures that the three strategies will be equal in the 
numbers of treatment failures that patients experience. Note in Figure 5.7 below -  where the 
mutation rate is ten times higher than in Figure 5.6 to demonstrate this principle -  drug 
resistance does emerge earlier in the 5-year cycling scenario and the final distribution of NTF 
values for 5-year cycling is noticeably lower than that observed under MFT.
Figure 5.8 shows comparisons among MFT, 5-year cycling, and sequential deployment, under 
the standard mutation rate used in Figure 5.6. Note that the principle described in Chapter 4 -  
namely that MFT creates the most variable environment, and thus the most difficult 
environment in which to evolve drug resistance — still holds. However, when the modeling 
assumes that drug resistance is partial, drug resistance will not always lead to treatment failure. 
Hence, when comparing the three strategies using a public-health measure like NTF, the relative 
advantage of MFT is smaller than that which we observed in Chapter 4. Essentially, drug 
resistance does not have the same detrimental public health outcomes in this scenario, and 
delaying drug resistance has a small public health benefit.
The analyses in Chapter 6 use this newer and more realistic version of my individual-based 
model. Chapter 6 will also show that there are additional parameters (compliance and the length 
of an ACT course) and additional types of strategies (e.g. multiple ACTs per patient) that need 
to be considered when trying to find best and most appropriate public health solution to 
antimalarial drug resistance.
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2%
9 123 60 15 18
Yeats
Figure 5.6. Expected paths of drug-resistance evolution and corresponding malaria prevalence under 
three different treatment regimes. 100 stochastic simulations were run in a population of one million 
individuals, in a low transmission setting (EIR around 1.7) with 60% treatment coverage and an assumed 
cost of resistance of 0.5% for all resistant genotypes. The mutation rate is assumed to be highest for 
intermediate drug concentrations. The black line shows the median prevalence across 100 simulations, 
and the violet areas show the interquartile and 90% ranges. The median number treatment failures (NTF) 
with interquartile ranges are shown in each panel. The dashed line shows 4% prevalence.
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Figure 5.7. As Figure 5.6, but the mutation rate is ten times higher.
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Figure 5.8. As Figure 4.3, but with new model features as described in this chapter.
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Chapter 6 
Comparison of Standard 3-Day Artemisinin Combination Therapies 
with Shorter and Longer Dosing Schedules
6.1 Introduction
Global malaria cases have declined by more than 40% over the past decade. This is because the 
improvements to health care access, wider distribution of ITNs, and the effectiveness of the 
artemisinin combination therapies (ACTs). However, artemisinin-resistant malaria has 
emerged on the Thai-Cambodian border and recently has spread as far as the border between 
Myanmar and India175. This situation reminds us of the previous emergence of resistance to 
chloroquine, sulfadoxine-pyrimethamine, and mefloquine all of which originated from South 
East Asia and spread globally. Artemisinin resistance is an extreme threat to the global health 
community’s plans for malaria control and elimination since artemisinin is currently the most 
powerful antimalarial drug available, with other potential drugs still in various phases of 
development or clinical trials. When artemisinin resistance spreads to sub-Saharan Africa, the 
situation may turn quite severe as Africa has the highest malaria disease burden and less 
adequate systems for monitoring and containing resistance.
To contain artemisinin resistance, many strategies have been proposed. At the population level, 
deployment of multiple first-line therapies (MFT), as discussed in this thesis and in past 
publications, has offered a potential solution to tackle the problem of artemisinin resistance. 
However, the global health community is not close to implementing MFT in real-world 
epidemiological settings.
Another population-level strategy to combat artemisinin resistance and accelerate malaria 
elimination is mass drug administration (MDA). MDA trials have been initiated to test 
elimination strategies in the context of artemisinin resistance (i.e. in Southeast Asia). Although
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an MDA strategy is believed to have a lot of promise, MDA implementation encounters 
significant challenges due to an inability to locate all residents of an area, refusal by individuals 
to be repeatedly treated with antimalarials, a lack of human resources in public health agencies 
to perform outreach and monitoring in an MDA strategy, and the obvious risk of malaria 
resurgence in the months after an MDA has been completed.
At the individual-level, one possible option to combat artemisinin-resistant parasites is to 
lengthen the course of ACT treatment. There are many reasons that lengthening the dose should 
be a good strategy. First of all, the prevalence of day-3 positives after ACT treatment is 
associated with novel mutations in the K13-propeller gene19, and therefore lengthening the 
course of ACT therapy (for more than 3 days) should improve the efficacy of the treatment by 
allowing artemisinin continue to killing partially-resistant parasites for a longer period. 
Secondly, results from modelling, which are based on data from Pailin, Cambodia, show that 
the efficacy of ACTs has been reduced due to the significant reduction in the efficacy of 
artesunate on ring-stage parasites201. With a lengthening of the ACT course, artemisinin would 
be able to kill the resistant ring-state parasites when they develop into schizonts, thus improving 
efficacy.
This type of treatment strategy -  a lengthened course of ACT -  has been used at the Shoklo 
Malaria Research Unit on the Myanmar-Thailand border, to treat uncomplicated 
hyperparasitaemic patients in order to improve treatment efficacy, as patients there may be 
infected with artemisinin-resistant parasites. The patients receive seven days of treatment with 
high-dose artesunate (4mg/kg) on days 0 to 3, followed by an ACT (3 to 5 day course) starting 
on day 4; in addition, this treatment is combined with single dose of primaquine on day 0. The 
options for ACT here are 3 days AS-MQ, 5 days of DHA-PPQ, or 5 days of Coartem (A L).'
From my experience in Chapter 4, the NTF comparisons between strategies show that small 
differences usually result in statistically significant results. Due to the volume of analyses
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performed in this chapter, I do not perform statistical tests for the results in this chapter to avoid 
cluttering the diagrams and figure captions.
6.2 Rationale for lengthen dosing schedule
Although ACTs may achieve a cure rate of 95%, according to detection by microscopy on day 
28, the true number of patients that are cleared of parasites is unknown. Since malaria clinical 
trials only perform PCR testing for participants who still have parasites detectable by 
microscopy on day 28, the microscopy-negative patients are not investigated further and it is 
unknown how many of these are PCR-positive for malaria parasites. Results from a study 
known as the “Targeted Malaria Elimination” (TME) study, currently being implemented in 
Southeast Asia, show that a blood-slide prevalence of about 1% corresponds to a PCR-positive 
prevalence of around 10-15% (unpublished data). These undetectable but parasite-positive 
patients may act as a source of re-infection in the community, and they may have a very 
detrimental role in malaria elimination campaigns. If we can lengthen dosing schedules, it 
would reduce the undetected malaria carriers and therefore reduce transmission and the spread 
of drug resistance.
Using the modified model as described in Chapter 5 ,1 evaluated the efficacy of different course 
durations for ACTs in 10,000 simulated patients. Although the 3-day course has a high 
efficacy, between 95% and 97%, the percentage of patients who still carry parasites on day 3 
(undetectable by microscopy, but present) was still high, between 20% and 30% in these model 
simulations. Figure 6.2 shows the effects of different course durations, ranging from one to six 
days, for Artemether-Lumefantrine. This figure was designed to show the distribution of 
parasite densities as a heat map (on a log scale) in 10,000 patients, so that we can visualize what 
percentage of patients are above certain critical parasite densities. The three orange bars in this 
plot demarcate the quartiles of the distribution, so that the central part of the distribution can be 
easily seen. As expected, 1-day and 2-day courses — representing situations in which patients 
fail to complete a course of ACT -  result in high numbers of patients with PCR-detectable
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parasitaemia on day 28. The top quartile of patients with 1-day or 2-day treatment courses had 
day-28 parasite levels above 7 parasites/microliter; even though some of these patients may 
meet the WHO definition of adequate clinical and parasitological response (due to lack of 
detection by microscopy) it is clear that this is a worrisome situation epidemiologically since it 
is very likely that these patients can continue transmitting. The same outcome is observed for 
dihydroartemisinin-piperaquine (DHA-PPQ) and artesunate-amodiaquine (ASAQ) in Figure 
6.3 and Figure 6.4, where the top quartile of patients treated for 1 or 2 days will have 
parasitaemia levels above 6/pl on day 28.
Contrasting 1-day and 2-day treatment courses to 5-day and 6-day courses shows a large 
difference. For 5- and 6-day courses, for AL, ASAQ and DHA-PPQ, 98% of patients of patients 
have day-28 parasitaemias lower than 2/pI and 99% have day-28 parasitaemias lower than 
45/pl. This suggests that, by any measure, the difference between a short course and a long 
course accounts for 23 or 24 percentage points in efficacy. In the next two sections I look at 
the individual and population-level effects of longer courses of artemisinin combination 
therapy.
Figure 6.1 shows the effect of lengthening the dosing schedule. Initial parasite density in hosts 
ranged from 2,000 to 200,000 parasites per microliter (chosen uniformly on a loglO scale). 
These graphs shows that while the efficacy of treatment only increases from 95% to around 
99% (microscopy detection), the percentage of patients that are still carrying parasites at day 
28 is reduced significantly from 40% to approximately 15% (PCR detection) as the number of 
dosing days increases from three to six.
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F i g u r e  6 .1 .  The effect of different dosing days on treatment efficacy as measured by microscopy and 
PCR. 10,000 clinical cases with different initial parasitaemia (ranging from 2000 to 200000 parasites per 
microliter) were treated with Artemether Lumefantrine.
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F i g u r e  6 .2 .  The asexual parasite density over 28 days when lengthening dosing from l to 6 days. The 
green line shows the detection level of microscopy. The intensity of the blue color represents the 
distribution of the individuals that carry a specific asexual parasite density. 10000 clinical cases with 
different initial parasitaemia (ranging from 2000 to 200000 parasite per microliter) were treated with 
Artemether Lumefantrine.
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Figure 6.3. As Figure 6.2, but ASAQ is used instead of AL. Here ASAQ has less of an effect than AL 
at day 3 because we assumed AQ, with longer half-life, has a lower power killing rate than lumefantrine. 
This allows us to maintain the same efficacy of both DHA-AQ and AL (around 95% at day 28, 3-day 
dosing).
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Figure 6.4. As Figure 6.2, but DHA-PPQ is used instead of AL. Here the DHA-PPQ has less of an effect 
than AL at day 3 because we assumed PPQ, with longer half-life, has a lower killing rate than 
lumefantrine. This allows us to maintain the same efficacy of both DHA-PPQ and AL (around 95% at 
day 28, 3-day dosing).
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6.3 Results - Changing the Length of a Single ACT Course
6.3.1 Effect of Lengthen Dosing on Population-Level Treatment Strategies
In this section, I present the population-level results of changing the duration of a single course 
of ACT. In keeping with the framework and analyses presented in Chapter 4 ,1 will evaluate 
the number of treatment failures (population wide) during a 20-year time span, and I will 
perform the comparisons for both cycling and MFT strategies. Initial comparisons are done in 
a low transmission setting with an EIR of approximately 1.7 at equilibrium when 50% of 
clinical cases are treated with a drug of 80% efficacy and a 7-day half-life.
Figure 6.5 shows the basic pattern of population-level changes as we vary the number of dosing 
days in an MFT strategy. As in other chapters, the quantity of interest here is the number of 
treatment failures (NTF) and a treatment failure is~ counted as such if on day 28 a patient still 
has microscopy-detectable parasitaemia. As in other chapters, a non-treatment is counted as a 
treatment failure. As expected, the number of treatment failures drops as the number of dosing 
days is increased. This is a straightforward result of the direct effect that a longer course has 
on reducing the probability that a patient still harbors high levels of parasitaemia after the 
treatment course is finished (as shown in Figure 6.2 to Figure 6.4). Note that the expected 
epidemiological indirect effect should also be observed here. That is, reducing the number of 
treatment failures reduces the amount of onward transmission, and this reduces the absolute 
numbers of cases and treatment failures in the future. For this reason, a larger absolute effect 
is seen at higher coverage (f~  0 .8 ,/=  0.9), as we are close to the steep part of the ^-prevalence 
curve in this scenario, and the indirect effects of reduced transmission are easier to see.
Similar effects are seen for Cycling and Sequential Deployment strategies (Figure 6.6 and 
Figure 6.7) assuring us that the dose lengthening has a population-level effect that is 
independent of the treatment strategies that were defined in Chapter 4. It is worth noting that 
longer courses are more likely to bring individual patients’ parasite counts to zero, and thus are
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more likely to end in malaria elimination in the model simulation. When looking at the high 
coverage scenario in which 90% o f patients receive treatment, under all treatment scenarios, 
we see a potential doubling o f the probability o f  extinction by increasing the length o f an ACT 
course from the currently recommended 3 days to 5 or 6 days.
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Figure 6.5. The effect of lengthen dosing days for MFT Strategy. The chart shows the NTF-values -  the 
annual number of combined treatment failures and non-treatments, per 100 individuals -  for different 
dosing days (ranging from 2 to 6-day dosing), different costs of resistance (cr), and different treatment 
coverages (/). Each row shows the NTF results of 100 model simulations with the colored bars spanning 
the interquartile range. For / >  0.9, the NTF distributions had a bimodal shape with NTF < 0.5 
corresponding to simulations that achieved extinction or near-extinction; the numbers on the left-hand 
side of each boxplot show the counts of these (near)-extinctions, and the interquartile ranges are plotted 
only for simulations that did not result in extinction. Simulations assume that three ACTs with 95% 
efficacy are available and that the three partner drugs have 4.5-day, 9-day, and 28-day half-lives 
(corresponding to lumefantrine, amodiaquine, and piperaquine, respectively). Population size is 
1,000 ,000 .
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Figure 6.6. As Figure 6.5, the strategy is Sequential Deployment Strategy.
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Figure 6.7. As Figure 6.5, the strategy is 5-year Cycling Strategy.
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6.3.2 Comparing Different Treatment Strategies with Different ACT Course 
Durations
As an additional analysis, we would like to verify here that the length of an ACT course does 
not have an effect on the results of Chapter 4: that MFT is associated with fewer treatment 
failures in the long term than either cycling strategy. The results from Section 6.3.1 are re­
grouped by the number of dosing days to perform the comparison between MFT and other 
cycling strategies.
Figure 6.8 to Figure 6.12 show that under the same transmission and dosing setting, MFT 
strategies have the lowest number of treatment failures than other cycling strategies. When 
resistance does evolve (0.5 < / <  0.9 for 2-day dosing and 0.5 < / <  0.8 for dosing longer than 
two days), MFT strategies have median NTF values that are between 2% and 23% lower than 
either sequential or cycling strategy. The one scenario that does not conform to this pattern is; 
the 6-day dosing 80%-coverage scenario with a cost of resistance equal to 0.001; here, the 
simulations performed under MFT have a median NTF value that is 5% higher than the cycling 
strategy. The two distributions are very similar in this case (p = 0.56; Kolmogorov-Smimov 
test), so this particular simulation set may simply be an aberration, given that the NTF of cycling 
strategies is usually higher than the NTF of MFT strategies. Finally, elimination was observed 
more often under MFT strategies as these strategies preserve full drug efficacy for longer than 
either cycling strategy.
In these simulations, the NTF-benefits of MFT over the two cycling strategies are lower than 
those presented in Chapter 4 where median NTF values of MFT were 16% to 40% lower than 
those for cycling strategies. This is likely due to the effect of the partial resistance feature that 
was introduced in Chapter 5. In the simulations presented in this chapter, ACTs still have up to 
30% efficacy to the fully resistant strain, and between 75% and 80% efficacy for other resistant 
strains. This makes drug resistance evolve more slowly and it lessens the differences among 
the treatment strategies.
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Figure 6.8. Comparisons of MFT, five-year cycling, and sequential deployment.-The chart shows the 
NTF-values-the annual number of combined treatment failures and non-treatments, per 100 individuals 
-  for different strategies, different costs of resistance (cr), and different treatment coverages (/). Each 
row shows the NTF results of 100 model simulations with the colored bars spanning the interquartile 
range. For / =  0.9, the NTF distributions had a bimodal shape with NTF < 0.5 corresponding to 
simulations that achieved extinction or near-extinction; the numbers on the left-hand side of each boxplot 
show the counts of these (near)-extinctions, and the interquartile ranges are plotted only for simulations 
that did not result in extinction. Simulations assume that three ACTs with 95% efficacy are available and 
that the three partner drugs have 4.5-day, 9-day, and 28-day half-lives (corresponding to lumefantrine, 
amodiaquine, and piperaquine, respectively). Population size is 1,000,000 and all therapies are 2-day 
dossing.
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Figure 6.9. As Figure 6.8, all therapies are 3-day dosing.
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130
Chapter 6. Comparison o f Standard 3-Pat ACTs with Shorter and Longer Dosing Schedules
7=0-5 7= 0.6 7=0.7 7=0.8 7=
Cycling f F -h Hh * § -
CR — .01 Seq Depi \ Y F - 4h e « -
MFT . } F- + - - f ~  7 ft-
Cycling f 4 f
c* = -005 Seq Depl F ■F- 4- - 1 -  6 4 * -
MFT f F* -1" -f|t- 64 -
Cycling F- +- Hh -fS— 53* ■-
r ,=  .00] Seq Depl f f- f - i -  4 3 ® -
MFT f
. ,
—§ -  47-: —
0 1 2 3 4 5 6 7 6  0 1 2 3 4 5 6 7 8  0 1 2 3 4 5 6 7 8  0 1 2 3 4 5 6 7 8  0 1 2 3 4 5 6 7 6  
NTF NTF NTF NTF NTF
Figure 6.10. As Figure 6.8, all therapies are 4-day dosing.
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Figure 6.11. As Figure 6.8, all therapies are 5-day dosing.
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Figure 6.12. As Figure 6.8, all therapies are 6-day dosing.
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6.4 Treatment Strategy Employing Multiple ACT Courses (MAC)
In this section, I will look at whether there is any benefit to one patient being treated with 
multiple ACTs sequentially during a single infection; for instance, the patient would take AL 
for 3 days which would be followed by a course of DHA-PPQ, either on days 4, 5, and 6, or 
with a delay on days 7, 8, and 9. This strategy was suggested recently by Sutherland et al, 
considering the current context of emerging artemisinin resistance and whether applying 
sequential 3-day courses of two different ACTs would improve the treatment efficacy202.
In modeling these scenarios, we label them with the acronym MAC for “multiple ACT courses” 
and in most scenarios we will be modeling the two ACTs artemether-lumefantrine and DHA- 
piperaquine. I will introduce multiple variations of MAC treatments with the total number o f 
dosing days being either four or six; these treatments will correspond to 2-day/3-day dosing 
with one ACT followed by 2-day/3-day dosing with a second ACT. A strategy I call “MAC41” 
will have four total days of dosing, and the “1” in the name means that this is version 1 of this 
strategy. In MAC41, patients are treated with AL for 2 days which is immediately followed by 
a 2-day course of DHA-PPQ. In a “MAC61” strategy, patients are treated with AL for 3 days 
which is immediately followed by a 3-day course of DHA-PPQ. Clinicians have recommended 
(personal communication: Francois Nosten, Nicholas White) that in order to reduce side effects 
of a long course of ACTs, it may be helpful to give the patient a break of a few days. Hence, I 
also evaluate two strategies I call MAC42 and MAC62 which include a 2- or 3-day break (equal 
to the length of first ACT course) before receiving the second ACT course. In other words, in 
MAC42 the patient receives AL on days 1 and 2, nothing on days 3 and 4, and DHA-PPQ on 
days 5 and 6.
In an additional scenario, I show how three different ACTs (described in Chapter 4) can be used 
in a MAC strategy, by allowing a patient to receive randomly two different ACTs (drawn 
randomly from 3 ACTs) and having them prescribed in a random order or either order, and this
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new strategy is called Randomized Multiple ACT Course (MACR). I denote these strategies 
with MACR41, MACR42, MACR61, and MACR62 meaning that they are random, that there 
is four or six total days of dosing, and the two versions (“ 1” and “2”) are as before (with and 
without a break, respectively, between doses of the two ACTs). The random MAC strategy 
with 3 different ACTs is identical to an MFT strategy with 6 different MAC therapies -  formed 
by three combinations of two ACTs -  which will allow us to evaluate the benefits of using or 
not using MFT with MAC strategies.
Also, note that in the first five chapters of this thesis, additional combination therapies were 
ignored. In other words, in deciding how best to deploy AL, ASAQ, and DHA-PPQ, we did 
not consider a hypothetical quadruple combination of Artemisinin coformulated with all three 
partner drugs. The reason we did not consider this is that a coformulated quadruple therapy 
would need to undergo safety and efficacy testing before it was approved by WHO and 
ministries of health in malaria-endemic countries. This would have been an ideal strategy to 
evaluate as past analyses -  such as Bonhoeffer et al (1997) and the early work done in 
evaluating the models in Boni et al (2008) (personal communication: Maciej Boni) -  have 
shown that combination therapy is generally a veiy favorable way of delaying/preventing 
resistance evolution. Veiy broadly, these results claimed that combination therapy should be 
as good or slightly better than MFT and better than cycling strategies, with the caveat that 
combination therapy carries the extra risk of driving the evolution of the multi-drug resistant if 
this completely resistant genotype were to emerge.
With the MAC strategies introduced in this chapter, we can evaluate a drug distribution strategy
that mimics a combination therapy. Because the two ACTs in a MAC strategy are given very
close together, this gives the parasite population a veiy small number of generations in which
multiple drug-resistance alleles would need to emerge to fend off all the different therapeutic
agents circulating in the blood. This is the same principle of'resistance prevention’ that is used
to justify combination therapies (for all diseases) and indeed it is also the principle at work in
making MFT strategies more optimal than cycling strategies. Thus, since MAC strategies are
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the closest imitation of “combination-ACT-therapy” (i.e. a combination of multiple ACTs) we 
expect that these strategies will be as good as or better than MFT at preventing resistance 
evolution.
6.5 Results -  Evaluation of MAC Strategies
My results show that MAC and MACR strategies have lower NTF values compared to MFT. 
Note that MFT and MACR use three ACTs while a normal MAC strategy only uses two ACTs.
Figure 6.13 shows the comparison among MFT strategies, MAC strategies, and MACR 
strategies. Initial comparisons are done in the same low-transmission setting as in Section 6.3; 
again, note that in some high-coverage settings treatment drives the parasite population an 
elimination. For intermediate coverage levels (0.5 < /<  0.7), MAC strategies have median NTF 
values that are between 6% and 49% lower than MFT strategies under the same number of total 
dosing days. In addition, elimination was observed more often under MAC strategies, possibly 
due to the fact that these strategies are better at preventing resistance.
Although the random MACR strategies, which take advantage of all three ACTs in the 
simulation, perform significantly better than MFT strategies, MACR strategies seem to have a 
slightly smaller effect compared to the simple MAC strategies which use only two ACTs. My 
initial investigations into this behavior did not lead to any obvious reasons for this difference. 
The expectation in fact is that the opposite would happen: that MACR strategies would be better 
at delaying resistance than MAC strategies since MACR strategies introduce more variation 
into the parasites5 environment. The difference in the strategies may come in the PK/PD 
parameters used for the three partner drugs. In the validation analysis in Chapter 5, 
lumefantrine (4.5-day half-life) was assigned a higher killing rate than piperaquine (28-day 
half-life) so that AL and DHA-PPQ would have equal efficacies, both around 95%. For this 
reason, reducing AL treatment from 50% (MAC strategy) to 33% (MACR strategy) may have 
an effect in lowering average efficacy for patients or in lowering the force of infection during
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the early days o f  infection. But, this needs to be investigated further as the explanation not 
likely to be this straightforward.
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Figure 6 .13. Comparisons of MFT and MAC strategies. The chart shows the NTF-values -  the annual 
number of combined treatment failures and non-treatments, per 100 individuals -  for different strategies, 
different costs of resistance ( c r ),  and different treatment coverages i f ) .  Each row shows the NTF results 
of 100 model simulations with the colored bars spanning the interquartile range; the green, blue and lime 
color bars show the results of MFT, MAC and MACR strategies respectively. The definition of MAC41, 
MAC42, MACR61, and MACR62 are shown in section 6.4. MFT4 and MFT6 are the MFT strategies 
that employed ACTs with 4 and 6-day dosing respectively. For/ >  0.8 the NTF distributions had a 
bimodal shape with NTF < 0.5 corresponding to simulations that achieved extinction or near-extinction; 
the numbers on the left-hand side of each boxplot show the counts of these (near)-extinctions, and the 
interquartile ranges are plotted only for simulations that did not result in extinction. Simulations assume 
that three ACTs with 95% efficacy are available and that the three partner drugs have 4.5-day, 9-day, 
and 28-day half-lives (corresponding to lumefantrine, amodiaquine, and piperaquine, respectively). 
Population size is 1,000,000.
The potential elimination scenarios for coverage levels of' / =  0.8 and/  = 0.9, show that MAC 
and MACR strategies are associated with more frequent elimination events in the simulations. 
This is likely due to the high efficacy o f individual treatments and the low probability o f
resistance evolution during individual treatment courses.
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6.6 Conclusions
In this chapter, I experimented with a new type of drug-deployment strategy that could be 
evaluated by the individual-based simulation that I developed for this thesis. This new strategy 
of “multiple ACT courses” (MAC) per patient seems to act as a good substitute for a triple 
combination therapy as individual patients in this strategy are given two different ACTs within 
the first week of a symptomatic malaria infection. As expected for a combination therapy, 
MAC outperforms both MFT and cycling strategies in that it dramatically reduced the 
probability of a de novo resistance evolution event. Both fixed MAC strategies (the order of 
the ACTs is predetermined) and random MAC strategies (two out of three ACTs are chosen to 
be prescribed in random order) are associated with fewer long-term treatment failures than MFT 
strategies. However, this is the first analysis, to my knowledge, of a population-level strategy 
employing multiple ACT courses per patient. These are early stage results, and may thus 
contain important caveats. In Chapter 7 ,1 discuss the potential of MAC strategies to help in 
the global health response to artemisinin resistance and the types of sensitivity analyses that 
should be done in future modeling analyses to ensure the robustness of the results obtained in 
this chapter.
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Chapter 7 
Discussion
This thesis demonstrates the ways that an individual-based model can be used to evaluate not 
only population-scale treatment strategies (Chapter 4) but also the long-term outcomes of 
individual level treatment strategy (Chapter 6) in the context of dealing with antimalarial 
resistance emerging in the population. This novel microsimulation model provides a unique 
high-performance framework that allows for drug-resistance evolution and can be run with 
millions individuals on a personal computer.
7.1 Individual-based Model Development
Chapter 2 describes the software architecture on which the microsimulation model is built. By 
separating the simulation into components and by giving each component its own functionality, 
this methodology not only provided the robustness for the framework but also the flexibility 
and modularity to extend the individual-based model to have more features as more scientific 
requirements were needed at a later time in the development process (as Chapter 5). The core 
framework of the simulation is easy to adapt to build up another individual-based model for 
other diseases, e.g. for influenza, as I did for a side project that is not contained in this thesis203 
or for vector-borne diseases as we hope to do for dengue in Vietnam when dengue vaccination 
planning is prioritized later this decade 204.
The most important technical developments in this part of my thesis work were the scheduler 
mechanisms and the object pooling methods that improved speed and memory management. 
The separate scheduler class was developed so that I could use a purely event-based framework 
during the model simulation; this also means that the model is asynchronous like other event- 
based models. (It is possible that these other event-based model used a similar scheduler class 
to mine, but I did not have access to their source code so the development here is all my own
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work). The scheduler-centered simulation allowed for a certain modularity in the functionality 
in the model so that any new type of event (e.g. a drug non-adherence event, or a biting-rate 
reduction while feverish event) could be added into the model, scheduled to “occur” when 
necessary, and thus evaluated as a potentially important factor for transmission. The scheduler 
also made the simulation much faster by not adding in unnecessary events when individuals 
were healthy, not at risk for being bitten, and thus not contributing meaningfully to the 
epidemiological dynamics in the model. Thus, in low transmission settings, model run times 
were quite fast as the vast majority of individuals avoided infection and did not need to be 
updated with any relevant events. In high-transmission settings, model run times were much 
slower as parasite density levels need to be updated frequently and for all infected hosts in these 
scenarios.
Object pooling allowed me to avoid the long-term drag of memory allocation, freeing, and 
reallocation. In a model simulation run over twenty years, with a large number of birth and 
death events, it was important to have a way to manage memory allocation so that individual 
allocation events were not called too frequently, thus not putting a strain on the operating 
system’s memory management processes.
One important technical shortcoming of the model is that it currently has a one-day time step, 
thus creating a framework where pharmacokinetics and pharmacodynamics must necessarily 
be modeling very approximately and coarsely. Initially, this seemed like a good choice for the 
model development: to hard-code a time step of a single day so that all other processes and 
parameters could be simplified to how often they occurred “per day.” However, once it became 
clear that the PK/PD dynamics would be a critical component of many of the outcomes and a 
desirable part of many sensitivity analyses, it was impossible to incorporate more detailed 
PK/PD dynamics than those observable at a 24-hour level. I cannot say whether this did or did 
not have an effect on the results. In the process of running the analyses Chapter 4, for example, 
I found that it was impossible to optimize MFT strategies according to drug half-life. In other
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words, it was impossible to state whether an ACT with a short- or long-lived partner drug should 
be used at a higher or lower frequency in an MFT policy. With more detailed PK/PD modeling, 
it may turn out the half-life length does have an effect on the optimal distribution patterns when 
using multiple ACTs. I plan to pursue this question as an extension of my PhD thesis.
One of the biggest changes in the individual-based model that was introduced in Chapter 5 is 
“partial resistance” feature. This feature was implemented to bring the model closer to the 
reality that antimalarials still have a certain level of efficacy to resistant parasites. However, the 
pre-chapter-5 version of the simulation has only two distinct efficacies for naive and resistant 
parasites: full efficacy and no efficacy. In the real world, drugs have reduced efficacies that 
vary by parasite genotype. This is especially important for the artemisinin-resistance kelchl3 
genotypes 19,175 as many alleles have been observed in nature and it is likely that they are all 
partially resistant. An additional feature of multiple resistant alleles will be implemented in the 
future by defining decreasing drug efficacies that are associated with particular genotypes,
Despite some shortcomings in the original model design and formulation, the model turned out 
to be a success in modeling the long-term epidemiology of malaria (Chapter 3). The results on 
multiple first-line therapies appeared to be veiy robust, and the analyses on multiple ACT 
courses were the first ones performed for this question and their results appeared to be in 
agreement with our expectations based on evolutionary theory.
7.2 Benefits of Multiple First-line Therapies
The malaria transmission model that I developed and validated for this thesis provides 
outcomes in accordance with expectations based on evolutionary theoiy: that challenging the 
parasite with an environment presenting simultaneous multiple lethal challenges significantly 
increases the time the parasite requires to defeat all of them. The analysis suggests that 
deployment of multiple first-line artemisinin-combination therapies should result in improved 
population-level treatment outcomes, delayed resistance emergence, and slower resistance
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evolution, as was seen in past more general analyses52,182,183,185. In addition, the major prevailing 
concern about MFT strategies -  that they would allow recombination to generate multi-drug 
resistant types earlier than other strategies -  proved not to be true in any of our simulations.
As population-level treatment strategies like the ones evaluated here will never be testable in 
the field, model-based recommendations may be the only evidence available for planning 
optimal distribution of antimalarial therapies. If the median predicted benefits are a 16% to 41% 
reduction in treatment failures over a 20-year period and a 40% increase to more than doubling 
of the useful therapeutic life of ACTs (Figure 4.3, 0.5 < / <  0.7)), we may want to consider 
model-based recommendations as sufficient evidence for managing the distribution and usage 
patterns of antimalarial drugs. As elimination campaigns move forward, the extra insurance 
provided by MFT strategies may allow elimination efforts to succeed before a fully artemisinin- 
resistant genotype emerges.
The key principle at work in the strategy comparisons presented here is the conservation of 
drug efficacy205. As drugs are used more sparingly, the risks of resistance evolution are lowered 
and drug efficacy is prolonged. An MFT strategy allows individual drugs to be used more 
sparingly without reducing the total number of patients we intend to treat. The scenario 
presented in Figure 4.6 specifically considers the conservation of artemisinin efficacy, and the 
potential for extending the useful therapeutic life of artemisinin drugs by pairing them with 
other highly-efficacious drugs in an MFT strategy. This conservation approach is logical from 
an evolutionary perspective, but its ethical dimension will need to be evaluated carefully as it 
is possible that some patients would be treated with a therapy whose measured efficacy is 
second best. To improve the chances that a strategy like this meets the highest medical and 
ethical acceptability criteria, the risks for patients treated with a non-ACT would need to be 
mitigated, possibly through frequent follow-up and availability of second-line treatments.
As in all past analyses on the dynamics of drug-resistant parasites, measuring fitness costs206- 
211 of drug-resistant genotypes is crucial for predicting the spread of resistance. For artemisinin
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resistance, the current dynamic picture (2002-2013) of the spread of Kelch 13-propeller 
resistance-associated alleles in Cambodia is the best starting point for investigating fitness 
costs. However, the fitness cost of any future hypothetical resistant genotype is impossible to 
predict. To be conservative, fitness costs in our analyses were varied between 0.1% and 1.0%, 
as scenarios with much higher fitness costs would result in a bigger advantage of MFT over 
either cycling or sequential strategy.
In-depth critiques of model structure and validations are necessary when interpreting results 
from mathematical models, including this one. The model presented here does not take into 
account fine-scale spatial structure, mosquito dynamics, gametocyte dynamics, genotype- 
specific drug efficacies, partial drug resistance (in Chapters 3 and 4), or seasonal/climate 
effects, but it is clear that all of these features should be considered when planning treatment 
campaigns and elimination strategies. In particular, the model’s one-day time step will make 
some future modifications difficult, e.g. detailed artemisinin action or stage-specific drug 
activity. For this reason, several lines of research have already begun (in my supervisor’s 
research group, and with my help) to determine if short-term dynamics can be implanted in a 
separate model and merged into the simulation I developed for this thesis. It is crucial to 
continually develop and validate models like this one by adding in realistic features that are 
known to have important effects on malaria transmission and evolution so that each iteration of 
development brings the model closer to resembling the real-world epidemiology of malaria. 
Comparison of these results with those of other models will be critical for testing robustness. 
Analyses in many types of transmission settings will need to be done in order to ensure that 
specific policy recommendations are optimal. The results in this thesis suggest that MFT’s 
relative benefits are smaller in higher transmission settings, but absolute benefits do not show 
this consistent pattern.
Potential caveats about the benefits of MFT strategies will need to be addressed and evaluated. 
First, strategy comparisons will likely be sensitive to the parity of the different available
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therapies. In a scenario where one ACT has much higher efficacy than the other two, it may be 
prudent to utilize the high-efficacy therapy first, as this would lower the parasite population 
size more quickly (across all hosts) and lower the probability that random mutation generates a 
drug-resistant genotype. Currently recommended and available ACTs have similar efficacies212, 
but this is location-dependent114; scenarios where, for example, two treatments with 90% and 
98% efficacy have different predicted effects on a desired epidemiological outcome such as 
elimination will need to be evaluated on a case by case basis. Second, in choosing the optimal 
strategy we will need to consider the multitude of resistance effects caused by individual loci, 
an important example being position 76 in the chloroquine resistance transporter gene (pfcrt), 
where the wild-type allele (K) confers lumefantrine resistance and the mutant allele (T) confers 
amodiaquine resistance2I3’214. Normally, cycling strategies have worse evolutionary outcomes 
because they drive the evolution of individual resistance types more quickly, but in the case o f 
K76T, amodiaquine resistance driving lumefantrine sensitivity may mitigate this problem. 
These effects may be present for other loci 215>216.
Implementation, compliance, and operations will be the next important areas of focus if MFT 
strategies are accepted as the best ways for distributing and prescribing antimalarial drugs. In 
addition, other factors, such as patient adherence, operational costs, or education programs for 
a new strategy implementation, would also have large impacts on the outcome. Additional 
research on health economics is currently an ongoing project of one of my fellow PhD students 
in order to quantify the costs and benefits of deploying MFT over other strategies. Flexibility 
and adaptability will be a key attributes of MFT policies if they are to succeed. If we are 
planning over a 20-year timeframe, transmission reductions resulting from other interventions, 
economic development, changes in the health care system, and many other political and 
geographic factors will affect future malaria prevalence. It is crucial that any long-term drug 
resistance management strategy that we implement is able to adapt to these changes.
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Operationally, MFT would have several advantages as it removes the need for large system- 
wide changes in drug policy and avoids problems of obsolete drug stocks. It is not yet known 
if randomly assigning therapies should be done by location, day of week, a true randomization 
scheme, or some other method. Variation in drug purchase patterns from private and public 
sectors217,218 will necessitate different implementations, and compliance monitoring will be 
challenging in contexts with high levels of private sector drug purchases. Nevertheless, some 
countries have successfully managed the roll-out of multiple ACTs219-222, and these examples 
demonstrate the feasibility of locally-determined drug distribution and flexible treatment 
guidelines that are based on changing epidemiology. A commitment to evaluating the 
effectiveness of new population-level malaria treatment programs and a willingness to adapt 
our approach as we continue down this path will be critical for maximizing the benefits of MFT 
to global malaria policy.
7.3 Benefits of Multiple ACT Courses in Individual Patients
If MFT policies prove too difficult to implement at the population level, perhaps an alternative 
strategy is to recommend the next closest “MFT-type” strategy for patients. This is something 
I have called multiple ACT courses (MAC) for individual patients, and I evaluated the 
population level effects of this simple strategy of (1) lengthening the course of an ACT and (2) 
increasing the drug variability that the parasite population sees during this time.
The two primary reasons that the medical and public health communities would want to
consider using multiple consecutive ACT courses for a single patient’s malaria treatment are
an increased chance of successful treatment and reduced probability of de novo resistance
evolution during the course of treatment. This “MAC” treatment essentially mimics a triple
combination therapy by forcing the asexual parasite population in the patient’s blood to adapt
to three different drugs simultaneously. The practical benefit of this “mimicked” combination
therapy is that two ACTs can be safely prescribed in succession; in other words, an additional
clinical trial establishing safety is not necessary.
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From the parasite’s perspective, the difference between MAC and MFT is the timeline of 
encountering different drugs. Both strategies are effective at delaying partner-drug resistance 
evolution, but in different ways. In an MFT strategy, a PPQ-resistant genotype may escape 
treatment with DHA-PPQ, after which it will have (1) a chance to establish itself within-host, 
if that particular patient’s sensitive parasites have been killed, and (2) a chance for further 
spread of escape if the parasite jumps to another host and again undergoes treatment with DHA- 
PPQ. These probabilities are small, but not negligible. However, in a MAC strategy, neither 
of these is a possibility. A PPQ-resistant genotype would immediately undergo treatment with 
the second ACT designated for that course, and in the parasite’s jump to the next patient it 
would be guaranteed to face at least one partner drug that was not piperaquine. For these 
reasons, MAC strategies seem to be associated with better outcomes in the presence of 
resistance evolution.
In my analysis, I assumed that different antimalarials drugs are acting independently on the 
parasite population and that the combined killing rate of different drugs follows the reasoning 
by Webb JL (1963)223. If drug A and B each has 80% parasite killing rate per day, then the 
additive killing rate is 1 - (1 - 0.8) x (1 - 0.8) = 96%. Webb’s method is valid when the effects 
of two drugs are mutually nonexclusive (e.g., totally independent) and is not valid for mutually 
exclusive (e.g., similar mechanisms or modes of actions). Hence, to achieve the best 
performance of MAC, the partner drugs of ACTs should be chosen to have different modes of 
action of parasite killing as well as independent drug absorption mechanisms. Even in this 
situation, clinical data and longitudinal patient data would be needed to reconfirm the additive 
killing effect of two independent antimalarials, or to find the correct killing rate for the 
particular drug combination. This, and other considerations of drug interactions for efficacy 
and safety will be crucial for the future analyses of MAC strategies.
To have robust results, a wider range of simulations with different MAC scenarios needs to be 
run. Specifically, parts of the PK/PD model in the simulation would need to be enhanced,
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varied, and revalidated to make sure that the long 6-day courses o f treatment evaluated in the 
different MAC analyses achieve the correct efficacies as seen in patients. Ideally, clinical trials 
would be run to evaluate MAC in individual patients.
There will also be a need to investigate the difference between MAC and MACR, to see what 
the different resistance evolution patterns are under the different drug orders that are prescribed. 
This will necessarily be a theoretical study at the outset, but if  MACR strategies prove 
beneficial in the majority o f situations (note that this behavior is not currently observed in my 
initial analyses), then MACR will face the same implementation challenges as MFT. MACR 
strategies will also face additional challenges as the order o f the ACTs, the combined killing 
rates of different partner drugs, and the half-life difference may create some unusual situations 
or results for particular pairs o f ACTs. The MACR analysis presented here did not originally 
meet my expectations that it would be an improvement on MAC, and the comparisons o f these 
two strategies will require significantly more work.
Due to time limitations, I was not able to perform a cost analysis for the MAC. It is true that 
increasing the number of dosing days from 3 days to 6 days and switching from single ACT to 
multiple ACTs should increase the treatment cost and operational cost. However, the benefit o f 
preventing drug resistance by applying MAC needs to be quantified as well. Thus, in the future, 
a health-economic analysis on this topic should be done to evaluate the cost effectiveness of 
the MAC strategy.
In addition, human behavior is one o f the most important factors that could have a large impact 
on these results. The adherence to a 6-days dosing treatment is crucial for the success o f MAC 
strategy. However, to improve the compliance o f patients, more efforts on public training and 
engagement have to be considered. To analyze the cost and the effect o f the public engagement 
program on the benefit o f the MAC strategy, additional health economic analysis will be 
necessary.
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The malaria drug policy analyses presented in this thesis are meant to evaluate several different 
methods the global health community may use to preserve the efficacy o f artemisinin-based 
drugs, in this crucial time o f the early stages of artemisinin resistance spread. The analysis on 
MFT is mature and robust, and I can confidently recommend this policy as one that would be 
an improvement o f the status quo. The MAC and MACR strategies hold a lot o f promise, but 
further investigation is needed before they can be recommended as national malaria policy.
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A PPE N D IX
Parameter Description
This section shows the parameters and inputs that were used in the simulation.
# total number of days the simulation is run, including the burn-in period which 
we normally set to 4000
# days; during the burn-in period, no one receives malaria treatement and the 
system sets into a natural
# equilibrium
total time: 4730
# length of burn-in period 
start_treatment_day: 4000
# the day at which the simulation's reporting functionality begins collecting 
data for
# the purposes of displaying it
start_collect__data_day: 4000
# probability that a symptomatic and infected individual seeks and receives 
antimalarial treatment
p_treatment: 0.600000
# this functionality works, but it was not used in any analyses for the 2015 LGH 
paper
number_of_locations: 1
# main scaling parameter for transmission, by location
# the last four terms are ignored when the number of locations is 1 
beta: [0.2 , 1.4 , 1.4, 1.4, 1]
# this functionality works, but it was not used in any analyses for the 2015 LGH 
paper
# seasonality parameters, by location 
seasonal_beta:
a [0, 0.25, 0.25, 0.25] 
phi: [200, 200, 200, 200]
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# the last four terms are ignored when the number of locations is 1 
population size by_location: [100000, 1000 , 1000, 1000, 500]
# probability that an infectious bite on a human causes a blood stage malaria 
infection
p_infection_from_an_infectious_bite: 0.1
# the simulation itself uses explicit ages and birthdays
# but for reporting purposes and for age-specific mortality calculations, 
individuals are grouped into the following age classes
number_of_age_classes: 15
age_structure: [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 15, 20, 60, 100]
# this is only used for initializing the population structure at time 0
# the last four rows of the matrix below are ignored when the number of 
locations is 1
initial_age_structure: [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 25, 
35, 45, 55, 65, 100]
age_distribution_by_location: [
[0.0334, 0.0300, 0.0329, 0.0324, 0.0332, 0.0314, 0.0316, 0.0310, 0.0285, 0.0256, 
0.0298, 0.0212, 0.0321, 0.0228, 0.0230, 0.1906, 0.1403, 0.0966, 0.0605, 0.0344, 
0.0387],
[0.0334, 0.0300, 0.0329, 0.0324, 0.0332, 0.0314, 0.0316, 0.0310, 0.0285, 0.0256, 
0.0298, 0.0212, 0.0321, 0.0228, 0.0230, 0.1906, 0.1403, 0.0966, 0.0605, 0.0344, 
0.0387],
[0.0334, 0.0300, 0.0329, 0.0324, 0.0332, 0.0314, 0.0316, 0.0310, 0.0285, 0.0256, 
0.0298, 0.0212, 0.0321, 0.0228, 0.0230, 0.1906, 0.1403, 0.0966, 0.0605, 0.0344, 
0.0387],
[0.0334, 0.0300, 0.0329, 0.0324, 0.0332, 0.0314, 0.0316, 0.0310, 0.0285, 0.0256, 
0.0298, 0.0212, 0.0321, 0.0228, 0.0230, 0.1906, 0.1403, 0.0966, 0.0605, 0.0344, 
0.0387]
]
# below value indicates 37.25 births per 1000 individuals per year
birth rate: 0.03725
# annual death rate (probability) by age group
death_rate by_age [0.053979329, 0.018935757, 0.006867257, 0.001124347, 
0.001136455, 0.001606066, 0.001953783, 0.001530096, 0.001299153, 0.001068073, 
0.000978264, 0.000978264, 0.0055, 0.0055, 0.04450]
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# number of days to keep track total number of parasites in population
# in other words, the simulation stores 11 days of mosquitoes-biting-on-humans 
history
# if an individual is infected today, the infection type and probability will be 
based
# on the biting that took place 11 days ago
number_of_tracking_days: 11
# probability of death for patients who are not treated or patients who 
experience a treatment failure (due to drug resistance, or otherwise)
mortality_when_treatment_fail_by_age: [0.040,
0.020,0.020,0.020,0.020,0.004,0.004,0.004,0.004,0.004,0.004, 0.001, 0.001,
0 .001 , 0 . 001]
# initial conditions for prevalence and drug resistance, by location
# parasite_type_id is the parasite genotype; 0 means completely sensitive to all 
drugs
# the parasite_type_id is a bit-string, so types 1, 2, 4, and 8 correspond to 
parasites
# that have a resistance to a single drug 
initial_parasite_info;
- location_id: 0 
parasite_info:
- parasite_type_id: 0
prevalence: 0.1
# - parasite_type_id: 2
# prevalence: 0.1
# - para5ite_type_id: 4
# prevalence: 0.1
- location_id: 1 
parasite_info:
- parasite_type_id: 0 
prevalence: 0.1
- location_id: 2 
parasite_info:
- parasite_type_id: 0 
prevalence: 0.1
- location_id: 3 
parasite_info:
- parasite_type_id: 0 
prevalence: 0.1
# - parasite_type_id: 4
# prevalence: 0.03
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# functional but not used in 2015 LGH paper
# allows for the introduction of a specific parasite type at a specific time
introduce_parasite:
# - location: 0
# parasite_info:
# - time: 4000
# genotype_id: 1
# number_of_cases: 5
# - time: 4000
# genotype_id: 2
# number_of_cases: 5
# - time: 4000
# genotype_id: 4
# number_of_cases: 5
# - time: 4000
# genotype_id: 8
# number_of_cases: 5
#
# periodic importation of drug-sensitive parasites; five new cases imported 
every seven days
introduce_parasite_periodically:
- location: 0 
parasite_info:
- duration: 7 
genotype_id: 0 
number_of_cases: 5
# drug information below
#
# maximum_parasite_killing_rate:
# e.g. 0.999 means the drug can kill 99.9% of parasites in 1 day if a 
person has
# the highest possible drug concentration
#
# n:
# the slope of the linear portion of the conentration-effect curve
#
# EC50:
# the drug concentration which produces 50% of the parasite killing
achieved at maximum-concentration
# ( the expected starting concentration is 1.0 )
#
# age_specific_drug_concentration_sd:
# the actual drug concentration, per individual, will be drawn from a
normal distribution with mean=l and this sd.
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## k:
# parameter that describes the change in the mutation probability when 
drug levels are intermediate
# - set k=0.5 for a simple linear model where mutation probablity 
decreases linearly with drug concentration
# - set k=2 or k=4 for a piecewise-linear model where mutation probability 
increases from high concentrations
# to intermediate concentrations, and then decreases linearly from
intermediate concentrations to zero
#
druglnfo:
1: # artemisinin (used for artemether, artesunate, and dihydroartemisinin)
half_life: 0.0
maximum_parasite_killing_rate: 0.999 
n: 25 
EC50; 0.7
age_specific_drug_concentration_sd:
[0.4,0.4,0.4,0.4,0.4,0.4,0.4,0.4,0.4,0.4,0.4,0.4,0.4,0.4,0.4]
mutation_probability: 0.005 
mutation_position: [0] 
k: 4
resistance_cost_multiple_infection: 0.01 
isArtermisininDerivative: 1 
2: # lumefantrine - use this for a standard simulation 
half_life: 4.5
maximum_parasite_killing_rate: 0.99 
n : 20
EC50: 0.65
age_specific_drug_concentration_sd:
[0.4,0.4,0.4,0.4,0.4,0.4,0.4,0.4,0.4,0.4,0.4,0.4,0.4,0.4,0.4]
mutation_probability: 0.005 
mutation_position: [1]
k: 4
resistance_cost_multiple_infection: 0.01 
isArtermisininDerivative: 0 
3: # lumefantrine - for advanced users only 
half_life; 4.5
maximum_parasite_killing_rate: 0.99 
n: 20
EC50: 0.65
age_specific_drug_concentration_sd:
[0.4,0.4,0.4,0.4,0.4,0.4,0.4,0.4,0.4,0.4,0.4,0.4,0,4,0.4,0.4]
mutation_probability; 0.005 
mutation_position: [2] 
k: 4
resistance_cost_multiple_infection; 0.01 
isArtermisininDerivative: 0 
4: # lumefantrine - for advanced users only
half life: 4.5
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•maximum_parasite_killing_rate: 0.99 
n: 20
EC50: 0.65
age_specific__drug_concentration_sd: 
[0.4,0.4,0.4,0.4,0.4,0.4,0.4,0.4,0.43 0.4,0.4,0.4,0.4,0.4,0.4]
mutation_probability: 0.005 
mutation_position: [3]
k:  4
resistance_cost_multiple_infection; 0.01 
isArtermisininDerivative: 0 
5: # amodiaquine - for advanced users only 
half_life: 9.0
maximum_parasite_killing_rate: 0.95 
n: 19
EC50: 0.65
age_specific_drug_concentration_sd:
[0.4,0.4,0.4,0.4,0.4,0.4,0.4,0.4,0,4,0.4,0.4,0.4,0.4,0.4,0.4]
mutation_probability: 0.00 
mutation_position: [1] 
k: 4
resistance_cost_multiple_infection: 0.01 
isArtermisininDerivative: 0 
6: # amodiaquine - use this for a standard simulation 
half_life: 9.0
maximum_parasite_killing_rate: 0.95 
n: 19
EC50: 0.65
age_specific_drug_concentration sd:
[0.4,0.4,0.4,0=4,0.4,0.4,0.4,0.4,0.4,8.4,0.4,0.4,0.4,0.4,0.4]
mutation_probability. 0.005 
mutation_position: [2] 
k: 4
resistance_cost_multiple_infection: 0.01 
isArtermisininDerivative: 0 
7: # amodiaquine - for advanced users only 
half_life: 9.0
maximum_parasite_killing_rate: 0.95 
n: 19
EC50: 0.65
age_specific_drug_concentration_sd:
[0,4,0.4,0.4,0.4,0.4,0.4,0.4,0.4,0.4,0.4,0.4,0.4,0.4,0.4,0.4]
mutation_probability: 0.005 
mutation_position: [3] 
k: 4
resistance_cost_multiple_infection: 0.01 
isArtermisininDerivative: 0 
8: # piperaquine - for advanced users only
half__life: 28.0
maximum_parasite killing_rat.e: 0.9 
n: 15
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EC50: 0.65
age_specific_drug_concentration_sd:
[0.4,0.4,0.4,0.4,0.4,0.4,0.4,0.4,0.4,0.4,0.4,0.4,0.4,0.4,0.4]
inutation_pnobability: 0.005 
mutation_position: [1] 
k: 4
resistance_cost_multiple_infection: 0.01 
isArtermisininDerivative: 0 
9: # piperaquine - for advanced users only 
half_life: 28.0
maximum_parasite_killingrate: 0.9 
n: 15
EC50: 0.65
age_specific_drug_concentration_sd:
[0.4,0.4,0.4,0.4,0.4,0.4,0.4,0.4,0.4,0.4,0.4,0.4,0.4,0.4,0.4]
mutation_probability: 0.005 
mutation_position: [2] 
k: 4
resistance_cost_multiple_infection: 0.01 
isArtermisininDerivative: 0 
10: # piperaquine - use this for a standard simulation 
half_life; 28.0
maximum_parasite_killing_rate: 0.9 
n: 15
EC50: 0.65
age_specific_drug_concentration_sd:
[0.4,0.4,0.4,0.4,0.4,0.4,0.4,0.4,0.4,0.4,0.4,0.4,0.4,0.4,0.4]
mutation_probability: 0.005 
mutation_position: [3]
k: 4
resistance_cost_multiple_infection: 0.01 
isArtermisininDerivative: 0
# therapy info
# the drug_ids that make up the therapy, and the number of days that the therapy 
is prescribed for
# testing day tells you the follow-up point at which it is determined if 
treatment failed or not
Therapylnfo:
1 :
drug_id: [1,2] 
dosing_days: 3
testing_day: 28
2 :
drug_id: [1,3] 
dosing_days: 3
testing_day: 28
3:
drug id: [1,4] 
dosing_days: 3
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testing_day: 28
4:
drug_id: [1,5] 
dosing_days: 3 
testing_day: 28
5:
drug^ id: [1,6] 
dosing_days: 3 
testing_day: 28
6 :
drug_id: [1,7] 
dosing_days: 3 
testing_day: 28
7:
drug_id: [1,8] 
dosing_days: 3 
testing_day: 28
8 :
drug_id: [1,9] 
dosing_days: 3 
testing_day: 28
9:
' drug_id: [1,10] 
dosing_days: 3 
testing_day: 28 
1 0:
dnug_id- [1,2] 
dosing_days: 3 
testing_day: 28 
11:
drug_id: [1,6] 
dosing_days: 3 
testing_day: 28 
12 :
drug_id: [1,10] 
dosingdays; 3 
testi.ng_day: 28
# drug-deployment strategy - simply uncomment below to turn on a particular 
strategy
Strategylnfo:
#strategyName can be SFTStrategy / CyclingStrategy / MFTStrategy /
AdaptiveCyclingStrategy
# strategyName: SFTStrategy
# strategyName: CyclingStrategy 
strategyName: MFTStrategy
# strategyName: AdaptiveCyclingStrategy
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SFTStrategy; 
therapylD. [10]
# cycle three ACTs in and out every five years 
CyclingStrategy:
therapylD: [10,11,12]
cycling_time: 1825
# deploy three ACTs simultaneously 
MFTStrategy:
therapylD: [10,11,12]
distribution: [0.33334,0.33333,0.33333]
# cycle three ACTs in and out - switch between ACTs when the fraction of 
patients experiencing
# treatment failure get to the trigger value below
# there is a one-year delay -until the actual switch is made in the field 
(delay_until_actual_trigger)
AdaptiveCyclingStrategy: 
therapylD: [10,11,12]
trigger_value: 0.1 
delay_until_actual_trigger: 1 
turn_off_days: 50
# this number use to detemine whether a therapy is "useful" or not and it is 
used to calculate
# the useful therapeutic duration of a therapy 
TF_rate: 0.1
# definitions of some log parasite density levels
#
parasite_density_level:
log_parasite_density_ cured; -2.699
parasites (0.002 per pi)
log_parasite_density_from_liver: - 2.000
parasites (0.01 per pi)
log_parasit.e_density_asymptomatic: 3 
per microliter of blood
log_parasite_density_clinical: 4. 301
per microliter of blood
log_parasite_density_detect.able: 1.000
microliter of blood
log_parasite_density pyrogenic: 3.398
per microliter of blood
# corresponds to 10,000 total
# corresponds to 50,000 total
# corresponds to 1000 parasites
# corresponds to 20,000 parasites
# corresponds to 10 parasites per
# corresponds to 2500 parasites
166
immune_system_information:
#rate at which antimalarial immune function increases when a host is 
parasitaemic 
bl: 0.00125
#rate at which antimalarial immune function decreases when a host is 
parasitaemic 
b2: 0.0025
# durations of infection of naive and fully-immune hosts.
# these parameters are used to calculate max and min killing rate by immune 
system
duration_for_naive: 300 
duration_for_fully_immune: 60
# initial conditions for the immune function of the population at time zero 
mean_initial_condition: 0.1
sd_initial_condition: 0.1
# (per year) age-dependent faster acquisition of immunity from age 1 to age 10
immune inflation rate: 0.01
# mix and max probabilities of experiencing symptoms as a result of a new 
infection
# the actual probability will depend on the host's immunity 
min_clinical_probability: 0.05 
max_clinical_probability: 0.99
# slope of sigmoidal prob-v-immunity function (parameter z in supplement of 
2015 LGH paper)
immune_effect_on_progression_to_clinical: 4
# age at which immune function is mature
age_mature_immunity: 10
# parameter kappa in supplement of 2015 LGH paper
factor_effect_agejnature .immunity : 1
# days from end of liver-stage infection to appearance of symptoms
days_to_clinical_under_five: 4 
days_to_clinical_over_five: 6
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# days that parasites develop mature gametocyte after exiting liverstage
# please read the documentation carefully - there are no explicit gametocytes in
# v3.0.2 of the simulation
days_mature_gametocyte_under_five: 4 
days_mature_gametocyte_over_five: 6
# probability that a patient completes a course of treatment
p_compliance: 1
# this functionality works. It is used when p_compliance (above) is less than 1.
# It was not used in any analyses for the 2015 LGH paper where p_compliance is 
always 1.
# this guarantees that the minimum number of dosing days for a poorly-complying
# patient is still 1 
min_dosing_days: 1
# relative biting rates for individuals; uncomment "distribution: Exponential" 
to use an
# exponentially distributed biting rate
relative_bitting_info:
max_relative_biting_value: 35 
number_of_biting_levels: 100 
biting_level_distribution:
# distribution: Exponential 
distribution; Gamma 
Exponential: 
scale: 0.17 
Gamma: 
mean: 5 
sd: 10
# this functionality works, but it was not used in any analyses for the 2015 LGH 
paper
percentMovement: [
[0.0, 0.01, 0.01 ]
[0.01, 0.01, 0.01],
[0.01, 0.04, 0.02]
meanDaysToReturn: [
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[3, 3, 3 ],
[7, 7, 7 ],
[14j 14, 14 ]
]
# do not change this
# this paramater was used in a different model version where gametocytes were
# modeled explicitly. In v3.0.2, this need to be set to 0.2.
gametocyte_level_under_artemisinin_action: 0.2
# these values are based on Ross 2006 - these parameters determine the 
probability a mosquito
# becomes infected based on the host's asexual parasitaemia level 
relative_infectivity:
sigma: 3.91 
ro: 0.00031
# on average 1 mosquito take 3 microliters of blood per bloodeal 
blood_meal_volume: 3
# probability to relapse after no treatment, or a treatment failure due to drug 
resistance
p_relapse: 0.01
# number of days before a relapse can occur 
relapse_duration: 30
# relapse rate - used to increase the parasite density after a treatment failure 
(at the drug clearance day)
# multiply by sqrt(20) per day 
relapseRate: 4.4721
# minimum update frequency for a host's attributes (esp. parasite density) is 
every 7 days, or
# more frequently if other events are occurring at this time 
update_frequency: 7
#report to GUI and console every 30 days 
report_frequency: 30
# if an infected and asymptomatic host is bitten and infected by a new
# parasite clone, this setting allows the new infection to cause symptoms
allow_new_coinfection_to_cause_symtoms: true
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# this functionality works, but it was not used in any analyses for the 2015 LGH 
paper
spatial_information:
max_relative_moving_value: 35 
number_of_moving_levels: 100 
moving_level_distribution:
# distribution: Exponential 
distribution: Gamma 
Exponential:
scale: 0.17 
Gamma: 
mean: 5 
sd: 10
circulation_percent: 0.0 
length_of_stay: 
mean: 5 
sd: 10
# this functionality works, but it was not used in any analyses for the 2015 LGH 
paper
spatial_external_population_information: 
max_relative_moving_value: 35 
number_of_moving_levels: 100 
moving_level_distribution:
# distribution: Exponential 
distribution: Gamma 
Exponential:
scale: 0.17 
Gamma: 
mean: 5 
sd: 10
circulation_percent: [0.0, 0.01, 0.01, 0.01, 0.01 ]
length_of_stay:
# drawn from gamma distribution? 
mean: 5 
sd: 10
daily_EIR: [ 0 . 0 1 , 0 . 0 1 , 0 . 0 1 , 0 . 0 1 , 0 . 1 ]
seasonal_EIR:
a: [ 0 . 2 5 , 0 . 2 5 , 0 . 2 5 , 0 . 2 5 ]  
phi: [200,200,200,200]
# this functionality works, but it was not used in any analyses for the 2015 LGH 
paper •
tme_info:
tme_starting_day: 0
mda_coverage: [0.8, 0.8, 0.8, 0.8]
mda_.duration: [4, 4, 4, 4]
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■ # free recombination among the drug resistance loci 
using_free_recombination: true 
#using_free_recombination: false
# the current treatment failure rate as observed in the population is not really
# today's treatment failure rate, as these data are never assembled that quickly 
in
# real life; rather, it is the average treatment failure rate observed over the
# past 60 days
tf_window_size: 60
# special function to make the mean biting rate (across hosts) depend on age
using_age_dependent_bitting_level: false
# special function which makes the probability of an infection (resulting
# from an infectious mosquito bite) age-dependent
using_variable_probability_infectious_bites_cause_infection: false
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